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T lymphocyte responses to 
equid herpesviruses 1 and 4 in horses 
Summary 
Terry O'Neill 
This thesis describes the development, optimisation and use of assays to measure 
equine herpesvirus-specific proliferative and cytotoxic T lymphocyte (CTL) responses 
in the blood of horses. 
Equine T cell blast cells stimulated from peripheral blood mononuclear cells (PBMC) 
with pokeweed mitogen were found to perform best as targets for CTL in "Cr release 
assays. CTL induced in vitro with an abortigenic strain of EHV-1 (EHV-1/Ab4) were 
shown to be antigen specific, genetically restricted and predominantly of the CD4' 
CD8+ phenotype. Cross-reactive CTL were induced in vitro with live EHV-4 virus, 
which killed EHV-1 infected blast cells. A proportion of EHV-1 induced CTL were 
shown to be directed against the immediate early gene products. 
A proliferative LDA was used to determine whether the frequency of precursor T cells 
detected before challenge with EHV-1 correlated with immune status. The precursor 
frequency of antigen-specific T cells increased in 3 out of 4 horses after infection. 
However, there was no correlation between precursor frequency and outcome of 
infection. 
A LDA was developed and used to evaluate the precursor frequencies of EHV-1 and 
EHV-4 induced CTL after infection with these viruses. Pre-infection CTLp 
frequencies in susceptible animals were <1/150,000. CTLp frequencies in animals 
which were immune to EHV-1 were between 1/10,000 and 1/20,000. 
To my knowledge, this is the first report of the use of LDA techniques in the horse. 
The development and use of CTL LDA assays have provided new information on 
CTL responses in horses after EHV-1 and EHV-4 infection. 
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I. I. The Herpesviruses 
The herpesviruses are a diverse group of viruses which infect a wide range of hosts 
with an equally wide range of clinical and pathological consequences. Membership of 
the family Herpesviridae is based on the architecture of the virion. A typical 
herpesvirus is made up of an icosahedral capsid containing about 162 capsomeres, an 
amorphous tegument, an envelope containing a number of glycoprotein spikes and a 
linear double stranded DNA genome. The family is split into a number of sub- 
families based on the biological properties of the individual viruses (Roizmann et. al., 
1981). Examples of the properties used to differentiate the sub-families are; tissue 
tropism, genomic organisation and amino acid identity (Karlin et. at, 1994) which 
enable researchers to classify herpesviruses into alpha (a), beta (ß) and gamma (y) 
sub-groups. 
The Alphaherpesvirinae include the Simplexvirus (herpes simplex types I and 2) and 
Varicellavirus (varicella-zoster virus, pseudorabies virus, equine herpes virus types 1 
and 4) genera and are classified on the basis of their short reproductive cycle, rapid 
spread in culture, efficient destruction of infected cells, capacity to establish latent 
infections and their limited host range. 
The Betaherpesvirinae are characterised by their long reproductive cycle and slow 
progress of infection in culture. This sub-family contains the Cytomegalovirus 
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(human cytomegalovirus) and the Muromegalovirus (murine cytomegalovirus) 
genera. 
Members of the Gammaherpesvirinae replicate in lymphoblastoid cells of either the T 
or B cell lineage. Latent virus can be demonstrated in lymphoid cells. This sub- 
family contains the Lymphocryptovirus (Epstein-Barr virus) and the Rhadinovirus 
(herpesvirus saimiri) genera. Equine herpesviruses type 2 and 5 have been classified 
as gammaherpesviruses. 
As this project is concerned with the immune response to the alphaherpesvirus equine 
herpesvirus-1, most of this thesis will concentrate on this group. 
Although this system of classification is simple and easy to follow, its disadvantage is 
that it is not based on objective criteria. The numerous herpesvirus genomic DNA 
sequences which are available allow evolutionary relationships to be established 
between and within the herpesvirus groups. These relationships are based on 
conservation of genes and gene sequences between particular viruses, arrangement of 
the terminal sequences and the presence of methylated nucleotides (Karlin et. at, 
1994). This type of study has not significantly re-classified any herpesvirus to date 
but it has allowed the assessment of which viruses evolved before others. The study 
shows that the closest to the consensus genome is that of human herpesvirus-6. The 
closer relationships between the members of the a-herpesviruses suggests that this 
class is of relatively recent ancestry. In the collection of viruses studied by Karlin et. 
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al. EHV-1 was the most central a-herpesvirus suggesting that it may approximate to 
an ancestral a-herpesvirus. 
1.1.1. The herpes simplex viruses 
Primary infections of humans with herpes simplex virus type I (HSV-1) or herpes 
simplex virus type 2 (HSV-2) cause different symptoms than secondary, reactivated 
infections. Vesicular, ulcerative lesions of the mouth and lips are usually the 
consequence of primary infection with HSV-1 although the disease may be 
asymptomatic or include fever, sore throat, oedema, localised lymphadenopathy and 
malaise. Genital vesicular lesions are the most common consequence of primary 
HSV-2 infection. HSV-1 may also cause a less severe genital infection (Corey et. al., 
1983). The disease caused by primary HSV infection lasts for between 10 and 14 
days after which latency is established. The establishment of the latent state depends 
on the existence of an intact anterior nerve route and peripheral nervous pathway (Hill 
et. al., 1972). Latency is established when the virus retreats via the nerves innervating 
the site of primary infection, into the trigeminal ganglion of the infected subject. 
During the interim period between primary infection and reactivation, viral protein 
synthesis is completely shut down. It is possible, however, to grow virus from 
explanted ganglia co-cultivated in vitro on a susceptible cell line. RNA transcripts, 
termed latency associated transcripts, can be detected during the latent phase of HSV 
within human ganglia derived from autopsy material (Croen et. al., 1987). 
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HSV shares the common herpesvirus structure mentioned above. The linear, double 
stranded DNA of HSV is made up of approximately 150,000 base pairs with a G+C 
content of 68% (HSV-1) or 69% (HSV-2). The HSV genome consists of one long 
unique and one short unique region linked covalently and bracketed by inverted repeat 
sequences. As both the long and short unique regions can invert with respect to each 
other, four isomers of the HSV genome exist. The genome of HSV has been fully 
sequenced (McGeoch et. al., 1985 and 1988). 
Replication of HSV proceeds with the attachment of the virus to cell receptors. 
Subsequently, the virus fuses with the cell membrane and the de-enveloped capsid is 
transported to the nucleus of the cell where the DNA is released. Transcription, 
replication and assembly of new capsids takes place in the nucleus. The regulation of 
the viral gene products after infection of a cell takes place in a coordinated manner. 
Viral proteins form into groups, the a, ß 1, ß2, y1 and y2 proteins. These protein 
groups are sequentially ordered and are translated in a cascade fashion (Roizman & 
Sears, 1990). The synthesis of the cc polypeptides, also called the immediate early 
(IE) proteins, reaches a peak at between 2 and 4 hours post-infection. These proteins 
are absolutely required for the synthesis of subsequent groups of polypeptides. The 
synthesis of the p1 and ß2 proteins reaches a peak at between 5 and 7 hours post 
infection. The ß1 proteins include the large component of the viral ribonucleotide 
reductase and the major DNA binding protein. The ß2 proteins include the viral 
thymidine kinase and DNA polymerase proteins. The expression of these proteins 
signals the onset of viral DNA synthesis. The expression of the yI and y2 proteins 
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depends on viral DNA synthesis. The yI proteins include the glycoproteins gB and 
gD which are expressed relatively early in infection, whilst the y2 proteins, including 
the other glycoproteins, are expressed later in infection. There are 11 known 
antigenically distinct glycoproteins expressed by HSV-1. These are gB, gC, gD, gE, 
gG, gH, gI, gJ, gK, gL and gM (Ghiasi et. at., 1994). Some of these glycoproteins 
form complexes in the envelope of the virus, for example an Fc receptor is formed via 
a complex between gI and gE (Johnson et. al., 1988). The location of the HSV 
glycoproteins, on the outer surface of the viral envelope, makes them likely candidates 
as stimulators of the anti HSV antibody response. 
1.1.2. Varicella-Zoster virus 
Varicella zoster virus (VZV) is transmitted primarily by aerosolization of droplets 
from skin lesions. The virus initially infects the respiratory tract but then moves via 
the bloodstream (viraemia) to the epithelium where infection is manifest as varicella 
vesicles on the skin. VZV establishes latency in the satellite cells around the ganglia 
of the sensory neurons from the skin, on the resolution of primary infection (Hay & 
Ruyechan, 1994). The latent state is maintained by the host immune response. When 
this is compromised by, for example, age or disease VZV reactivates to cause zoster, a 
localised rash restricted to the skin innervated by the ganglia in which the VZV 
established the initial latent infection. Complications can occur during VZV 
infections, including varicella meningoencephalitis. 
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VZV DNA consists of one long and one short unique region separated by an internal 
repeat region. The short unique region is linked to a terminal repeat region. Isomers 
of this genome exist as the short unique region (and, less frequently, the long unique 
region) is able to invert. The VZV genome is 125,000 base pairs in size with a G+C 
content of 46%. The genome of VZV has been fully sequenced (Davison & Scott, 
1986). 
Detailed study of the replication of VZV has been hampered by the extreme species 
specificity of the virus. The only small animal model available, the guinea pig model, 
is less than ideal as only highly adapted strains of VZV can be used. From about 70 
open reading frames specified in the genome of VZV, five of the encoded viral 
glycoproteins have been identified. These glycoproteins were termed gI, gII, gIII, gIV 
and gV, their HSV homologs being gE, gB, gH, gI and gC respectively. Each of these 
glycoproteins may play a role in stimulating anti VZV immunity (Grose, 1991). 
1.1.3. Pseudorabies virus 
The clinical features of disease caused by pseudorabies virus (PRV-the agent of 
Aujeszky's disease) depend on the age of the animal. The most acute and fatal form 
of the disease occurs in new born pigs and the disease is most common in 2-3 week 
old pigs. PRV is transmitted by droplet infection or by ingestion. The virus replicates 
in the nasal mucosa, tonsillar tissue and upper respiratory tract. Subsequently, it 
invades the lower respiratory tract and local lymph nodes from where it is 
disseminated via the lymph. Peripheral blood mononuclear cells (PBMC) may also 
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harbour the virus although cell-free viraemia is rare. In older animals the disease is 
characterised by encephalitis, pneumonia, resorption and mummification of the foetus 
and abortion. Studies have shown that mononuclear cells infected in vitro and re- 
introduced into immunised, pregnant sows caused abortion whilst cell-free virus did 
not (Nauwynck & Pensaert, 1992). After primary infection, the virus may become 
latent in the trigeminal ganglia in a similar way to HSV. 
The genome of PRV has not yet been fully sequenced but it is clear that it contains a 
high G+C content (73%). The genome structure is similar to that of VZV. To date 8 
glycoproteins have been identified in PRV. These have been correlated with those of 
HSV and thus consist of; gD (gp50), gE (gI), gG (gX), gI (gp63), gB (gII), gC (gIII), 
gH and gL. 
1.1.4. The equine herpesviruses 
Equine herpesviruses contain at least five recognised types, equine herpesvirus (EHV) 
-1, -2, -3, -4 and 5 which infect horses predominantly. 
EHV-2 can be isolated from apparently healthy horses (Bagust, 1971, Harden et. al., 
1974). This virus is characterised by it's very slow replicative cycle, alternative 
designations being; slow-growing herpesvirus or equine cytomegalovirus. EHV-2 
and EHV-5 were previously classified as a members of the betaherpesviridae 
(Roizmann et al., 1992. Browning & Studdert, 1987), although partial sequence 
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analysis has revealed that both of these viruses are distinct y-herpesviruses (Telford 
et. al., 1993). 
EHV-3 causes a relatively innocuous genital infection commonly known as equine 
coital exanthema. The virus has been classified as an a herpesvirus and this is 
supported by genetic data (Baumann et. al., 1986). There seems to be little 
serological relationship between EHV-3 and the other equine herpesviruses (Thomson 
et. al., 1976a). 
Economically, the most important equine herpesviruses are EHV-1 and EHV-4. 
These viruses cause a range of diseases including respiratory disease and abortion. 
Abortion of the equine foetus was first studied clinically by Dimock & Edwards 
(1932) whose further studies established a viral aetiology and defined the pathological 
lesions within the foetus (Dimock & Edwards, 1933 and 1936. Dimock, 1940). 
Manninger & Csontos, (1941) inoculated pregnant mares with bacteriologically sterile 
filtrates from aborted foetuses and observed influenza-like symptoms. Further studies 
suggested that virally induced abortion of the equine foetus was caused by infection of 
the mare with influenza virus (Manninger, 1949). 
The respiratory disease associated with the so called equine abortion virus (EAV) was 
first studied in detail by Doll et. al. (1954b). Doll also showed that EAV was the 
aetiological agent causing respiratory disease in young horses and that several 
putative equine influenza isolates were identical to EAV (Doll et. al., 1954a, Doll & 
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Kintner, 1954, Doll & Wallace, 1954). As the principal lesion in young horses and 
aborted foetuses occurred in the respiratory tract, Doll suggested that EAV be 
regarded as a respiratory virus (Doll et. al., 1957). In this study, the authors 
designated the disease caused by EAV as equine rhinopneumonitis and the virus as 
equine rhinopneumonitis virus. EAV was later designated as EHV-1 subtype 1 (the 
abortogenic strain) and subtype 2 (the respiratory strain, Matthews, 1979). 
EHV-1 (old designation) was recognised as causing four distinct syndromes; 
respiratory disease, abortion, neonatal foal disease and occasionally, paralysis 
(Mumford, 1994). In an extensive study of the capacity of the two subtypes of EHV-1 
to cause disease, Allen & Bryans (1986) showed that the vast majority (all but one) of 
the abortion epizootics studied were caused by subtype-1 viruses and only this virus 
was ever isolated from cases of central nervous system disease. However, both 
subtype-1 and subtype-2 viruses were isolated from outbreaks of respiratory disease, 
although the majority were subtype-2 (86%). The distinct restriction endonuclease 
analysis patterns of the two sub-types suggested that they should be regarded as 
separate viruses (Studdert et. al., 1981). The latest International Committee an the 
Taxonomy of viruses (ICTV) suggests the use of EHV-1 for the former subtype-1 
virus and EHV-4 for the former subtype-2 virus, based on the differences outlined 
above (Roizman et, al., 1992). 
Comparative studies between EHV-1 and EHV-4, using immunofluorescent 
techniques, showed that EHV-4 replicated in the epithelium of the nasopharynx and 
9 
the bronchial tree, macrophages and lymph nodes only. In contrast, EHV-1 replicated 
in these sites as well as the endothelial lining of the vasculature of the nasopharynx 
and the lung (Patel et. al., 1982, Patel & Edington, 1983). EHV-1 was also found in 
circulating leukocytes whereas EHV-4 was not. The pathogenesis of EHV-1 and 
EHV-4 will be discussed in more detail later in this chapter. 
As with all other herpesviruses, EHV-1 and EHV-4 become latent after the primary 
infection. Unlike HSV and PRV, there is evidence that EHV does not become latent 
in sensory ganglia (Allen & Bryans, 1986, Edington et. al., 1985). However, recent 
studies dispute this (Slater, 1994) and suggest that EHV-1 may, indeed, be 
neurotropic. The site or sites of latency of EHV have not yet been conclusively 
identified. 
The genome of EHV-1 has been fully sequenced (Telford et at., 1992) has been 
shown to consist of approximately 150,000 base pairs, with a G+C content of 56 or 
57% (Whalley et. at., 1981, Soehner et al., 1965). The DNA is divided into one long 
and one short unique region flanked by inverted and terminal repeat regions in a 
similar arrangement to the genomes of PRV and VZV (Ben-Porat et. at, 1979, 
Davison et al., 1984). 
The structure of the EHV virion is typical of the other members of the herpesviridae. 
It has an icosahedral capsid enclosing the DNA core. This is surrounded by a loose 
envelope which is derived from the nuclear membrane of the infected cell. The 
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envelope is a triple layered membranous structure which contains lipid, 
phosphoproteins and glycoproteins. The viral glycoproteins of EHV-1 and EHV-4 are 
the most immunodominant antigens, at least in terms of antibody production (Tewari 
et. al., 1993). There are six major glycoproteins (in terms of abundance, Allen & 
Yeargan, 1987) specified by EFiV-1 and EHV-4. Some of these have equivalents in 
HSV whilst others do not. The EHV glycoproteins are referred to as follows (the 
HSV equivalents are in parenthesis); gp2 (-), gp I0 (gH), gp 13 (gC), gp l4 (gB), gp 18 
(gD) and gp2l/22a (-). 
1.2. Immune responses to herpesviruses 
1.2.1. Introduction 
An animal's defence against foreign material entering the body and causing 
pathological change consists of a wide range of innate and adaptive mechanisms. 
One of the most effective defense mechanisms is the physical barrier formed by the 
skin and mucosal surfaces. The mucocilliary escalator in the trachea and the acid 
environment of the stomach also form barriers against entry of infectious material. If 
these primary barriers are breached and the foreign material enters the internal 
environment of the animal then the immune system is activated in an attempt to 
eliminate the potential threat. 
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An infectious agent which has entered the body becomes a focus for inflammatory 
and innate immune responses, which are triggered immediately when a microbial 
challenge is encountered. These responses may involve tissue macrophages, 
monocytes, neutrophils, natural killer cells (NK cells) and endothelial cells and also 
cytokines, complement and arachidonic acid metabolites. Tissue macrophages, which 
develop from blood monocytes, are able to phagocytose pathogens via interactions 
with receptors such as the mannose-fucose and complement receptors. Actively 
phagocytic tissue macrophages become stimulated to produce a number of products 
which are capable of inducing the expression of adhesion molecules which enhance 
the interaction of neutrophils and endothelial cells. This allows the egress of 
neutrophils from the blood into the tissues down a concentration gradient of numerous 
chemotactic factors. These peptide factors, produced by macrophages and endothelial 
cells, also have strong neutrophil arming properties which enables the neutrophils to 
phagocytose and kill bacteria using a number of highly toxic proteinases and reactive 
oxygen intermediates. On completion of their main function, the neutrophils die and 
are rapidly removed from the tissues via phagocytosis by macrophages. 
NK cells are able to kill certain tumour or virally infected target cells in vitro, in a 
non-genetically restricted manner. They often appear as large granular lymphocytes 
(LGL) and they do not produce a secondary, memory response. However, they are 
able to lyse cells quickly after challenge with some infectious agents and have been 
implicated as a natural resistance mechanism in some herpesviral systems. 
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As an infectious episode progresses the components of the adaptive immune system 
begin to have an effect. Specific antibody is produced against the pathogen by B cells 
which differentiate, under the control of helper T cells, into antibody producing 
plasma cells. Effector Cytotoxic T lymphocytes (CTL) differentiate from precursors 
and lyse virally infected cells in a genetically restricted, antigen-specific manner. 
Cytokines are produced by T cells, which are able to modulate the immune response 
to the pathogen and also inactivate certain viruses directly. 
The outcome of a herpesvirus infection depends on the immune status of the host 
when the virus enters the body. If no pre-existing immunity exists then it is likely that 
the virus will cause pathological change and illness until components of the adaptive 
immune system can be activated and eliminate the virus or force it to become latent. 
If however, the animal has had a recent exposure to the same virus, then not only will 
pre-existing immunity increase the chances of inactivating the virus before it 
establishes an infection but the increased speed and magnitude of the secondary 
response will have an earlier effect on established infection by preventing its spread. 
As herpesviruses have co-evolved with the immune systems of animals, numerous 
escape mechanisms which ensure their survival have developed. Probably the most 
effective of these escape mechanisms is their ability to become latent. This is a 
common property of all herpesviruses and enables the virus to persist in the host until 
favourable conditions exist for its re-activation. 
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What follows is an overview of the mechanisms involved in the attempted elimination 
of viruses and viral antigens from animals infected with herpesviruses. As this study 
is concerned with equine herpesvirus type 1 (EHV-1), an a-herpesvirus, the majority 
of the work described in the text will concentrate on this class of virus. 
1.2.2. Innate immune responses 
The innate immune system exists to provide a first line of defence against infectious 
challenge. As outlined above, it consists of specialised cells capable of mounting a 
rapid response to a challenge without having previously encountered the antigens of 
the pathogen. The majority of the work on natural resistance to herpesvirus infections 
has been carried out in mouse models. Inbred mouse strains have been identified 
which are either resistant, moderately susceptible or susceptible to HSV infection 
(Lopez, 1975). 
1.2.2.1. Macrophages 
Phagocytosis is an important process in the initiation of an innate response. The 
phagocytic cells present in the tissues are members of the mononuclear phagocyte or 
macrophage family. Macrophages are present in all major tissues of the body. Tissue 
macrophages are derived from blood monocytes which migrate into the tissues and 
become one of a number of specialised tissue macrophage type cells e. g. microglial 
cells of the brain, Kupffer cells in the liver and pulmonary macrophages in the lung. 
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After gaining entry into the tissues a herpesvirus will immediately come into contact 
with phagocytic tissue macrophages. Depending on a number of factors, an infectious 
state will be established or, if the animal is naturally resistant to the virus, there will 
be no infection. If the macrophage phagocytoses the virus, then the internal 
environment of the lysosome may be enough to inactivate it. This is the case when 
C57BL (HSV resistant) mice are infected with HSV-1 (Sarmiento et. al., 1988). Bone 
marrow, peritoneal, and splenic macrophages from these mice consistently inhibit 
HSV-1 replication before the onset of immediate early gene expression or viral 
protein synthesis. Molecular analysis of "infected" resistant peritoneal macrophages 
from resistant mice (Morahan et. al., 1989) indicated that the immediate early and 
early thymidine kinase (tk) genes were expressed whilst transcripts for the early DNA 
polymerase, delayed early glycoprotein D and the late glycoprotein C genes were not 
detectable. This suggests that there is a block in virus replication in macrophages 
from resistant mice which lies between the expression of the early to delayed early 
viral genes. 
The activational state of the macrophage also influences the outcome of infection with 
HSV-1. Tenney er al. (1987) showed that undifferentiated macrophage like cells 
were non-permissive to HSV-1 infection whereas the same cells activated with 
phorbol esters (PMA) became permissive to infection with the same virus. Mouse 
peritoneal macrophages stimulated with Corynebacterium parvum or thyoglycolate 
showed increased levels of productive infection, cytopathic effect and DNA 
replication when compared with resident macrophages (Sit et. al., 1988). 
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The resistance of macrophages to HSV infection may also be due to their high 
secretory potential. Resident macrophages can be stimulated to secrete a wide range 
of molecules, for example, interleukin 1 (IL1), interleukin 6 (IL6), eicosanoids, 
interferon alpha (IFNa) and tumour necrosis factor alpha (TNFa). The infecting virus 
may also act as a physiological activator of macrophages (Giridhar et. al., 1991). 
Proteolytic enzymes and reactive oxygen intermediates produced by macrophages can 
directly inactivate extracellular particles and IFN may inhibit viral replication in 
surrounding cells. The importance of IFN in protection of cells against HSV infection 
was indicated by Pyo et at (1991) who showed that resistance of inflammatory 
macrophages to infection with HSV-1 induced by the IFN inducer 
polyriboinosinic: polyribocytidylic acid (poly I-C) was completely abrogated by 
antibody to interferon beta (IFNß). Interferon gamma (IFNy) present in supernatants 
from T helper cell clones was implicated in increasing the in vitro anti-HSV virucidal 
activity of macrophages (Seid et. al., 1986). Current nomenclature refers to IFNa and 
IFNß (produced by a wide range of cell types) as type I IFNs and IFNy (produced by 
activated T cells and NK cells) as type II. Recently, Muller et, al. (1994) have 
published results of studies on the role of the IFN system in antiviral defence. Mutant 
mice with deleted IFN receptor genes (either type I or type II IFN receptors) were 
infected with vesicular stomatitis virus (VSV), SEntiki Forest virus (SFV), vaccinia 
virus and lymphocytic choriomeningitis virus (LCMV). Comparison of mice lacking 
either type I or type II IFN receptors showed that, at least in some of these infections, 
both IFN systems were essential for antiviral defense and they were functionally non- 
redundant. 
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The only report of experiments to test whether mononuclear phagocytes are important 
in protection against EHV-1 infection was published by Darlington (1978) who 
demonstrated that macrophages from yearling horses supported the replication of 
EHV-1 whilst those from older animals did not. Macrophages from the older horses 
were resistant to infection with EHV- 1, however, abortogenic infections and 
viraemias did occur suggesting that macrophages did not protect against these very 
important consequences of infection. 
1.2.2.2. Natural Killer (NK) cells 
NK cells were first described as an unwanted background in studies of antigen 
specific T cell mediated cytolysis of tumour target cells. Since then they have been 
widely studied as a component of the natural immune response against viral 
infections. They are characterised by their ability to lyse various tumour cell lines 
(eg. K562 cells) and virally infected (eg. HSV infected fibroblasts) targets in vitro 
without previous experience of the expressed tumour or viral antigens and in a non- 
MHC restricted manner. NK cell function can be augmented in vitro by IL2 (Shaw et. 
al., 1985) and IFN (Colmenares and Lopez, 1986). 
NK cells have largely been defined in terms of their function (reviewed by Reynolds 
& Ortaldo, 1987). In both mice (Lust et. al., 1981) and humans (Fitzgerald et. al., 
1983) NK cell functional activity has been shown to be due to a heterogeneous 
population of cells. This heterogeneity is manifest by the differential lysis of NK 
sensitive target cells by NK cells. For example, NK cells from one patient may lyse 
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HSV infected fibroblasts but not K562 cells whereas NK cells from another patient 
may do the opposite, suggesting that there are at least two populations of NK cell 
(Fitzgerald et. al., 1983). 
All mouse NK cells can be characterised as low density lymphocytes (Bukowski & 
Welsh, 1985) and are within the large granular lymphocyte (LGL) population (Minato 
et. al., 1985). Depending on the species, NK cell identification varies, for example, 
porcine NK cells are low density lymphocytes but not LGL (Yang et. a!., 1987) 
whereas bovine NK cells lack the large intracytoplasmic granules identifying human 
LGL (reviewed in Cook & Splitter, 1989). Phenotypically, human NK cells are 
characterised by the expression of CD16 (Fc receptor y IIIa/b) and CD57 (NKH-1) 
and the lack of expression of CD3 and the T cell receptor. A sub-set of human NK 
cells also expresses CD8 and CD2 although the functions of these molecules, which 
are found mainly on T cells, on NK cells is uncertain although they may suggest a 
common lineage between these cell types. Murine NK cells are defined by the 
expression of NK1.1 and asialo GM 1 on the cell surface. 
Most viral infections, including HSV-1 and HSV-2, augment NK cell function 1-3 
days after infection. Welsh et. al. (1978) showed that this augmentation followed 
closely the generation of IFN in the mouse. However, Fitzgerald et. al. (1982) 
showed that NK cell lysis of HSV infected fibroblasts did not correlate with the 
amount of IFN-a produced in the assay. They also showed that, in some humans, NK 
cell activity against HSV infected fibroblasts was normal despite the generation of 
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only small amounts of IFN. In a mouse model of acute ocular HSV-1 infection, 
Brandt and Salkowski (1992) showed that, using a natural route of infection, splenic 
NK activity was augmented after infection. They also assessed the role of IFN and 
IL2 in the NK cell activation by treating the mice with antibodies to IFN-a/p, IFN-y 
and IL2 before infection. Treatment with anti IFN-a/p or IFN-y resulted in reduced 
NK cell cytotoxicity whereas treatment with anti IL2 resulted in increased 
cytotoxicity suggesting that in vivo IFN is important in NK cell activation whilst IL2 
is involved in suppression of NK cell activation. 
The role of NK cells in limiting the replication of HSV-1 was studied by Leibson et. 
al. (1986) who found that cytotoxic NK cells reduced virus yield from infected 
fibroblasts by up to 90%. There was an inverse relationship between the number of 
NK cells in the culture and the virus yield. Experiments using murine 
cytomegalovirus (MCMV) infection have demonstrated the important role of NK cells 
in recovery from this disease. Beige mice were found to have low NK responses and 
were more susceptible to severe herpesvirus infections than normal litter-mates. 
Replication of MCMV was also enhanced in young mice and mice depleted of NK 
cells using anti-NK1.1 and anti-asialo GM1 antibodies (Welsh & Vargas-Cortes, 
1992). An antiviral role for NK cells has also been demonstrated in mice with severe 
combined immunodeficiency (SCID), indicating that they are able to function in the 
complete absence of T or B cells (Welsh et. aL, 1991). The role of NK cells in 
resistance to herpesvirus infections has also been studied in humans. Biron et. al. 
(1989) described a patient with a complete NK cell immunodeficiency who 
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succumbed to exceptionally severe CMV, VZV and HSV-1 infections. Other studies 
have also linked low NK cell activity to severe cases of HCMV (Quinnan et. al., 
1982) and HSV (Lopez et al., 1983). 
NK cells have not been extensively studied in the horse. The only report of equine 
NK activity was published by Chong et. al. (1992) who demonstrated that NK cell 
activity was not enhanced after EHV-1 infection of specific pathogen free (SPF) foals. 
1.2.2.3. Antibody dependent cell mediated cytotoxicity 
Antibody-dependent cell-mediated cytotoxicity (ADCC) is facilitated when antibody 
binds specifically to antigen expressed on the surface of a target cell and non- 
specifically to Fc receptors on the surface of an effector cell. Any effector cell 
capable of participating in the ADCC reaction must, therefore, express at least one 
type of Fc receptor on its surface. The cells involved in mediating ADCC are usually 
termed killer (K) cells although they consist of a heterogeneous group of leukocyte 
effector cells including LGLs, a small proportion of T cells and some macrophages. 
The major isotype of antibody responsible for ADCC function, at least in the HSV 
system, is IgG. Methiesen (1988) found that anti HSV-1 ADCC mediating activity 
was detectable mainly in the IgG1 and IgG3 fractions. In order for effective ADCC to 
occur, molecules other than immunoglobulin need to participate. For example, Kohl 
et. al. (1986) showed that patients genetically deficient in the leukocyte cell surface 
glycoproteins CD l1a (LFA-1), CD 11 b (Mac-1) and p 150,95 were unable to provide 
leukocyte effector cells able to mediate ADCC in vitro. The main emphasis of the 
20 
published literature concerning ADCC has been in neonatal HSV infections. Both 
human (Kohl et al., 1984) and murine (Kohl & Loo, 1980) neonates are potentially 
deficient in anti HSV ADCC activity. A correlation between level of ADCC antibody 
and HSV disease has been demonstrated in human neonates (Kohl et al., 1989). In 
particular, individuals with disseminated disease were shown to have significantly 
lower levels of anti-HSV ADCC mediating antibody than those with localised disease. 
The implication from these studies is that ADCC is important in controlling neonatal 
HSV infections and that passively acquired maternal antibody participates in the 
ADCC reaction. 
1.2.3. The role of antibody in herpesvirus immunity 
The role of anti herpesvirus antibodies in protection against, and recovery from 
infection has been partially covered with the discussion of the ADCC reaction in the 
previous section (see 1.2.2.3. ). Many studies have concluded that the general 
mechanism of antibody mediated protection against herpesvirus infection is via 
ADCC. For example, Hayashida et. al. (1982) concluded that antibody mediated 
protection from HSV infection of athymic nude mice required the Fc portion of the 
antibody molecule implying that ADCC was involved. IIalachandran et. al. (1982) 
concluded that the protection of complement-deficient and normal mice with non- 
neutralising monoclonal antibodies specific for HSV-1 gC, gB, gD, gE and gF was 
due to ADCC. Kapoor et. at (1982b) showed that passive transfer of polyclonal 
neutralising antibody to nude mice resulted in a reduction in the level of virus in 
ganglia. When monoclonal antibodies were transferred to these mice only one 
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neutralising antibody reduced virus spread to the ganglia which, the authors suggest, 
argues in favour of neutralisation per se being the mechanism in use. All of these 
studies were based on the passive immunisation of animals with polyclonal or 
monoclonal antibody preparations which may not reflect the levels of antibody 
present in normal mice after an ongoing immune response. In a more natural situation 
Mishkin et. al. (1992) immunised normal mice with HSV-1 gD, depleted of various 
cell types and then challenged with HSV-2. After challenge of these animals with low 
to moderate levels of HSV-2, vaccine elicited antibody played a primary role in 
limiting the severity of infection whereas at high challenge levels T cell mediated 
mechanisms became important. Analysis of a large number of herpes simplex virus 
type I or 2 infected patients by Reeves et. al. (1981) revealed that among patients 
with primary HSV-2 infections, the probability of recurrence directly related to the 
presence and level of anti HSV-2 neutralising antibody. This result, based solely on 
antibody measurements, does not preclude the presence of other protective 
mechanisms within the same patients. 
The majority of studies concerned with the role of antibody in protection against 
herpesvirus disease have used circulating antibody as a measure of protective 
potential. However, there is a growing body of evidence implicating mucosal antibody 
as a major determinant of anti-herpesvirus immunity. Irie et. al. (1993) showed that 
mice could be protected against ocular and cutaneous infection with herpes simplex 
virus type 1 by intra-gastric immunisation with live virus. A mucosal barrier against 
infection with bovine herpesvirus I (BHV-1) was achieved when calves were 
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immunised with BHV-1 viral envelope glycoproteins combined with the potent 
mucosal adjuvant cholera toxin beta subunit (Israel et. al., 1992). 
1.2.4. Specific cellular responses 
Although cellular mechanisms are involved in all aspects of innate and specific 
immunity to infectious agents, the term cell-mediated immunity (CMI) has come to be 
synonymous with the T cell immune response. 
Mature T cells are bone marrow derived cells which express the clonotypic, T cell 
receptor (TcR) complex which includes the CD3 signal transduction apparatus. 
Immature T cell precursors migrate from the bone marrow to the thymus where, as 
pro-T cells, they undergo a process of division and differentiation during which they 
are educated to recognise antigenic peptides embedded in the peptide binding groove 
of either MHC class I or MHC class II proteins. Both MHC class I and MHC class II 
proteins are specialised polymorphic peptide binding molecules. Class I proteins 
consist of a 45kD membrane bound heavy chain non-covalently linked to a 12kD 
polypeptide termed p2-microglobulin (ß2M). The class I heavy chain can be divided 
into three extracellular domains, the a3 domain is membrane proximal and has 
homology to an immunoglobulin domain whilst the a1 and a2 domains contain 
extensive intraspecies polymorphism and form a peptide binding groove. Class II 
proteins are non-covalently linked aß heterodimers (a chain 33kD, ß chain 29kD). 
Both chains are membrane bound and the peptide binding groove is formed between 
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the a1 and the ß1 domains. The majority of the polymorphism in MHC class II 
molecules is in the ß1 domain. 
1.2.4.1. Thymic education 
On entering the thymus from the foetal liver, spleen or bone marrow, the 
developmentally immature pro-T cells undergo a process by which they are either 
eliminated if their TcR has high affinity for self MHC (negative selection, Kappler et. 
al., 1988) or they are selected if the TcR has an intermediate affinity for self MHC 
(positive selection, Blackman et. al., 1989). This ensures that, whilst T cell responses 
against self proteins are prevented, TcR molecules retain the capacity to recognise self 
MHC and distinguish it from self MHC containing foreign peptide. The cell which 
leaves the thymus expresses high levels of the TCR/CD3 complex and either CD4 or 
CD8. The CD4 and CD8 molecules have similar functions in that they both act as 
accessory molecules by stabilising the interaction between MHC molecules and the 
TcR. These molecules also act as co-receptors by transducing a signal via the tyrosine 
kinase, p56'ck which associates with the cytoplasmic domains of both molecules 
(Veillette et. al., 1989). The cells which leave the thymus are referred to as the naive 
T cell pool. An extra-thymic maturation process for some T cells has also been 
suggested. Recent evidence has implicated gut-associated lymphoid tissue in the 
extra-thymic maturation of intra-epithelial lymphocytes of the small intestine 
(Lefrancois & Puddington, 1995). After the thymic education process T cells are only 
able to recognise antigens in the form of MHC protein-peptide. The obligate 
recognition of MHC bound peptide antigen is termed MHC restriction. 
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1.2.4.2. Antigen processing 
Naive T cells continually re-circulate between the peripheral lymphoid tissues via 
lymphatics and the blood. This ensures that an individual T cell comes into contact 
with a large number of antigen presenting cells (APC) which present peptide 
fragments within their cell surface MHC molecules. These peptide fragments are 
derived from the internal environment of the APC (self or viral peptides) and from 
any foreign material which enters the body and drains into the lymphoid tissue where 
it can be taken up by APCs. 
The mechanisms by which APCs derive antigenic peptide from native antigens and 
present them to T cells has been intensively studied in recent years. Studies using the 
mutant cell line RMA-S (Townsend, 1989), which has a defect in the association of 
ß2M with the class I heavy chain, have shown that the folding of Class I molecules is 
dependent on the availability of peptide. This means that Class I-peptide interaction 
must take place soon after the biosynthesis of the Class I molecule. The endoplasmic 
reticulum (ER) has been shown to be the site of class I-peptide interaction (Yewdell & 
Bennink, 1989). The major source of peptide for this interaction is the cytoplasm. 
Therefore, it is clear that peptides must enter the ER in order to associate with class I 
molecules. Recent studies have identified two genes in the MHC region (Trowsdale 
et. al., 1990) that code for the heterodimeric ER membrane bound protein components 
TAP-1 and TAP-2 which have a peptide transporting function (Powis et. al., 1992). 
The mechanism of generation of the peptides which become available for transport 
into the ER is not clear. However, a number of MHC linked genes which encode low 
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molecular weight proteins, the LMP genes, and which are closely linked to the TAP 
genes encode proteins with homologies to molecules contained in multicatalytic 
proteases assembled in structures termed proteasomes (Goldberg & Rock., 1992). 
Two LMP genes (LMP2 and LMP7) have been shown to modify the peptidase 
activity of proteosomes towards the production of peptide able to bind to MHC class I 
molecules (Gaczynska et al., 1994). Thus, it is possible that proteins derived from 
intracellular events are produced in the cytoplasm of APCs where they may be 
degraded by multicatalytic proteasomes into peptides of optimal length for transport 
across the ER membrane by TAP-1 and TAP-2 after which they combine with the 
newly synthesised MHC class I proteins. 
Processing of antigen for presentation in the context of MHC class II molecules 
begins with endocytosis of extraceilular antigen. The processing of exogenous 
antigen is rapid and efficient and is generally inhibited by agents which interfere with 
the acidification of endosomes. It has also been shown that class II molecules bind 
peptides later after their biosynthesis than do MHC class I molecules (Germaine, 
1986). This delay in peptide binding is a function of the more stable, two membrane 
bound chain, structure of class II molecules and the fact that they are "protected" from 
peptide binding in the ER by their association with a molecule known as the invariant 
chain (Ii). Ii also facilitates dimerisation of class II and regulates the export of intact 
molecules to the cell surface. Class II-Ii complexes move from the Golgi through 
early endosomes after which they accumulate in late endosomes/pre-lysosomes. Ii is 
removed in this compartment due to the acidic and proteolytic environment which 
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makes the class II available for the binding of peptides which are also produced at this 
site. The removal of the Ii in the late endosomes/pre-lysosomes allows the class II- 
peptide complexes to escape from the endosomal pathway and become expressed on 
the cell surface. 
1.2.4.3. T cell activation 
The sampling of peptide specificities via interaction of the TcR with MHC-peptide on 
the surface of APCs is facilitated by a range of adhesion molecules on the surface of 
the T cell which have ligands on the APC surface. Thus, naive T cells work their way 
through lymphoid tissues always in full contact with other cells via the interactions 
between LFA-1 (binds ICAM-1, -2 and -3) and CD2 (binds LFA-3) on the T cell 
surface and between ICAM-1 (CD54), ICAM-2 and ICAM-3 (CD50) and LFA-3 
(CD58) on the APC surface. 
The majority of these interactions do not result in T cell activation. TcR recognition 
of a specific peptide is not sufficient for T cell activation and this event in isolation 
results in T cell tolerance. In order for T cell activation to occur TcR ligation must be 
accompanied by the delivery of a co-stimulatory signal. This level of regulation 
ensures that only interactions between antigenic peptide presented on the surface of 
professional APCs trigger naive T cells to become activated and develop into effector 
T cells. When an antigenic peptide is recognised by a re-circulating T cell and the co- 
stimulatory signal is delivered, adhesion to the APC presenting the peptide is 
enhanced and T cell activation ensues. 
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The APC type on which the antigenic peptide was presented to the T cell is crucial in 
determining the outcome of the interaction. For example, dendritic cells are thought 
to be the only APCs able to activate naive T cells and thus trigger true primary 
responses. Human dendritic cells express both MHC class I and MHC class II 
molecules, ICAM -1, -2, and -3, LFA-3 and the co-stimulatory molecule B7. Other 
professional APCs, for example macrophages and B cells do not constitutively 
express co-stimulatory (B7) activity and need to be activated before being able to 
function fully as APCs. 
Activation of aT cell begins with the binding of the TcR to MHC/peptide and the 
binding of the co-stimulatory signal B7 (and the related molecule B7.2) to its ligand 
CD28 (also CTLA-4 on activated cells which binds B7 with a 20 fold higher avidity 
than CD28). After these events occur, proliferation of the T cell ensues which is 
driven by the production of the autocrine T cell growth factor interleukin 2 (IL2) and 
the expression of its receptor CD25. The co-stimulatory signal has the function of 
stabilising the production of IL2 and inducing proliferation of the T cell which dilutes 
the inhibitory signals that accumulate when the TCR is ligated in isolation (Jenkins, 
1992). 
1.2.4.4. T cell effector functions 
After a period of proliferation the T cells differentiate into one of a number of effector 
T cells. Effector T cells differ from naive T cells in that they can respond to antigenic 
peptide presented in the absence of any co-stimulatory signal which means that they 
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can have an effect in tissues which do not express B7. They also express higher levels 
of the adhesion molecules CD2 and LFA-1 and begin to express the vascular 
endothelial homing receptor VLA-4 and the CD45RO isoform of CD45. This means 
that effector T cells become more sensitive to further stimulation with MHC bound 
specific antigenic peptide. 
There are two major types of effector T cell, the helper T cell and the cytotoxic T cell. 
These cells are often differentiated from each other by their expression of CD4 and 
CD8 respectively. The terms helper and cytotoxic T cells are, however, functional 
descriptions and, at best, their designation as CD4+ and CD8+ respectively is 
misleading. The CD4 and CD8 molecules expressed on the cell surface of T cell sub- 
sets correlate well with the MHC reactivity of the particular T cell; thus, CD4 binds 
specifically to MHC class II molecules whilst CD8 binds to MHC class I molecules. 
T helper (Th) cells are mainly involved in the regulation of immune responses via the 
production of soluble cytokines. An in vivo consequence of the production of 
cytokines by Th cells is a reaction known as delayed type hypersensitivity (DTH) 
which has been used as an indication that cellular immune mechanisms are at work in 
model systems. Th cells can be divided into two distinct sub-populations based on 
their cytokine secretion profiles (Mossmann et. al., 1986). Type 1 helper cells (Thl) 
produce IL3, GM-CSF, IL2, IFN y and lymphotoxin. Type 2 helper cells (Th2) 
produce IL3, GM-CSF, IL4, IL5, IL6 and IL10. 
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Thl cells produce cytokines which are involved in the mediation of DTH reactions 
and in the activation of macrophages which are then able to kill intracellular or 
extracellular pathogens (Cher & Mossmann, 1987). Some of the cytokines produced 
by these cells (e. g. TNF and IFN-y) also have direct cytotoxic effects on cells. Th2 
cells have the main function of helping B cells to produce high levels of specific 
antibody. Some IgM responses and all other Ig responses are T (predominantly Th2) 
cell dependent. Thus, in the mouse, IL4 induces a switch in antibody production by B 
cells from IgM to IgGI and IgE and TGF-p induces a switch to IgG2b and IgA. Help 
with antibody production is not the exclusive preserve of Th2 cells as some Thl 
cytokines induce an isotype switch, e. g. IFN-y induces a switch from IgM to IgG3 
and IgG2a synthesis. A third type of T helper cell has been described, the ThO cell. 
These cells produce a mixture of Thl and Th2 cytokines and are said to be the 
precursors of these cells. 
Most of the research carried out on T helper cell sub-sets has used T cell lines or 
clones from mice. However, there is growing evidence for the existence of similar 
sub-sets in rats and in humans. (Noble et. al., 1993, van-der-Pouw-Kraan et, ad., 1993) 
In addition to their positive effects on the immune response, Th cells have negative or 
inhibitory effects. Thus, Thl cells inhibit the growth and differentiation of B cells 
stimulated by IL4, a Th2 cytokine. Conversely, IL4 and ILI0, both Th2 cytokines, 
inhibit IFN-y induced macrophage killing of pathogens. Th cell sub-sets also have 
inhibitory effects on each other. IFN-y has been shown to inhibit the growth of 
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murine Th2 cells whilst ILI0 and, to some extent IL4, can reduce cytokine production 
by Thl cells (Fiorentino et. al., 1989). 
The in-vivo significance of T helper cell sub-sets to the resolution of disease 
processes can be illustrated by studies of Leishmania major infection of mice. 
Infection of most strains of in-bred mice with this parasite results in the production of 
localised lesions which resolve within two weeks, resulting in a state of resistance to 
re-infection. The response of these mice is characterised by a strong DTH response 
but only low levels of antibody. Cells derived from these mice produce high levels of 
IFN-y but little or no IL4 or ILS. This is therefore a typical Thl type response 
(Belosevic et. al. 1989). However, when BALB/c mice are infected sub-cutaneously 
with the same parasite the resultant localised lesions spread, resulting in disseminated 
disease and death. High levels of antibody are produced along with a low DTH 
response. Cells derived from these mice produce high levels of IL4 and ILS but little 
IFN-y. This is a typical Th2 response. It is known that the most effective mechanism 
for the killing of L. major parasites is via activated macrophages, which are primarily 
induced by Thl cells. This example illustrates the consequence of an inappropriate 
immune response to a pathogen. 
The activation of naive CD4` and CD8` T cells is essentially the same except that 
CD4` T cells are stimulated by antigen presented by MHC class II molecules whilst 
CD8' T cells are stimulated by antigen presented by MHC class I molecules. 
Cytotoxic T lymphocytes (CTL), sometimes referred to as CD 8"' T cells, differ from 
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helper T cells, sometimes referred to as CD4+ T cells, in their effector functions within 
target tissues. 
The primary effector function of CTL is the lysis of cells infected with intracellular 
pathogens, e. g. all viruses, some bacteria and a few parasites. The display of 
endogenously processed peptide antigens within the cell surface MHC class I 
molecules of the infected cells makes the cell "visible" to antigen specific effector 
CTL and hence susceptible to lysis. This situation is analogous to the presentation of 
antigen to naive CTL by, for example, dendritic cells, which results in its 
differentiation into an armed effector CTL. 
1.2.4.5. Cytotoxic mechanisms 
The end result of an encounter between an infected cell and an effector CTL is usually 
the destruction of the infected target cell. The initial recognition event between the 
target cell and the effector CTL involves linkages between antigen specific TcR and 
the MHC-peptide molecule. This is followed by the numerous adhesion molecule 
interactions described above, which are critical for efficient target cell killing. After 
the recognition event, target cell killing can be mediated using one of a number of 
proposed mechanisms which are probably not mutually exclusive. 
The first mechanism is receptor mediated triggering of apoptosis. Apoptosis is a 
normal cellular mechanism which, for example, deletes all thymocytes that fail 
positive selection or have a high affinity to self MHC in the thymus (Smith et. al., 
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1989). The process of apoptotic cell death involves DNA fragmentation, cytoplasmic 
streaming, membrane blebbing and the eventual destruction of the cell. The initiation 
of apoptosis in target cells via cross linking of cell surface receptors by effector CTL 
is accompanied by an increase in intracellular Caz+ (McConkey et at, 1989). It has 
been suggested that the rise in intracellular Ca2+ initiates the action of endogenous 
endonucleases which bring about pre-lyric DNA fragmentation, although the link has 
not been shown experimentally. The Fas/Fas ligand interaction plays a role in the 
initiation of apoptotic cell death in a number of systems (Nagata & Suda, 1995). Fas 
ligand is a factor which binds its receptor, Fas (CD95), and induces cell death by 
apoptosis. A role for this interaction in CTL killing has been suggested as CTL 
hybridomas have been isolated which kill Fast cells but not Fas' cells (Rouvier et. al., 
1993). Whatever the mechanism, DNA fragmentation occurs followed by membrane 
blebbing and cell lysis. CTL DNA fragmentation can be detected within 10-15 
minutes after effector-target cell binding. Any intracellular viral DNA present during 
this process may also be degraded by the endogenous endonucleases (Martz & 
Howell, 1989). Although this model was first described by Russell in 1983 the 
triggering mechanism and the target cell "second messenger" responsible for the 
induction of DNA fragmentation has still to be defined. 
The second model of CTL mediated lysis of target cells is the granule exocytosis 
model. The initial steps of this model are the adhesion between granular CTL and the 
target cell, and the polarization of the CTL cytoplasm towards the target cell. This 
polarization allows the CTL to deliver a lethal hit to the target cell without affecting 
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the surrounding cells. The lethal hit consists of the secretion of the pre-formed 
contents of cytoplasmic granules into the gap junctions between the CTL and the 
target cell. Isolated granules from CTL and NK cells contain a 65kD protein called 
perform (or cytolysin), hydrolytic lysosomal enzymes, several serine proteases 
(granzymes) and proteoglycans. The perforin molecule is able to polymerise in the 
presence of Caz+ to form hollow tubular structures which span the membrane of the 
target cell. Perforin is antigenically related to the ninth component of complement 
(C9). After the polymerization of perforin and the subsequent pore formation, serine 
protease influx into the target cell has been implicated in the observed DNA 
breakdown. The evidence for this comes from experiments in which DNA lytic 
activity was inhibited using protease inhibitors and target cells were lysed using 
mixed, purified preparations of serine protease and perform (Hayes et. al., 1989). 
Recently, the granule exocytosis model of CTL killing has been shown to be 
important in vivo by the development of perforin deficient mice (Kagi et. al., 1994). 
These mice have normal numbers of both CD8+ cytolytic T cells and NK cells which 
do not lyse virus infected or allogeneic fibroblasts or natural killer target cells (e. g, 
YAC-1 cells) in vitro. However, cytolytic activity against LCMV peptide labelled 
RMA lymphoma cells was observed using cells from these mice, which suggests that 
a second cytolytic mechanism exists. This residual cytotoxic activity appeared to be 
mediated by Fas ligand (Lowin et. al., 1994) 
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1.2.4.6. Immunity to herpes simplex virus in the mouse 
Innate mechanisms represent a formidable barrier to infection with herpesviruses (see 
section 1.3.1. ). However, if this barrier is breached and infection becomes 
established, adaptive immune responses, in particular T cell responses, play a major 
role in elimination of virus from infected tissues and subsequent recovery from 
infection. A large body of work has been produced in which basic mechanisms of T 
cell immunity to most of the herpesviruses have been studied. 
The most widely studied virus in the herpesvirus group is the prototype a-herpesvirus, 
Herpes Simplex virus (HSV). One of the reasons for the predominance of HSV 
research is the existence of well characterised animal models of human disease. The 
HSV mouse model is, in fact, a collection of different models some of which resemble 
HSV infection in humans. The main differences between murine and human HSV 
infection are that systemic infections of mice usually result in death of the animal and 
secondary and recurrent infections cannot be demonstrated in the mouse. It is clear 
that, if a disease model is to be used experimentally, then attempts must be made to 
ensure that it has some relevance to the host animal. For example, experiments using 
the intra-peritoneal (IP) route of infection show little resemblance to the muco- 
cutaneous route seen in humans, are very much influenced by innate immune 
mechanisms and give little quantitative information on the growth of HSV as the end 
point is death; therefore the usefulness of the IP mouse model is questionable. 
However, the ear clearance (EC) or the footpad clearance (FC) mouse models allow 
quantitative assessments of the level of virus growth in the tissues of the animal and 
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the rate of clearance of the virus after adoptive transfer of virus specific antibodies or 
immune cells after challenge. Despite these problems, the HSV mouse models have 
proven to be reliable tools for the delineation of basic mechanisms involved in 
immunity to HSV. 
Initial, adoptive transfer experiments showed that HSV immune T cells protected X- 
irradiated and anti-thymocyte antibody treated mice against an otherwise lethal HSV 
infection (Oakes, 1975). This was confirmed when adoptive transfer of immune T 
cells to congenitally athymic (nude) mice protected them against lethal HSV infection 
whereas transfer of neutralising antibody merely prolonged the survival time of the 
mice (Nagafuchi et. al., 1979). Later it was shown that neutralising antibody does 
play a role in anti HSV immunity in mice when Kapoor et. al. (1982a) showed that 
HSV infection of B cell suppressed mice resulted in a more florid infection of the 
ganglia and spinal cord which led to a higher incidence of latency. Conclusions from 
this and another study (Kapoor et. al., 1982b) suggested that neutralising antibody 
plays a role in restricting the spread of HSV to the nervous system whilst CMI is 
important in clearing virus from the site of infection. 
The mouse models of HSV disease have also produced data which outline the roles of 
T cell sub-sets in the clearance of virus from various tissues, Nash & Gell (1983) 
showed that activated CD4* T cells could transfer DTH to mice which could then 
clear infectious virus from epidermal surfaces. These cells produce IFNy and have 
the general properties of Thl cells (Seid et. al., 1987). The mechanism by which 
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IFNy producing CD4; T cells cleared virus from the tissues was discussed by Nash & 
Cambouropoulos (1993) who suggested that IFNy induced the recruitment of 
monocytes from the blood which accumulated at the site of infection and became 
activated macrophages under the influence of IFNy. These were then able to clear 
virus via the production of TNFa, IFNa/p, arginase and cationic proteins. 
The role of CD8+ T cells, particularly CTL, in the clearance of HSV from infected 
tissues is controversial. Adoptive transfer of HSV specific CTL protects mice against 
disease (Larsen et al., 1983, Sethi et. al., 1983), however, the relevance of in vitro 
matured or cloned CTL to the in vivo situation is questionable. Nash et. al., (1987) 
showed that CD8 'T cells contribute to the control of infectious HSV in the neurons, 
however, the lack of any neural cell damage caused by these cells suggests that 
cytolysis was not a major mechanism in controlling virus levels. A study by Smith et. 
al., (1994) specifically designed to elucidate the roles of CD4+ and CD8* T cells in the 
clearance of HSV from the footpad of C57BL/6 (B6) mice showed that depletion of 
both subsets resulted in failure to clear virus from the skin. Depletion of either CD4* 
or CD8' T cell subsets, using monoclonal antibodies, had little effect on the amount of 
virus isolated. Interestingly, depletion of either subset abolished CD8+ CTL activity 
from the lymph nodes and the spleen, confirming that, in B6 mice, the anti HSV CTL 
response was CD4' T cell dependent (Jennings et, al., 1991). These data suggest that 
the mechanism of virus clearance was common between both subsets and, whilst 
cytolytic mechanisms active in the skin, could not be discounted, IFNy dependent 
mechanisms were implicated as mice injected with neutralising anti-IFNy antibody 
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failed to clear virus from the footpad. It is now well documented that CD8* T cells as 
well as CD4; T cells are able to produce relatively high levels of cytokines, 
particularly IFNy (Fong & Mossman, 1990. Taguchi et. at, 1990). 
The ultimate goal of many viral immunologists is to identify the minimal epitopes 
present in virus proteins which are recognised by specific antiviral T cells. This can 
be achieved on a number of levels, for example, T cells can by distinguished as type 
specific or cross-reactive (Doherty et. al., 1977), the broad classes of proteins 
recognised by antiviral T cells can be determined (Tigges et. al., 1992), the specific 
virus proteins which elicit aT cell response can be identified, and ultimately, the 
minimal T cell epitopes within a protein can be isolated (Bonneau et. al., 1993). 
Analysis of these responses in in-bred mouse strains is the norm in this type of study 
although it is likely that mouse strain-specific epitopes will be identified. 
Initial studies identified HSV glycoproteins as being important in stimulating cell- 
mediated immunity and in particular, CTL (Lawman et al., 1980a, Carteret al., 
1981). The use of T cell cloning methods indicated that the majority of HSV specific 
CTL clones from C57/BI mice recognised the glycoprotein gC (Glorioso et. al., 
1985). Rosenthal et. al. (1987) showed that HSV-specific CTL from CBA mice 
recognised gC but not gB, gD or gE. Studies using recombinant vaccinia viruses 
expressing isolated glycoproteins from HSV (Mester & Rouse, 1991) have shown that 
a gC expressing recombinant generated gC specific CTL in b haplotype mice but not 
in k or d haplotype mice. In the same study recombinant vaccinia viruses expressing 
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gB or gD were unable to consistently generate CTL activity. However, expression of 
gB and gD in mouse L cells and subsequent immunisation of mice with these cell 
lines did elicit protective responses (Blacklaws et. al., 1987). Vaccination of Balb/c 
mice with recombinant baculoviruses expressing seven different HSV-1 glycoproteins 
showed that protection against lethal intraperitoneal or ocular challenge was 
stimulated using gB, gC, gD, or gI recombinants (Ghiasi et. al., 1994). DTH 
responses in these mice were highest on day 3 using gG, gH or gE recombinants and 
on day 6 using gC, gE and gI recombinants. The same five glycoproteins expressed in 
recombinant baculoviruses (i. e. gC, gE, gß, gA and gI) which stimulated protection 
also elicited CTL activity, although the anti gE response only stimulated CTL 
measurable at the 100: 1 effector: target ratio. The minimal epitope on gB recognised 
by HSV-1/2 cross-reactive CTL derived from C57BV6 (H-2b) mice was determined by 
Bonneau et. al. (1993). In this study, CTL clones were isolated which recognised an 
epitope consisting of residues 498-505 from HSV gB. Immunisation of mice with the 
free synthetic peptide resulted in the generation of CD8+ CTL in lymph nodes. In a 
further study by the same group (Salvucci et. a!., 1995) HSV-1 specific CTL clones 
were isolated from H-2Kb mice which recognised an epitope on the HSV-1 non- 
structural ribonucleotide reductase large subunit (ICP6) consisting of residues 822- 
829. 
Other non-structural viral proteins, for example the immediate early (IE) proteins, 
have been investigated as target antigens for CTL in the mouse. The HSV IE proteins 
ICP4 and ICP27 act as target antigens in H-2b and H-21 mice respectively (Martin et. 
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al., 1990, Banks et. al., 1991). ICP27 expressed in a recombinant vaccinia virus 
stimulated HSV-1 specific CTL activity and also protected mice from a lethal 
challenge with HSV-1 and HSV-2 (Banks et. al., 1991). Two minimal T cell epitopes 
were generated from ICP27 (Banks et. al., 1993). Both peptides, residues 322-332 
and 448-456, sensitised target cells for recognition by HSV-specific CTL and 
generated primary CTL in vitro. The advantage of using non-structural proteins as 
CTL epitopes rather than viral glycoproteins is that the virus may be eliminated before 
progeny virus is produced. 
In summary, the recognition of antigens by HSV-specific T cells in mice depends on 
the mouse strain being studied, the method of production of the antigen and the route 
of infection of any subsequent challenge. However, it does seem likely that T cells 
recognise a spectrum of HSV proteins during an active infection, including the non- 
structural proteins and a number of glycoproteins. 
1.2.4.7. Immunity to HSV in humans 
In recent years, research on the murine immune response to HSV has outweighed 
research on the human response. Studies in humans have concentrated on the CTL 
responses to HSV, although some papers outline the proliferative and cytokine 
responses, especially to viral glycoproteins. For example, Torseth et. al. (1987) 
showed that combinations of purified glycoproteins stimulated in vitro lymphocyte 
proliferation and cytokine production as efficiently as whole HSV preparations. 
Zarling et. al. (1986) demonstrated that purified HSV gB-1 and gD-1 stimulated 
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proliferation, IL-2 production and CTL activity in PBMC from HSV sero-positive 
individuals. Damhof et. al., (1993) used overlapping peptides derived from gD to 
stimulate proliferation of PBMC from 10 healthy HSV sero-positive individuals. The 
results from this study suggested that there was no correlation between sero-positivity 
and proliferative response and that there were no immuno-dominant epitopes within 
the gD molecule, at least as far as the proliferative response was concerned. Antigen- 
specific proliferation assays were useful in the detection of immune activity in sites 
other than the blood, for example, Mathiesen et. al. (1990) demonstrated antibody 
producing and proliferative lymphocytes in peripheral blood and cerebro-spinal fluid 
from patients with HSV encephalitis. 
HSV-1/HSV-2 cross-reactive and HSV-1 type common T cell clones which were both 
cytotoxic and able to proliferate in vitro were isolated in a study by Yasukawa & 
Zarling (1984). These T cells were CD4+CD8' and also had the capacity to produce 
IL-2. The multi functional nature of these CTL clones and the class II MHC 
restriction was probably due to the use of UV inactivated virus in the cloning 
procedure. The stimulation of anti-IHSV CD4+CD8' CTL using UV inactivated virus 
was confirmed (Schmid, 1988 and Torpley et. al., 1989) although the contention by 
Schmid that the human CTL response to HSV-1 was mainly restricted by class II 
MHC fuelled debate. It is now clear that, whilst induction of CTL in vitro with 
inactivated HSV results in CD4+CD8' CTL, the more relevant induction using 
infected cells results in the stimulation of, mainly, CD4-CD8+ CTL (Yasukawa et. al., 
1989 and Maccario et al., 1992). However, the isolation of T cell clones derived 
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directly from HSV-2 lesions and stimulated in vitro in cultures containing no HSV 
antigen resulted in CD4+CD8' clones exhibiting proliferative or cytotoxic activity 
against numerous epitopes within gB, gC, gD and VP 16 (Koelle et. aL, 1994). Tigges 
et. al. (1992) demonstrated that seven CD4-CD8' CTL clones recognised five 
different patterns of HSV proteins with one clone recognising HSV IE protein and six 
recognising virion proteins amongst them gD but not gB or VP 16 (the tegument 
protein). 
1.2.4.8. Immunity to other herpesviruses 
As outlined above, the immune response to HSV has been widely studied. Significant 
progress has also been made in the study of the immune response to other 
herpesviruses. 
T cell-mediated immunity is important in maintaining the latent state of VZV as 
shown by the occurrence of VZV reactivations in elderly patients whose T cell, but 
not antibody, levels have been reduced as a result of ageing (Hayward & Herberger, 
1987). The T cell proliferative response of PBMC to VZV antigens has been used to 
correlate virus-specific CMI with disease outcome (Arvin, 1992). For example, 
immunodeficient children who fail to acquire a VZV proliferative response develop 
progressive disseminated disease, whereas, healthy children who develop a detectable 
response after the appearance of a varicella rash develop a mild primary VZV disease. 
Studies on the T cell response to VZV have been stimulated by the fact that 
vaccination with the live attenuated Oka strain of VZV occasionally results in clinical 
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symptoms of herpes zoster in vaccinated individuals as a result of reactivation of the 
vaccine strain (Lawrence et. al., 1988). The need to replace the live attenuated 
vaccine has led to numerous studies to determine which VZV proteins stimulate CMI. 
In T cell proliferation assays, gpl, gpIII and p170 (the product of the VZV IE gene) 
are recognised (Arvin et. al., 1986). Hayward showed that gpII and gpIV synthetic 
peptides stimulated CD4* cells to proliferate (Hayward, 1990). Natural infection also 
elicits CMI against gpII and gpV. Responses to all of these proteins lasts for years 
after primary infection (Arvin, 1992). Both CD4+ and CD8' CTL have been 
demonstrated after VZV infection (Arvin et. al., 1991). These CTL recognise gpl, 
gpIV, gpV and p170 (Huang et. al., 1992). 
There is little correlation between anti-PRV antibody titre and protection against 
infection with PRV (Martin et. al., 1986, Matsuda-Tsuchida et, al., 1992). Anti-PRV 
CTL activity has been demonstrated in pigs and in a mouse model of PRV disease 
(Zuckermann et al., 1990). In this study, CD4-CD8+ CTL were induced using PRV 
and assayed on target cells infected with mutant PRV viruses lacking one of the non- 
essential glycoproteins gI/gp63, gX or gIII. The results show that lysis of targets 
lacking gIII was significantly reduced when compared with targets infected with the 
wild type virus or viruses lacking the other glycoproteins. This result indicated that 
the gill molecule was recognised by anti-PRV CTL. 
CTL against the bovine respiratory virus Bovine herpesvirus-I (BHV-1) were first 
demonstrated by Campos and Rossi (Campos & Rossi, 1986). It was shown that 
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different BHV-1 glycoproteins were recognised by CTL depending on the method of 
in vitro stimulation (Denis et, al., 1993). In this study, target cells expressing gIV 
were lysed when CTL were induced using fixed infected fibroblasts whilst gIII 
expressing target cells were predominantly lysed when CTL were induced with UV 
inactivated virus. This result suggests that the antigenic specificity of CTL detected 
in vitro could be influenced by the culture system used. 
Anti CMV antibodies are not important in protection of patients from CMV infection 
as seropositive allograft recipients are still at risk of reactivation or super-infection 
with CMV (Pasternack et. al., 1990). Studies of murine CMV (mCMV) have shown 
that the dominant antigens recognised by anti mCMV CTL were the products of the 
IE genes (Reddehase & Koszinowski, 1984). This result indicates that the search for 
immunodominant antigens should not be restricted to the structural proteins. 
1.2.4.9. Evasion of the immune response 
Many viruses have evolved mechanisms by which they evade the immune responses 
of the host. Antigenic drift, the gradual changes in the antigenicity of the HA 
molecule in the influenza A viruses, is probably the best studied escape mechanism 
(Webster et. al., 1982). Antigenic drift is a result of pre-existing antibody guiding the 
evolution of new influenza strains. A similar type of escape from CTL recognition 
has been demonstrated in vitro for lymphocytic choriomeningitis virus (Aebischer et. 
al., 1991). 
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Human immunodeficiency virus (HIV) employs numerous mechanisms in order to 
evade the host immune response. Firstly, it infects cells of the immune system which 
may prevent them from mounting a relevant response. Secondly, sequence variations 
within the CTL epitopes of HIV proteins mean that the virus can replicate in the face 
of a vigorous CTL response (Koup, 1994). Recent studies have shown that HIV is 
able to stimulate an oligoclonal B cell response which predominates in the face of 
HIV mutation. The resultant, altered virus is then able to escape neutralisation by the 
oligoclonal antibody (Kohler et. al., 1995). 
Retroviruses also affect the host immune response by inducing a state of 
hyporesponsiveness in T lymphocytes (Orosz et al., 1985). A similar phenomenon 
has also been reported in association with infection with measles virus (Lucas, 1977), 
herpes simplex virus (Plaeger-Marshal & Smith, 1978) and EHV-1 (Hannant et. al., 
1991). Persistence of herpesviruses within the host is facilitated by latency (Ahmed, 
1990). Latency allows herpesviruses to avoid immune recognition until the host 
immune system is compromised at which point reactivation occurs. 
Viral structural proteins may be directly immuno-suppressive as Newman et. al. 
(1991) reported for equine infectious anaemia virus. Certain viruses contain genes the 
products of which, interfere with immune processes. Human CMV expresses a 
homologue of MHC class I heavy chain which can bind to ß2M preventing the 
maturation of cellular class I molecules and subsequent recognition by CTL (Browne 
et. al., 1990). Infection of human dermal fibroblasts with HSV has also been shown 
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to result in the down regulation of the cell surface MHC class I (Hill et. al., 1994). 
Epstein-Barr virus has the potential to suppress the host's immune system due to the 
presence in its genome of an IL10-like gene; this cytokine is capable of inhibiting 
Thl T cell responses (Moore et. al., 1990). A similar gene is present in the equine 
herpesvirus 2 genome (Rode et al., 1993) but this has not been described for EHV- 1. 
Ward et. al. (1990) reported that the transient depression of DTH and mitogen 
induced proliferation of human PBMC after measles virus infection (or vaccination 
with a live vaccine) was related to the preferential activation of Th2 cells producing 
high levels of IL4. This preferential activation of either Thl or Th2 cells may have 
the effect of skewing the immune response away from an effective response. This 
also may occur after infection with HIV (Clerici & Shearer, 1993). 
1.3. Equine herpesvirus types 1 and 4 
EHV-1 and EHV-4 are primarily transmitted via inhalation of infected particles and 
acute infections with both viruses causes respiratory disease. Infection with EHV-1 
may also result in abortion and neurological disease (Allen & Bryans, 1986). Both 
EHV-1 and EHV-4 have the capacity to become latent, probably residing in the 
lymphoreticular system (Welch et. al., 1992). Together, these viruses cause 
considerable, worldwide economic loss within the racing and breeding industries. 
1.3.1. Pathogenesis 
Infection of young, immunologically naive, horses with either EHV-1 or EHV-4 is 
clinically manifest by a biphasic pyrexic response and a serous nasal discharge which 
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rapidly becomes mucopurulent (Allen & Bryans, 1986). Anorexia and depression, 
coughing, enlarged intermandibular and retropharyngeal lymph nodes and congestion 
of the nasal mucosa may also occur (Bryans, 1964,1980. Coggins, 1979). In older, 
immunologically experienced animals infection may give rise to mild or inapparent 
clinical symptoms (Bryans, 1981). The majority of studies on the pathogenesis of 
EHV infection have looked at EHV-1. Strains of EHV-4 are usually cleared from the 
respiratory tract within 7 to 20 days after primary infection and within 2 to 7 days 
following subsequent infections (Mumford, 1994). Infection with EHV-4 in most 
instances is limited to the respiratory tract because the virus does not usually cause a 
cell associated viraemia (Burrows & Goodridge, 1972. Edington et. al., 1986). EHV- 
4 is, therefore, often perceived as a less severe, primarily respiratory, infection 
(Coignoul et. al., 1984) although in very rare cases it may cause viraemia and 
abortion. 
After inhalation of infected particles EHV-1 replicates in the epithelial lining of the 
respiratory tract and spreads, intracellularly. Patel et. al. (1982) showed that 
infectious virus and viral antigens were present in the nasal mucosa, lungs and 
retropharyngeal lymph nodes 4 days after infection and in the submandibular lymph 
nodes 8 days after infection of a naive foal with EHV- 1. Some EHV-1 strains then 
infect vascular endothelial cells (Patel et. al., 1982. Edington et. al., 1986) and 
subsequently cause a cell-associated viraemia, abortion andlor paresis (Edington et. 
al., 1991). However, some other EHV-1 isolates do not replicate in endothelial cells. 
Kydd et al. (1994a & 1994b) showed, using both virus isolation and an indirect 
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immunoperoxidase technique to detect viral antigens, that EHV-1 was present in the 
lymph nodes draining the respiratory tract of horses within 12 hours after infection 
with a known abortogenic strain of EHV-1 (EHV-1/Ab4) which was originally 
isolated from a paraplegic gelding (Edington et. al., 1986). A model for the 
progression of this strain of EHV-1 from the respiratory tract was suggested (Kydd et. 
al., 1994b) in which a productive infection of the epithelial lining of the nasopharynx 
results in spread of the virus through susceptible cells, including leucocytes, resulting 
in the infection of vascular or lymphatic endothelium and the establishment of 
viraemia. Edington et. al. (1986) showed that endothelial cell infection, followed by 
thrombus formation, associated haemorrhage and ischaemic anoxia in the central 
nervous system occurred in animals infected with EHV-l strain Ab4. Endothelial cell 
infection by EHV-1 was also implicated in the pathogenesis of EHV-1 strain A183- 
induced abortion (Edington et. al., 1991). The endotheliotropism of EHV-1 has been 
demonstrated by immunohistochemical investigation of a natural outbreak of EHV-1 
abortion and neurological disease (Whitwell & Blunden, 1992). 
The mechanisms involved in the abortion of the equine foetus due to EHV"1 remain 
elusive although recent studies have shown that infection of endothelial cells is 
associated with endometrial vasculitis and thrombosis (Smith et. aL, 1993). In the 
model suggested by Smith et. al. the degree of thrombosis determines the outcome of 
pregnancy. Widespread thrombus formation and severe endometrial infarction results 
in the early expulsion of a virus-negative foetus; limited infarction results in the 
expulsion of a virus-positive foetus and no infarction results in a normal foetus. The 
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occurrence of virus-negative aborted foetuses prior to a major EHV-1 induced 
abortion storm has been documented (Mumford et. al., 1987). Such foetuses are also 
produced in a proportion of animals after experimental challenge of pregnant pony 
mares with EHV-1 strain Ab4 (Smith et. al., 1992). In these cases, abortion results 
from virus-induced immunopathology at the maternal side of the materno-foetal 
interface and consequent rapid expulsion of the foetus, before infection becomes 
established. 
1.3.2. The antibody response 
Doll (1961) showed that horses become susceptible to re-infection with a homologous 
strain of EHV-1 3-5 months after a primary infection. This re-infection can take place 
despite the presence of high levels of virus neutralising antibody in the serum 
(Mumford et al., 1987). Notwithstanding the apparent insignificance of antibody to 
protection against EHV-1 infection, a considerable amount of work has been carried 
out on characterising the antibody response to EHV-1/-4 in conventionally reared 
(Coignoul et a1., 1984. Stokes et. al., 1991. Dolby et. al., 1995) and SPF (Gibson et. 
aL, 1992a) horses. After EHV"1 or EHV-4 infection of naive horses, antibody, as 
measured using a complement fixation (CF) or virus neutralisation (VN) assay, 
appears in the serum after approximately 6-8 days (Stokes et. al, 1991. Gibson et. al., 
1992a). VN antibody is relatively long lived persisting for months after infection, 
particularly in older animals. CF antibody becomes undetectable relatively quickly 
after infection (Thomson et. al, 1976b) making this a reliable marker for recent 
exposure to the virus. After secondary infection an anamnestic response occurs. 
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The production of a wide range of anti EHV-1 and EHV-4 monoclonal antibodies has 
allowed improvements in the diagnosis (Dutta et. al., 1983. Allen & Bryans, 1986. 
Sinclair & Mumford, 1992) and epzootiological (Matsumura et. al., 1992) aspects of 
EHV infection. However, the cross-reactive nature of most EHV-1/-4 glycoproteins 
limits the usefulness of these reagents (Crabb & Studdert, 1990. Crabb et. at., 1991. 
Sinclair, 1991). Recently, an EHV-4 type specific glycoprotein (gG) has been 
identified (Crabb et. at, 1992); the EHV-1 counterpart also contains type specific 
epitopes (Crabb & Studdert, 1993). 
One aspect of the antibody response to EHV-1 or EHV-4 which has not been 
extensively studied, yet holds great potential to control natural infections with both 
viruses is that of mucosal immunity. The fact that both EHV-1 and EHV-4 infect 
mucosal surfaces initially suggests that infection could be blocked via the stimulation 
of mucosal antibody. This has been achieved experimentally with BHV-1 (Israel et. 
al., 1992) using mucosal vaccination with inactivated antigens. Nasopharyngeal 
antibody was stimulated in horses vaccinated with EHV-1 in Freund's complete 
adjuvant (Dolby et. a!., 1995). These horses were protected from experimental 
infection. More work needs to be done in this area. 
1.3.3. Cell-mediated immunity 
Until recently, the study of CMI responses of horses to EHV-1 or EHV-4 concentrated 
on the in vitro proliferation of isolated equine PBMC (Thomson & Mumford, 1977, 
Dutta et aL, 1980). Valuable data were obtained from these early studies; for 
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example, Dutta & Campbell (1977) showed that some mares with high VN antibody 
titres and proliferative responses to inactivated EHV-1 antigen aborted after infection 
whilst others did not. This suggested that neither of these immune functions were 
reliable markers of protection against infection with EHV-1. 
Thomson & Mumford (1977) produced the first evidence that equine mitogen- 
stimulated PBMC were able to support a productive infection with EHV-1 (strain 
RAC-H). These workers also produced evidence that infection of horses with certain 
strains of EHV-1 suppressed in vitro lymphocyte functions (Thomson & Mumford, 
1977. Dutta et. al., 1980). Hannant et. al. (1991) showed that the in vitro response of 
equine PBMC to the mitogen PHA was suppressed in 6 ponies after infection with 
EHV-1 (strain V592), whereas antigen-specific proliferative responses in these 
animals were not suppressed. This immunosuppression induced by infection with 
EHV-1 may predispose horses to more severe, unrelated infections. 
The pace of research into the CMI response to EHV-1/-4 has been accelerated by the 
provision of monoclonal antibodies specific for equine lymphocyte cell surface 
markers (Kydd et. al., 1994c). These monoclonal antibodies are invaluable in studies 
of the phenotype of responding cells. 
A mouse model of EHV-1 infection has been developed (Awan et. al., 1990) in order 
to study the pathogenesis of and immune response against EHV-1. Despite major 
differences to EHV-1 infection of the horse (low antibody titres, failure to induce VN 
51 
antibody and relatively long-lived immunity stimulated by infection), studies have 
demonstrated that DTH responses develop in infected mice (Azmi & Field, 1993a). 
These were of a higher magnitude in intranasally infected than in intravenously 
inoculated mice, although intravenous inoculation produced a higher antibody 
response. Further studies showed that EHV-4 was apathogenic in BALB/c mice 
although exposure to EHV-4 conferred some protection against EHV-1 infection (a 
reduction in the level of virus excreted from the respiratory tract). In vivo depletion of 
CD4' or CD8' cells from EHV-4 infected (EHV-1 immune) mice prior to infection 
with EHV-1 showed that only depletion of CD8* cells resulted in a reduction of the 
protective effect. Although the protective immune response resulted in a reduction in 
the amount of virus isolated from the tissues, this did not necessarily, correlate with a 
reduction in mortality (Azmi & Field, 1993b). 
Recently, Allen et. al. (1995) have developed methods for the characterisation of the 
anti EHV-1 CTL response of horses after infection. This will prove valuable in the 
evaluation of the role of CTL in protection against EHV-1 infection. 
1.3.4. Vaccination 
Although effective management of horses at stud can go some way to reducing the 
incidence of EHV infections, vaccination of the horse population with an effective 
vaccine is the only practical way to prevent EHV disease. 
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The observation that mares rarely abort as a result of EHV-1 infection in consecutive 
seasons prompted a large scale planned infection of mares in Kentucky. The virus 
used was a partially attenuated, hamster adapted strain of EHV-1 (Rac-H). Rates of 
abortion were reduced from 30% in the untreated population to 1.5% in treated 
animals as a result of the planned infection (Doll & Bryans, 1963). 
Two subsequent commercially produced live attenuated vaccines based on the Rac-H 
strain were produced. Rhinomune (Beckenhauser & Bass, 1973) was further passaged 
in equine cell culture and Prevaccinol (Mayr, 1970) was further passaged in pig 
kidney cells. Both of these live attenuated vaccines were shown to cause a low 
incidence of abortion. Following field immunisation studies with Rhinomune, a virus 
identical to the vaccine strain was isolated from aborted foetuses (Allen et. al., 1983). 
Similarly the vaccine virus was isolated from aborted foetuses after intra-uterine 
inoculation (Burrows & Goodridge, 1978) with the vaccine Prevaccinol. 
As it is clearly difficult to produce a safe and effective live attenuated vaccine for 
control of EHV-1, attempts have been made to produce killed or subunit vaccines. A 
commercially licensed, killed vaccine, Pneumabort K, was introduced in 1980. This 
contained EHV-1 strain A183 grown in equine cell culture, inactivated with 
formaldehyde and combined with an oil adjuvant. Although Pneumabort K failed to 
prevent abortion in some individual animals (Burrows et. al., 1984) it's widespread 
use in the Kentucky area has more than halved the number of abortions per 1000 
mares. 
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The techniques are now available with which to produce subunit vaccines although 
none have been licensed for use as yet. Potential vaccines based on the production of 
mutant viruses lacking genes that determine virulence, large amounts of isolated viral 
antigens (e. g. glycoproteins) and hybrid viruses incorporating genes from EHV-1 and 
EHV-4 have all attracted research effort recently. 
As mentioned above, perhaps the best candidate for an effective and safe EHV-1 
vaccine is a mucosally applied preparation combining viral proteins with adjuvants 
which target the antigens to lymphoid tissue. This type of vaccine is still some way 
from even being experimentally produced. 
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2.1. Introduction 
As outlined in the previous chapter, CTL may be generated in vivo by herpesvirus 
infection (Rouse & Horohov. 1984) and also, under certain circumstances, using 
isolated viral proteins (Bachmann et. al., 1994). On secondary culture of lymphoid 
cells in vitro with specific antigen, precursor cytotoxic T lymphocytes (CTLp) are 
induced to develop into effector CTL capable of killing virally infected cells in an 
antigen specific, genetically restricted manner. The measurement of effector CTL 
involves providing optimum conditions under which effector and target cells 
recognise each other via contact between the T cell receptor and MHC/peptide 
complex. A stable conjugate, strengthened by non-specific attachments between 
numerous molecules (e. g. LFA-1 to ICAM-1, CD2 to LFA-3 and CD8 to MHC class 
I), is formed which leads to the delivery of a lethal hit to the target cell. The 
mechanisms involved in the delivery of the lethal hit are outlined in chapter 1. 
The quantitation of this process in vitro is usually carried out by means of the release 
of radioactive label from target cells - the "Chromium release assay. As applied to 
viral infections, the assay is performed by mixing virus-infected or peptide pulsed, 
autologous, 51Cr labelled target cells with putative effector CTL populations 
(Zweerink et al., 1977). After a period of time, the cells are removed by 
centrifugation and the amount of 5 Cr released by the target cells is estimated by 
counting the radioactivity in cell-free supernatants in a gamma counter. The released 
radioactivity (i. e. s'Cr) must be considered to be proportional to the amount of target 
cell lysis rather than an exact measure of it (Martz, 1993). Other factors affecting the 
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release of "Cr are the type of target cell used, the history of the target cell (i. e. the 
labelling procedure, time since labelling etc), the chemical environment prior to lysis 
and the time interval between lysis and separation of soluble from insoluble S'Cr. 
When labelled with IICr a target cell will spontaneously release between 1% and 10% 
of the total incorporated radioactivity per hour (Martz, 1993). This leakage is mainly 
due to cell damage during preparation although isotope may also be slowly released 
from some viable cells. This effectively limits the duration of cytotoxicity assays to a 
maximum of about 18 hours. However, the majority of "Cr release assays used in 
viral systems are performed over a period of between 4 and 6 hours. Control 
measurements are a necessary part of "Cr release assays. Spontaneous release of 
label over the period of the assay is measured by culturing target cells without effector 
cells. This should always be less than 35% of the total releasable label as spontaneous 
release exceeding 35% may not represent lysis at all, but changes in the chemical 
association of the label with cellular debris (Martz, 1993). Measurement of total 
releasable label (an assessment of 100% lysis) is carried out by lysing the target cells 
using either detergents (e. g. triton x100 or NP40) or by freezing and thawing the 
target cells. Either of these two measurements are used to calculate the % specific 
release of label. Detergent lysis often produces higher total releasable values than 
freezing and thawing presumably due to the proteins being released from membrane 
fragments. 
Other methods for quantitation of cytolysis do exist, for example the amount of target 
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cell killing in a culture can be assessed by counting the number of dead cells which 
are able to take up a dye reagent e. g. trypan blue or eosin. These counting methods, 
although used extensively in early cytotoxicity studies (Takasugi & Klein, 1970) are 
now recognised as being subjective, tedious and imprecise. 
However, there are disadvantages in using "Cr release assays to measure CTL 
activity. They are unable to provide precise measurements of high levels of killing 
because of the crude means of assessing 100% lysis. However, when used under 
optimum conditions the major advantages of "Cr as a target cell label are that it is 
relatively non-toxic to the target cells, is not significantly reutilised by effector cells 
on release from target cells and allows the processing of large numbers of effector 
populations in one assay (Martz, 1993). 
A wide range of target cell types have been used to quantify CTL activity (e. g. 
hepatocytes by Ayres et. al., 1991, kidney cells by Mc Guire et. a!., 1994, 
macrophages by Kasper er at., 1992). In theory, any cell type which expresses the 
appropriate MHC can be used as a target cell for CTL. However, the limitations of 
the assay mean that cells which spontaneously release high levels of chromium and 
those which cannot present viral peptides to active CTL are unsuitable. The target 
cell type should also be easy to isolate and manipulate in vitro. The popularity of 
murine models for human and other animal diseases, means that murine MHC typed 
fibroblastic cell lines are increasingly being used as targets (Shultz et. al., 1991). In 
many human diseases CTL may be measured using Epstein-Barr virus transformed B 
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cells as targets (Green et. al., 1993). In order to measure anti EHV-1 specific CTL, 
the target cell must also be permissive to infection with the virus. Moreover, it is 
desirable for the majority of the permissive target cells in a population to be infected. 
The infection of the majority of the target cells means that viral peptides are likely to 
be presented in the context of MHC molecules and the target cells are therefore likely 
to be recognised by CTL. 
In summary, the critical properties of a useful CTL target are, ease of isolation and 
handling, retention of the majority of the label (more than 65%) over the period of the 
CTL assay and the presentation of viral peptides within MHC on the surface of the 
majority of the permissive cells in the target cell population. 
This chapter outlines experiments carried out in order to evaluate a range of equine 
cells as potential targets for use in an EHV-1 specific CTL assay. Cells were isolated 
from peritoneal fluid, vascular endothelium and peripheral blood mononuclear cell 
(PBMC) preparations and tested for their permissiveness to EHV-1 infection, and 
ability to retain "Cr label. 
2.2. Materials and Methods 
2.2.1. Isolation of equine peritoneal macrophages 
Equine peritoneal fluid was collected by mid-line puncture of the peritoneal cavity of 
adult mares with a large gauge needle under local anaesthesia. The fluid was 
collected into preservative-free heparin, centrifuged, and the cells were washed in 
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Hank's balanced salts solution (HBSS). Peritoneal macrophages (PM) were isolated 
from the polymorphonuclear leucocytes in the fluid by adhering them to the plastic 
surface of a sterile petri dish for 60 minutes at 37°C. The non-adherent cells were 
removed from the dish which was washed in HBSS. The PM were scraped from the 
dish into complete RPMI (cRPMI) using a rubber policeman. 
2.2.2. Isolation of equine vascular endothelial cells 
Equine vascular endothelial cells were isolated at postmortem from the carotid artery 
using the method of Lamar et. al. (1986). The isolated cells were maintained in T1 SO 
tissue culture flasks and passaged when confluent. They were periodically tested for 
the expression of the endothelial cell marker von Willibrands factor using a specific 
monoclonal antibody (Dako) in the immunoperoxidase test described in 2.2.6. 
2.2.3. Production of in vitro matured PBMC 
Blood was collected from horses by jugular venipuncture into preservative-free 
heparin (300 units per 20ml tube) using evacuated blood tubes (Vacutainer, Becton 
Dickinson). The blood was kept at room temperature for approximately 30 min until a 
distinct leucocyte rich plasma layer could be seen. The leukocyte rich plasma was 
gently layered onto 3ml of Ficoll Hypaque (Pharmacia) in a 10ml conical centrifuge 
tube so that a distinct interface could be seen between the plasma and the separation 
medium. The tubes were centrifuged at 400g for 30 min at 22°C, with the brake off. 
The resulting band between the plasma and Ficoll layers contained the PBMC 
fraction. The band was removed and the cells were washed twice in HBSS (see 
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appendix A for formulation). The PBMC were resuspended at a concentration of 
1x10' cells ml'I in cRPMI containing 20% normal horse serum. The cells were 
incubated at 37°C for 21 days by which time large macrophage-like cells constituted 
about 50% of the live cells. They were then washed in HBSS and resuspended in 
cRPMI. 
2.2.4. Production of lymphoblasts 
Equine PBMC were isolated using Ficoll Hypaque as described above. The resultant 
PBMC were then cultured with mitogen in order to produce maximum proliferation. 
The optimal concentration for each mitogen used was as follows: 
Mitogen Optimum concentration 
Concanavalin A 5. Opg/ml 
Phytohaemagglutinin 2.5µg/ml 
Pokeweed mitogen 2.5µg/ml 
Maximal proliferation was achieved with a culture time of 72 hours. In practice, 
incubation times were varied in order to accommodate any further treatment of the 
target cells depending on the experiment e. g. infection or chromium labelling. 
2.2.5. Antibody binding assays 
Equine cells were isolated and resuspended to the required concentration in cold 
HBSS. Cells were dispensed into sterile plastic removawells (Dynatech) at between 1 
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and 2x105 cells/well. The plates were centrifuged for 3 min at 180g to pellet the cells, 
the supernatant was removed using a vacuum pump and an optimal dilution of the 
primary antibody in cRPMI was added. Wells were incubated for 1 hour at 4°C in 
order to avoid antibody capping. The wells were washed 3 times with ice cold cRPMI 
by centrifugation and removal of the supernatants. If the primary antibody was from a 
rabbit then 1x105 counts per minute of12Slodine-labelled Staphylococcus aureus 
Protein A (Prot A) was added to each well. If the primary antibody was from any 
other species, then an appropriate dilution of rabbit anti-species immunoglobulin was 
added, incubated as above for 1 hour, washed three times and then the Prot A was 
added. Wells were incubated for 1 hour at 4°C. The wells were washed 3 times with 
ice cold cRPMI leaving the pellet dry after the third wash. Individual wells were 
counted in ay counter (Philips). Controls were mock-infected cells incubated with 
the test antibodies. 
2.2.6. Immunoperoxidase staining of cytospin preparations 
This method was used to demonstrate the proportion of a population of cells which 
expressed viral antigen after infection. This was more useful than the results of the 
antibody binding assay which only provided an estimate of the presence of antigen 
expression. 
Cytospins were prepared using 2 drops of cells from a 2x106 cells ml" suspension and 
preparations were air dried for 30 minutes and then fixed in acetone for 10 minutes. 
Fixed cytospin preparations were stored at -20°C. Before staining, the cytospins were 
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equilibrated at room temperature for 10 minutes. The disks of cellular material were 
ringed with a water resistant pen (Dakopen, Dako Ltd. ) in order to contain the 
antibody solutions. 
All incubations were carried out at room temperature in a humidified box. The 
cytospin disks were flooded with 150µ1 of primary antibody (e. g. rabbit anti EHV-1 
which had been extensively absorbed against equine PBMC) diluted to an optimal 
concentration (11500) in Tris buffered saline (TBS) containing 2% bovine serum 
albumin (BSA, Sigma Chemical Co, Poole, Dorset). They were incubated for 45 min, 
washed in fresh TBS for 5 min and flooded with 150µI of a 1/200 dilution of 
secondary antibody peroxidase conjugate (e. g. goat anti rabbit peroxidase conjugate, 
Dako Ltd. ) in TBS + 2% BSA. After a further 45 min incubation, the slides were 
washed in fresh TBS and flooded with l50µ1 of substrate mixture (22.5m10.85% 
NaCl, 2.5mI fresh 0.2M sodium acetate at pH5.5,200µ1 of a 0.3% hydrogen peroxide 
solution in distilled water and 3m13-Amino-9-Ethylcarbazole in dimethyl sulphoxide, 
all reagents from Sigma Chemical Co, Poole, Dorset). After incubation for 45 min the 
slides were washed in fresh TBS and counterstained for 2 min in Mayer's haemalum 
(Raymond A Lamb, London). They were washed in running water for 5 min and 
mounted in a glycerol/gelatin mountant (Sigma). 
2.2.7. "Chromium labelling of cells 
The methods of labelling equine cells with "Cr varied depending on the cell type 
used. For the majority of the preliminary studies, cells were labelled for 60 min. 
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The "Cr labelling procedure was based on that used by O'Brien (1992). Briefly, cells 
were pelleted and resuspended in approximately 200µl of cRPMI containing 10% 
foetal bovine serum. This medium was found to give the highest uptake of "Cr and 
showed the lowest spontaneous release of label in a preliminary experiment when 
cells from the stable rabbit kidney cell line RK13 were labelled with 5'Cr. 
Approximately 100iCi of S'Cr(Amersham International PLC) per 5x106 cells were 
added to the cell suspension and the cells were incubated for 60 min at 37°C in an 
atmosphere of 5% C02 in air. The labelled cells were then washed twice in 10m1 
HBSS and once in 10ml cRPMI. They were resuspended to a concentration of 
IxIObml"l in cRPMI and I00µ1 of the cell suspension was counted in ay counter in 
order to derive a figure for the total incorporated label, and hence the amount of label 
per cell. Labelled cells were then plated in round bottomed 96 well plates containing 
either cRPMI or the detergent triton x100 (2.5% in PBS) in order to derive figures for 
percentage release of label over time for each cell type. 
The method for the spontaneous/total release determination was as follows: Samples 
of the labelled target cells were dispensed in 100 pI at a number of concentrations in 
triplicate in 96 well plates (U shaped wells). The cell number per well was usually 
between 1x104 and 1x101. An equal volume (1001il) of cRPMI was added to one set 
of wells and an equal volume of triton x100 was added to the other. Plates were 
centrifuged at 180g for 2 min. Volumes of l00µ1 of the supernatants from the cRPMI 
wells (spontaneous release) and the triton wells (total release) were counted in ay 
counter. The % spontaneous release of chromium from the culture was derived using 
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the formula: cpm spontaneous/cpm total x 100. 
2.3. Results 
2.3.1. Evaluation of labelling media 
In order to assess which type of medium supported the most efficient labelling of cells 
with "chromium, 1x10' RK13 cells were labelled with 200µCi (units of radioactive 
activity used throughout this thesis will be Curies) "Cr in cRPMI, in undiluted FBS or 
in serum-free HBSS. The labelling efficiencies (i. e. the counts per minute per cell) of 
each set of cells were calculated (Table 2.1). 
Labelling medium cpm per cell 
cRPMI 0.095 
FBS 0.121 
HBSS 0.079 
Table 2.1: The labelling efficiencies of RK13 cells labelled with "Chromium 
using different media. 
After labelling, each set of cells was plated at 1x105 cells per well and evaluated for 
spontaneous and total releasable "Cr after 0,2 and 4 hours incubation at 37°C (i. e. 
under CTL assay conditions). 
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% Spontaneous release 
Time after labelling (hrs) 
Labelling medium 0 2 4 
cRPMI 20.27 27.23 21.99 
FBS 22.89 29.22 35.67 
HBSS 24.49 ND 51.22 
Table 2.2: Spontaneous release of "Chromium from labelled RK13 cells. 
It is clear from the results in tables 2.1 and 2.2 that, although the cells labelled in 
cRPMI did not label as efficiently as those in FBS, they did not leak as much 
chromium over the period of a typical CTL assay. As the spontaneous leakage of 
label is a critical parameter in this type of assay, cRPMI was used for all subsequent 
labelling procedures. 
In another experiment designed to derive optimum conditions for labelling of cells 
with "Cr, equine PBMC were labelled and washed as above. They were then 
incubated in 25m1 of cRPMI for various times, washed and then evaluated for 
spontaneous and total release of label after 4 hours in culture. 
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% Spontaneous release of "Cr 
Bulk culture time 0 hours 4 hours 
0 hours 17.3% 19.5% 
1 hours 7.7% 11.7% 
2 hours 9.5% 16.0% 
Table 2.3. % Spontaneous release for label of PBMC incubated in bulk for 
various times after labelling. 
The results in table 2.3 show that a bulk incubation of labelled target cells for I hour 
in cRPMI followed by washing, markedly reduces the percent spontaneous release of 
label. Consequently, all short term labelling procedures included this extra incubation 
period. 
2.3.2. Equine peritoneal macrophages as CTL targets 
PM from young adult mice have been used as targets in the measurement of CTL 
against lymphocytic choriomeningitis virus and ectromelia virus (Zinkernagel & 
Doherty, 1975). Equine peritoneal fluid is relatively easy to obtain and the PM 
contained in the fluid are readily isolated. However, unlike peritoneal fluid from 
mice, equine fluid contains up to 50% poiymorphonuclear neutrophils (PMN) 
(Brownlow et aL, 1981. Brownlow, 1982 & 1983). Between IOmi and 20m1 of 
peritoneal fluid containing between 2x10' and 2x108 cells was obtained from each 
animal. Typically, when PM were isolated using adherence to polystyrene the 
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recovery of macrophages, identified by morphology, was around 30% of the starting 
population. Isolation of macrophages using Ficoll hypaque, which depletes PMN, 
yielded around 10% of the starting population (data not shown). 
Productive infection of isolated equine PM with EHV-1 strain Ab4 was demonstrated 
by infecting PM at an moi of 2.5, for 1 hour and collecting cell-free supernatants at 
time periods post-infection. The cell-free supernatants were then titrated using RK13 
indicator cells. 
TCID50ml'1 
Infected Mock inf 
Inoculum 6.35 0 
0 hours 1.85 0 
22 hours 3.85 0 
29 hours 4.85 0 
48 hours 4.35 0 
Table 2.4. Release of live EHV-1 strain Ab4 from infected PM. 
EHV-1 antigen expression was demonstrated on the cell surface of infected PM using 
the antibody binding assay described in 2.2.5. (data not shown). However, this assay 
did not allow the assessment of the percentage of infected cells in the PM population. 
Immunoperoxidase staining of cytospins for EHV-1 antigen, using a rabbit polyclonal 
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antiserum, showed that approximately 15% of the PM were infected (Fig 2.1). 
Infected and mock-infected PM were labelled with "Cr and the spontaneous and total 
release values were calculated after 0,3 and 6 hours using 5x104 cells well''. 
Infected Mock Infected 
Time Spon Tot %S Spon Tot %S 
0 hrs 387 2,789 13.9 688 4,984 13.8 
3 hrs 1,344 3,027 21.2 1,154 5,457 21.2 
6 hrs 785 2,988 26.3 1,456 5,349 27.2 
Table 2.5. Spontaneous release of "Cr from PM. 
Spon = Spontaneous release of IICr. (Or) 
Tot = Total releasable s'Cr. (crn' L 
%S =% Spontaneous release of "Cr (Spon/Tot x 100). 
It is clear from the data presented above that PM were infectable with EHV-1 and they 
did not release large amounts of incorporated label over the period of a typical CTL 
assay. However, the problems of the low yield of cells, the low percentage of cells 
infectable with EHV-1 and the need for peritoneal lavage mean that PM were of little 
use as CTL target cells. 
2.3.3. Vascular Endothelial cells as CTL targets 
The tropism of EHV-1 (AB4) for endothelial cells in vivo (Edington et. at., 1986) 
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Figure 2.1. Immunoperoxidase staining of EHV-1 strain Abo infected 
peritoneal cells. 
a) Rabbit anti EHV-1 strain Ab4. 
b) Normal Rabbit immunoglobulins. 
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suggests that this cell type would be a relevant target for CTL in vitro. Vascular 
endothelial cell (VEC) lines were derived from the blood vessels of a horse obtained 
immediately following slaughter. The cell lines were identified as endothelial cells by 
their expression of cell surface von Willibrands factor (data not shown). VEC were 
adherent and were therefore easy to grow as a monolayer culture. 
VEC were readily infected with EHV-1 strain Ab4. Cytopathic effect was visible by 
24 hours and widespread after about 36 hours after infection of the cell sheet. This 
infection was productive as shown by a 100-fold increase in released virus from 
washed, infected cells 24 hours after infection (data not shown). Cell surface antigen 
expression was demonstrated using a mouse monoclonal antibody specific for 
glycoprotein C (gC, Sinclair, 1991) of EHV-1 in the antibody binding assay, Cells 
were plated at 2x10' viable cells well'. 
Counts per minute (+/- %CV) 
Antibody Infected Mock infected 
Rabbit anti EHV-1 6,188 +/- 9.35% 983 +1- 4.41% 
Monoclonal anti gC 11,169 +/- 3.13% 811 +/- 20.3% 
Table 2.6. Expression of viral antigens on the surface of VEC. 
%CV = Percent coefficient of variation. 
Infected and mock-infected VEC (5x104 cells well'') were labelled with s'Cr and the 
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spontaneous and total release values were calculated after 0,3 and 6 hours. Because 
of the slow uptake of label by these cell it was necessary to label VEC with "Cr for 18 
hours in order to incorporate sufficient label. 
Infected Mock-Infected 
Time Spon Tot %S Spon Tot %S 
0 hrs 484 3,802 12.7 725 4,724 15.3 
3 hrs 1,442 3,979 36.2 1,970 4,983 39.5 
6 hrs 1,828 4,074 44.9 2,585 5,204 49.7 
Table 2.7. Spontaneous release of "Cr from VEC. 
The abbreviations are as in Table 4. 
Although these cells were directly relevant to EHV- I infection in vivo, they were not 
of practical use as CTL targets because they released over 35% of the incorporated 
label within the time period of the assay. Also, it was not possible to isolate VEC 
from living horses. 
2.3.4. In vitro matured PBMC (blast-like cells) as CTL targets 
Equine PBMC cultured in vitro in medium containing 20% autologous serum with no 
mitogenic or antigenic stimulation for up to I month showed the development of large 
blast-like cells. The majority of these large cells expressed a macrophage phenotype 
as demonstrated in cytospin preparations using the monoclonal antibody COR CZ3.3 
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which according to the First International Workshop on equine leukocyte antigens 
(Kydd & Antczak, 1991. Kydd et. at., 1994c) is specific for a marker present on 
macrophages. 
Infection of these cells was demonstrated in cytospin preparations using the 
immunoperoxidase method outlined above. The percentage of the cells expressing 
viral antigen after 20 hours of infection was approximately 15% (Fig 2.2). 
In vitro matured PBMC were derived from three animals, infected with EHV-I strain 
Ab4 at an moi of 10 and labelled with "Cr for 90 min. Spontaneous and total release 
values were calculated after 6 hours incubation of 5x10° cells well''. 
Infected Mock Infected 
Horse # Spon Tot %S Spon Tot %S 
# 223 334 1,199 27.9 369 1,884 19.6 
# 370 854 3,962 21.6 950 8,092 11.7 
# 382 722 4,884 14.8 911 8,197 11.1 
Table 2.8. Spontaneous release of "Cr from in vitro matured PBMC. 
The abbreviations are as in table 4. 
The % spontaneous release values were within acceptable ranges. The labelling 
efficiencies of the macrophage-like cells from the three animals used varied 
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Fi; ure 2.2. Immunopemaidase staining of EHV"1 strain Abo infected 
in vitro matured PBMC. 
a) Rabbit anti EHV-1 strain Ab4. 
b) Normal Rabbit immunoglobulins. 
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considerably ranging from 0.0 12 counts per cell (pony #223 infected cells) to 0.109 
counts per cell (pony #370 mock-infected cells). This suggested that the populations 
of these cells derived from different animals were heterogeneous. This was confirmed 
using FACS analysis of in vitro matured cells derived from a range of animals (table 
2.9). Unfortunately, antibody COR CZ3.3 did not function in FACS analysis (J. 
Kydd, AHT, Newmarket, personal communication), therefore the heterogeneity of cell 
populations was confirmed using T and B cell markers. 
Monoclonal antibody specificity 
Pony CD2 CD4 CD8 B cell 
165 17.8% 14.2% 2.7% 0.0% 
168 6.5% 4.4% 1.9% 0.2% 
232 10.2% 8.4% 3.0% 0.3% 
236 7.4% 3.9% 2.6% 0.0% 
259 22.1% 12.2% 4.0% 0.2% 
270 15.1% 5.4% 5.2% 0.1% 
276 20.4% 16.3% 3.6% 0.0% 
PBMC 76.4% 53.3% 19.5% 21.1% 
Table 2.9. Heterogeneity of in vitro matured macrophage-like cells. 
The FACS gates were set on the large lymphocyte population. The results refer to the 
percentage of cells which stained positive with each monoclonal antibody. 
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The results in Table 2.9 showed that cells matured in vitro developed into populations 
which were phenotypically different from fresh PBMC preparations. Matured cells 
from the seven ponies tested contained between 6.5% and 22.1% T cells (EgCD2' 
cells) and very few B cells. This implies that the remainder of the cells in the matured 
populations were of non-T, non-B cell origin. The cells matured from PBMC from 
different animals did not develop into populations of consistent composition despite 
being cultured under identical conditions. If these cells were to be used in a CTL 
assay any differences in the % specific cytotoxicity between animals could be 
attributed to the heterogeneity of the target cells rather than to differences in the CTL 
activity. Because of this and the relatively low percentage of cells expressing viral 
antigens after infection (20-30%) these macrophage-like cells would not make good 
CTL targets. 
2.3.5. Equine blast cells as CTL targets 
Equine PBMC were assessed for their ability to become infected with EHV-1. 
Immunoperoxidase staining of infected PBMC (moi of 10 and cultured for 18 hours) 
with a rabbit anti EHV-I antiserum (extensively pre-absorbed against uninfected 
PBMC) showed that between 10% and 20% of the total cells expressed viral antigens. 
On stimulation of PBMC with 2.5µgm14 PHA this increased slightly to about 30% of 
the total cells. Dr. G. Allen (University of Kentucky) suggested that the low 
percentage of infected cells in the blast population was probably due to their reversion 
back to the resting state during the 18 hour infection period after the stimulus had 
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been removed. Following Dr. Allen's advice, 48 hour blast cells were produced using 
2.5µgml-' PWM in AIM-V/SM medium (Gibco). These cells were then infected at a 
multiplicity of infection of 10 for 14 hours in the presence of 20 international units m1' 
I of recombinant human interleukin 2 (rhIL2). After infection cytospins were 
produced and stained with the absorbed rabbit anti EHV-1 antiserum. As can be seen 
in Fig 2.3, a large proportion of the cells in the blast cell population expressed viral 
antigen on the cell surface. This was also the case when other mitogens (e. g. PHA) 
were used (Fig 2.4). Again, on the advice of Dr. Allen, these cells were labelled with 
"Cr during 12 hours of the infection period. Aliquots of 2.5x106 cells m1'' were 
infected for 1.5 hours with EHV-1 at an moi of 10, washed and labelled with 150µCi 
of "Cr. The cells were incubated with the isotope for 12 hours and evaluated for 
spontaneous and total release of label over a4 hour period. Cells were tested at 1x104 
cells well-'. 
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Figure 2.3. Immunoperoxidase staining of EHV-1 strain Abo infected 
PWM blast cells. 
a) Rabbit anti EHV-1 strain : ßb4. 
b) Normal Rabbit immunoglobulins. 
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Figure 2.4. Immunoperomidase staining of tf1V-1 strain Abo infected 
PHA blast cells. 
a) Rabbit anti EHV-1 strain Ab4. 
b) Normal Rabbit immunoglobulins. 
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Infected Mock-Infected 
Horse Spon Tot %S Spon Tot %S 
219 301 1,535 19.6 256 1,032 24.8 
302 249 1,149 21.7 454 1,522 29.8 
168f 163 1,249 13.0 144 1,071 13.4 
701 113 760 14.9 112 855 13.1 
Cl 206 1,040 19.8 206 1,227 16.8 
235 195 1,012 19.2 173 694 24.9 
Table 2.10. Spontaneous release of "Cr from PWM blast cells after 4 hours. 
The abbreviations are as in table 4. 
The spontaneous release values shown in Table 2.10 were within acceptable limits for 
use in CTL assays. The spontaneous release characteristics were further studied over 
a longer period of time in order to determine the time limit for a CTL assay using 
these cells as targets as shown in Fig 2.5. PWM blast cells released over 30% of label 
when they were incubated for longer than about 6 hours. However, as the majority of 
CTL assays are between 4 and 6 hours in duration, this was not thought to be a 
problem. 
An initial assay of CTL activity in an immune animal was carried out using the 
induction culture method developed by Dr. Allen (Allen et. al., 1995). The results of 
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Figure 2.5. Spontaneous release of radioactive chromium from labelled 
equine PWi\1 blast cells. 
open circles = mare #1 infected blast cells. 
closed circles = mare 41 mock-infected blast cells. 
open squares = mare #2 infected blast cells, 
closed squares = mare #2 mock-infected blast cells. 
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this assay can be seen in Figures 2.6 and 2.7. Equine PWM blast cells were 
susceptible to lysis by EHV-1 induced CTL effector cells (mare #302 in Fig 2.6a). 
Effector cells from an MHC class I mis-matched horse (mare #219 in Fig 2.6a) did not 
kill infected targets, although they did kill autologous (i. e. mare #219), infected 
targets (Fig. 2.7). Autologous mock-infected target cells were not susceptible to 
killing by EHV-1 induced CTL (Figs. 2.6b and 2.7b). 
2.4. Discussion 
A wide range of target cells have been used by researchers to quantify CTL activity. 
The study of CTL in inbred mouse models of disease has spawned the production of 
many MHC typed cell lines. For example, Gao et al., (1991) used the murine tumour 
cell lines P815 (H-21), EL4 (H-2b), and BW5147 (H-2k) to demonstrate CTL induced 
by priming mice with short synthetic peptides of influenza virus. These target cells 
were easily grown in vitro in tissue culture. The wide availability of tissue typing 
reagents has meant that target cells for use in the study of human CTL can easily be 
matched to a particular patient's MHC type and grown in tissue culture for use in CTL 
assays. The use of Epstein Barr virus (EBV) to transform human PBMC into 
continuously growing B cell lymphoblastoid cell lines (B-LCL) has also improved the 
capacity to measure human CTL specific for a number of viruses (Cherrie et al., 
1992, Posavad and Rosenthal, 1992). The study of virus-specific CTL in veterinary 
species has been compromised due to the lack of suitable target cells. Hence, cell 
lines suitable as target cells for the study of viruses important in sheep, cattle or 
horses are not available. Also, MHC typing of cells from these species is not always 
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Figure 2.6. EHV-1 specific CTL from mare #302 assayed using PWM 
blast cells as targets. 
a) Autologous, EHV-1 infected targets. 
b) Autologous, mock-infected targets, 
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Figure 2.7. EHV-1 specific CTL from male #219 assayed using PWM 
blast cells as targets. 
a) Autologous, EHV-1 infected targets. 
b) Autologous, mock-infected targets. 
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possible. Sharma and Woldehiwet (1991) studied bovine respiratory syncytial virus 
specific CTL derived from sheep using cultured lamb testis cells as targets, whilst 
McGuire et. al., (1994) studied equine infectious anaemia virus specific CTL using 
autologous primary equine kidney cells. 
It is clear from the results presented in this chapter, that the most promising cell type 
for use in an EHV-1 specific CTL assay is the PWM-stimulated blast cell. The use of 
PWM is not a prerequisite as other mitogens, e. g. PHA and Con A, can be used. 
Mitogen-stimulated blast cells are easy to produce, support replication of EHV-1 in a 
high proportion of the cells and retain IICr long enough for an assay to be completed. 
Of the other cell types tested, PM labelled well and did not release significant 
amounts of "Cr spontaneously. However, their low levels of infection and the low 
yield of viable macrophages from whole peritoneal fluid meant that they were 
unsuitable for large studies of EHV-1 specific CTL activity. VEC proved to be of 
little use as CTL targets due to the difficulty of isolation and their high spontaneous 
release of label (about 35% after 3 hours). In vitro matured PBMC did not release 
excessive amounts of label spontaneously. However, the low levels of infection of 
these cells rendered them unsuitable as targets for CTL. 
In conclusion, PWM blast cells were found to be easily isolated, infected and labelled 
with "Cr. Furthermore, they released relatively low levels of label spontaneously 
over a four hour CTL assay. These cells have, therefore, been used to optimise an 
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EHV-1 specific CTL assay, to determine the phenotype of the cells responsible for 
CTL mediated killing in this system, to screen a large number of horses with diverse 
infection histories in order to determine their immune status in terms of CTL activity 
and to develop CTL LDA methods in order to determine the frequencies of CTL 
precursors present before and after infection with EHV-1 and EHV-4. 
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3.1. Introduction 
The "Chromium ("Cr) release assay was first applied to the study of the cellular 
mechanisms involved in immunity when Brunner et. al. (1968) used it to measure the in 
vitro cytotoxic effect of spleen cells on 51Cr labelled, allogeneic target cells. Since then 
the assay has been used extensively to study the cytolytic activity of a wide range of cell 
types. 
One of the most widely used applications for the "Cr release assay is in the study of 
cytotoxic lymphocytes which are involved in protection against and recovery from 
infectious diseases. As outlined in chapter 1, these lymphocytes are functionally and 
phenotypically diverse but fall into two main types, the natural killer (NK) cell and the 
cytotoxic T lymphocyte (CTL). The use of the assay to study virus-specific CTL began 
with the work of Zinkernagel and Doherty when they demonstrated that the T cell- 
mediated cytolytic response to lymphocytic choriomeningitis virus (LCMV) of mice was 
virus-specific and genetically restricted (Zinkernagel and Doherty, 1974). The role of 
anti-viral CTL in protection against and recovery from infection was initially studied 
using LCMV infection of mice as a model. In this model, CTL were generated which 
were directly measurable ex vivo from spleens of infected mice, 6 to 10 days after 
infection (Marker & Volkert, 1973). Levels of in vitro specific lysis of infected target 
cells mediated by anti LCMV CTL were equivalent to those seen with CTL clones 
induced with other viruses. There was a distinct immunopathological aspect to LCMV 
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infection of mice where intracerebral injection with virus caused a lethal chriomeningitis 
(Doherty & Zinkernagel, 1974). However, T cell deficient mice infected with the virus 
did not develop choriomeningitis disease but became LCMV carriers. Due to the above 
properties of LCMV infection of the mouse and in particular to the vigorous CTL 
response after infection this model has yielded some important findings. Information has 
been produced concerning the clearance of LCMV in vivo using adoptively transferred, 
cloned anti-viral CTL (Byrne & Oldstone, 1984); the role of polyclonal CTL in the 
clearance of LCMV from the spleens of infected mice (Lehmann-Grube et. al., 1988); 
the induction of anti-viral CTL with non-replicating protein antigens derived from LCMV 
(Bachmann et. al., 1994) and the in vitro selection of LCMV escape mutants by CTL 
(Aebischer et. a!., 1991). This work led to the realisation that the biological role of CTL 
was immune surveillance and elimination of virus infected cells (Doherty and 
Zinkernagel, 1977) rather than the previously held view that CTL were, simply, effectors 
of allograft rejection. 
The measurement of CTL from the horse has been hindered by the lack of equine 
reagents. Allospecific CTL were demonstrated after induction in a one way mixed 
lymphocyte reaction (MLR) culture by O'Brien (PhD thesis, 1992). This established that 
"classical" CTL activity was measurable in equine leucocytes. Recently, McGuire et. al. 
have demonstrated equine CD8+ CTL specific for equine infectious anaemia virus 
(EIAV) in infected horses (McGuire et. al., 1994). The method used in this study was a 
17 hour "Cr release assay using autologous equine kidney cell targets either infected with 
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EIAV or recombinant vaccinia viruses expressing EIAV genes (env, gag or 5' pol). The 
effector cells generated in this study did not require any in vitro culture in order to kill 
virus infected target cells. Hannant and Mumford (1989) induced equine influenza virus- 
specific CTL usingan in vitro culture which included equine T cell growth factor (TCGF) 
preparations. The resultant CTL were assayed using autologous and allogeneic, influenza 
virus-infected PBMC. They found that CTL induced with moderate amounts of TCGF 
killed both autologous and allogeneic target cells. It was only when the amount of TCGF 
was reduced to 5% of the induction culture volume that genetically restricted CTL were 
revealed. The non-genetically restricted CTL measured in this study were in vitro 
induced lymphokine activated killer (LAK) cells. Hormanski et, al. (1992), reported that 
equine LAK cells lysed the equine lymphosarcoma cell line EqT8888, whilst they failed 
to lyse human (Daudi) or murine (EL4) tumour cell lines. The assay for MI-IC restricted, 
EHV-l specific CTL developed and described in this chapter has avoided the use of 
TCGF in induction cultures in order to minimise the induction of these types of cells. 
EHV-4 specific CTL were described by Bridges & Edington (1987). In this study, equine 
skin fibroblasts pulsed with inactivated EHV-4 antigen were used as target cells in order 
to demonstrate genetically restricted CTL. As outlined previously, in order to measure 
"classical" MHC class I restricted, CD8' CTL, infection of a target cell is absolutely 
necessary unless the target peptides are available. 
This chapter will describe the optimisation and use of a bulk culture assay for the 
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measurement of EHV-1 specific CTL. The optimised assay used in this study was based 
on that described by Allen et. al. (1995) who's collaboration is kindly appreciated. In 
order to maintain clarity of the text, all of the media formulations are described in 
appendix A. 
The aims of the experimental work in this chapter were to develop virus-specific assays 
for CTL using EHV-1 Ab4 as the in vitro inducing antigen and as the infecting virus for 
target cells. Specific objectives were: 
a) to optimise the EHV-1 specific CTL assay in terms of induction culture duration, 
antigen input and cold target inhibition; 
b) to confirm MHC restriction and CD8 phenotype of EHV-1 specific CTL; 
c) to measure CTL activity in a selection of foals maintained in the AHT breeding 
herd; 
d) to measure the development of CTL activity after primary EHV-1 infection of 
specific pathogen free (SPF) foals; 
e) to measure cross-reactive CTL, i. e. CTL induced with EHV-4 and assayed using 
EHV-1 infected target cells; 
0 to determine whether immediate early proteins of EHV-1 are recognised by EHV- 
1 specific CTL. 
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3.2. Materials and Methods 
3.2.1. Isolation of equine PBMC 
Equine PBMC were isolated from whole blood using the method described in section 
2.2.3. The cells were then resuspended in AIM-V/SM containing 5% heat-inactivated 
autologous horse serum and counted using a Nueberger haemacytometer. The cells were 
resuspended at a concentration of Ix10' cells ml'' in AIM-V/SM. 
3.2.2. Induction of EHV-1 specific CTL 
In order to induce EHV-1 specific CTL in vitro, 1.1x108 isolated equine PBMC were 
cultured in upright T75 tissue culture flasks (Corning) in 30m1 of AIM-V/SM containing 
5% heat-inactivated autologous horse serum (a concentration of 3.67x106 cells ml''). 
Live EHV-1 strain Ab4/9 (1.5m1 at a concentration of 1x107.6 TCIDSOm1'') was added to 
one set of cultures at a concentration approximating to a multiplicity of infection of 0.5. 
Another set of cultures were mock-induced by substituting mock-infected tissue culture 
supernatant for the live virus. The cultures were incubated at 37°C for six days in an 
atmosphere of 5% CO2 in air. The remaining PBMC at 1x108 cells ml'' were incubated in 
5% CO2 in air for 10 min and kept in tightly closed tubes at 4°C for use as target cells. 
3.2.3. EHV-1 specific $'Chromium release assay 
On day 3 of the induction culture, PBMC for use as target cells were retrieved from 4°C, 
washed in HBSS and counted in trypan blue in order to determine the % viability of the 
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cells. They were then incubated at a concentration of 3xl O6m1'' viable cells in l Oml of 
AIM-V/SM-5% containing 2.5µgmi-I Pokeweed mitogen (PWM, Sigma). These cultures 
were incubated upright in T25 tissue culture flasks (Coming) for a further 48 hours in 
order for the PBMC to develop into actively proliferating blast cells. 
On day 5 of the induction culture the PWM blast cells were harvested and the dead cells 
removed by layering them onto a Ficoll Hypaque gradient using the same method as for 
the isolation of the PBMC except that the resultant band of cells was washed in HBSS 
containing 20 units ml-' of recombinant human Interleukin 2 (rhIL2) in order to maintain 
the blast cells in an actively proliferating state. Aliquots (2.5xI06 cells) of the PWM blast 
cells from autologous and allogeneic sources were either infected with EHV-I strain 
Ab4/9 at a multiplicity of infection of greater than 10, or mock-infected, and incubated 
for 90 min at 37°C in 5% CO2 in air with frequent gentle resuspension. The target cells 
were then washed and resuspended in 1. Oml of cRPMI containing 20 units m1'' rhIL2. 
The cell suspension was transferred to one well of a 48 well culture plate to which 
1504i of "Chromium had been added. The plates were then incubated for 12 hours at 
37°C in 5% CO2 in air. 
Approximately 2 hours before the end of the target cell infection period, the induction 
cultures were harvested and washed twice in HBSS and once in cRPMI. The cells were 
then counted using trypan blue to determine the viability of the effector cells and 
resuspended at a concentration of 1x10' viable cells ml"I in cRPMI. The effector cells 
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were kept on ice. Each effector cell type was titrated in quadruplicate in round bottom 
microtitre plates from 1x106 cells well" using doubling dilutions. The target cells were 
harvested and washed twice in HBSS and once in cRPMI. The supernatants were 
discarded into a radioactive waste bottle after each wash to minimise any radioactive 
hazard. After the final wash the target cells were resuspended in 2ml of cRPMI and 
counted in trypan blue to determine the % viability. They were resuspended to give 
1x105 cell ml'' and I00µ1 of the cell suspension was counted in a gamma counter to 
determine the total incorporated "Cr. The target cells were added to the effector cells at 
1x104 cells well'' to give effector: target ratios of 100: 1,50: 1,25: 1 and 12.5: 1 (unless 
otherwise stated) and the plates were centrifuged at 100g for 3 min in order to allow the 
effectors and targets to come into contact. A control plate was set up so that the 
spontaneous (1001il of target cells + 10041 of cRPMI) and total (l00µ1 of targets + 100µ1 
of 5% triton x100) isotope release could be determined. The plates were incubated for 4 
hours at 37°C in 5% C02 in air. For initial experiments, each effector cell type was 
assayed using autologous and allogeneic infected and mock-infected target cells. At the 
end of the incubation period the plates were centrifuged at 100g for 3 min and 100µl of 
supernatant was removed from each well. The supernatants from the assay and the control 
plates were counted in a gamma counter (Philips PW4000). The background mean 
counts per minute (cpm), obtained by counting 24 empty tubes prior to counting the assay 
samples, was subtracted from each experimental and control value. 
The % specific cytotoxicity (corrected to take account of the background cpm) for each 
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well was calculated using the following formula: 
(cpm sample-cpm spontaneous)/(cpm total-cpm spontaneous) x 100 
The data were analyzed and reduced using a computer spreadsheet package (Lotus 1.2-3) 
which calculated the % spontaneous release of chromium from the target cell, the 
individual % specific cytotoxicity values for each well, the mean % specific cytotoxicity 
for each E: T ratio and the standard deviation using a replicate number of 4. 
Significant differences between individual mean % specific cytotoxicity values were 
determined using the Student's t test. 
3.2.4. Inhibition of specific killing using cold targets. 
Infected or mock-infected unlabelled target cells from autologous or MHC mis-matched 
animals were tested for their ability to inhibit EHV-1 specific CTL activity by adding. 
them in excess to the assay wells. 
3.2.5. Time course of EHV-1 specific CTL induction 
This experiment was designed to determine the effect of induction culture duration on the 
development of EHV"1 specific CTL. CTL induction cultures were set up 10,8,6,4 and 
2 days before carrying out a CTL assay. The protocol described above (see 3.2.3. ) was 
used except that the cultures were scaled down to T25 tissue culture flasks. The total 
culture volumes were 10ml each containing 0.5m1 of Ab4/9 (1x10'-6 TCIDsom1'') or mock 
supernatant. The experiment was carried out on two EHV-1 immune horses which were 
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equine leucocyte antigen (ELA) class I mis-matched as determined by iso-electric 
focusing of immuno-precipitated class I proteins derived from PBMC. All effector 
populations were assayed simultaneously using infected and mock-infected target cells 
from both animals, thus giving results for autologous and allogeneic killing. 
3.2.6. The effect of virus concentration on CTL induction 
The effect of varying the amount of live EHV-I strain Ab4 in the CTL induction culture 
was assessed in two experiments. In the first experiment, the amount of EHV-1 was 
titrated from 3.6x101 TCID50m1'' to 1.75x10$ TCIDsom1''. In the second experiment the 
amount of EHV-1 was titrated from 4.0x102 TCIDSOm1'' to 1.0x106 TCID50 ml''. The 
assays were performed as described in section 3.2.2. using a total culture volume of l Oml. 
3.2.7. Cross reactivity of EHV induced CTL 
In order to assess the extent of cross-reactivity of in vitro induced CTL, induction 
cultures were set up with either EHV-1 strain Ab4/9, EHV-1 strain Ab4/13 cloned 
(Glasgow) or EHV-4 strain MD. The individual virus isolates were adjusted in order to 
provide an equivalent TCID5Q in each induction culture. As EHV-4 was found not to 
infect PWM blast cells to a sufficiently high level for target cell production (see chapter 
2), all induced effector cells were assayed on EHV-1 strain Ab4-infected and mock- 
infected targets. Cross-reactive cytotoxic effector cells were induced from PBMC of a 
number of conventional and SPF foals in order to determine whether CTL develop after a 
true primary infection with EHV-1. 
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3.2.8. The effect of rhIL2 on EHV-1 specific CTL induction 
The effect of inducing EHV-1 specific CTL in the presence of rhIL2 was studied. 
Cytotoxic effector cells were induced from PBMC of two ELA mis-matched horses in the 
presence of 200 IUm1'', 20 IUml", 2 IUm1'' and 0 IUmI'' of rhIL2. The resultant CTL 
were assayed on infected and mock-infected autologous and allogeneic target cells. 
3.2.9. Depletion of T cell sub-sets 
In order to determine the phenotype of the cells responsible for the CTL activity in EHV- 
1 specific CTL effector cell cultures, assays were performed using effector populations 
depleted of cells expressing either CD4'' or CD8+ on the cell surface. 
Effector CTL were induced in bulk culture using live EHV"l for six days as described 
above. The cells were harvested and the number of viable cells was determined using 
trypan blue exclusion. Aliquots of 1.5x 10' viable effector cells were labelled with a 
1/500 dilution of monoclonal antibodies specific for either equine CD4 (HB61A, VMRD 
inc. ), equine CD8 (HT14A, VMRD inc. ) or equine thymocytes (EqT6, VMRD inc. ), on 
ice for 15 min. The equine thymocyte antibody was included as a negative control as it 
has been shown not to bind to equine PBMC. The cells were washed twice in cold HBSS 
+ 10% FCS and resuspended in 180µl of medium to which was added 2Oµ1 of MACS 
colloidal super-paramagnetic microbeads conjugated with goat anti-mouse 
immunoglobulin G (Miltenyi Biotec GmbH, Germany). The cells were incubated at 4°C 
for 15 min and then applied to a pre-washed mini MACS column (Miltenyi Biotec 
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GmbH, Germany). The mini MACS system is a method for separating cells which have 
been labelled with very small (100nm diameter) super-paramagnetic microparticles. 
After labelling, the cells are applied to high gradient magnetic (HGM) columns which 
bind the labelled cell population (Miltenyi et. al. 1990). The non-bound cells were 
pelleted and applied to another mini MACS column in order to increase the efficiency of 
the separation. The resultant effector CTL were washed and used in a standard EHV-1 
CTL assay using infected and mock-infected autologous and infected allogeneic target 
cells. 
3.2.10. Viral protein specificity of anti EHV-1 CTL 
In a number of herpesvirus infections, CTL are produced which are specific for 
immediate early (IE) proteins (Reddehase & Koszinowski, 1984 and Banks et. at., 1993). 
The specificity of the CTL expressed at different stages of infection was assessed in an 
experiment based on the selective inhibition of EHV-1 proteins expressed on target cells. 
The method, based on that used by Tigges et. al. (1992), compared the specific cytotoxic 
activity of effectors against drug-treated and untreated, infected and mock-infected target 
cells. Target PWM blast cells (2.5x106 cells) were treated with 25µgml cycloheximide 
(Sigma) for one hour and then infected with EHV-1 strain Ab4/9 at a moi of 10 in serum- 
free RPMI containing 20IUm1'' rhIL2 (Chiron) and 25ggm1'' cycloheximide for four 
hours. The cells were then washed in HBSS containing 5µgml' actimomycin D (Sigma) 
and labelled for 90 min with s'Chromium in 200µl cRPMI containing 10pgm1'' 
actimomycin D and rhIL2. The treated and untreated target cells were then washed 3 
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times in HBSS and added to effector cells in 96 well round bottomed microtitre plates. 
The treated target cells were added to the CTL assay in medium containing 20µgm1'l 
Actinomycin D. The CTL assay was carried out as described above. 
3.3. Results 
3.3.1. Time course of EHV-1 specific CTL induction 
Using "Chromium release assays, it is vital to know at what time after the initiation of 
the induction culture the CTL activity is maximal. The results from the EHV-1 CTL time 
course experiment described in section 3.2. can be seen in Figures 3.1 and 3.2. Analysis 
of the CTL activity in PBMC from horse #302 on autologous infected target cells (Fig. 
3.1) revealed that specific cytotoxicity significantly above background was not detectable 
until the PBMC were cultured with live EHV-1 for 4 days. Culture times longer than 4 
days (up to a maximum of 10 days) resulted in very similar specific release values 
(around 50%) when the effector cells were assayed on autologous infected target cells. 
This high level of cytotoxicity was maintained when the effector cells were assayed at an 
effector: target ratio of 50: 1 (Fig. 3.1b). A reduction in CTL activity in cultures incubated 
for 10 days was seen. When CTL from horse #302 were assayed on allogeneic infected 
target cells (i. e. those from the mis-matched horse #219) the specific cytotoxicity 
increased as the induction culture time increased (Fig. 3.2). This indicated that, in this 
particular animal, increasing the induction culture time resulted in the appearence of an 
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Figure 3.1. Time course of EHV-I strain Abo specific CTL induction. 
Mare #302 EHV-1 infected targets. 
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Figure 3.2. Time course of EHV-1 strain Abo specific CTL induction. 
Mare #219 infected targets. 
a) Effector: Target ratio =100: 1. 
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additional population of non-genetically restricted cells. The cytotoxicity due to this 
additional population of cells was reduced when the effectors were assayed at an 
effector: target ratio of 50: 1 (Fig. 3.2b). Cytotoxicity against both sets of target cells due 
to mock-induced PBMC from #302 was negligible indicating that the CTL activity was 
EHV-1 specific. 
The results obtained using PBMC from #219 as effectors showed that the maximal 
specific cytotoxicity value using autologous infected target cells (Fig. 3.2) was lower than 
that obtained with #302 effector cells. This was a consistent result when measuring CTL 
from these two animals. Significant cytotoxicity was demonstrable against autologous 
infected target cells by effector cells from horse #219 after 2 days induction. This CTL 
activity was, however, not genetically restricted as similar cytotoxicity was detected 
using allogeneic target cells (see Fig. 3.1). Specific cytotoxicity above background was 
measurable using effector CTL from horse #219 after induction cultures were induced for 
between 4 and 10 days. The significant increase in allospecific killing with increasing 
time in culture seen when using #302 effector cells was not seen with #219 effectors. 
Again, cytotoxicity in mock-induced cultures was negligible. 
These results indicate that CTL activity was demonstrable in cultures of PBMC induced 
with live EHV-1 Ab4 for between 4 and 10 days. The difference in the pattern of 
response between #302 and #219 indicates that different horses may respond differently 
to the same stimulus. 
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3.3.2. The effect of virus concentration on CTL induction 
The effect of increasing the amount of live EHV- I in CTL induction cultures from 
3.6x105 to 1.75x108 TCID50ml'' was studied. The induction cultures and assays were 
carried out as described above except for the concentration of inducing virus. Figure 3.3a 
shows that antigen-specific genetically restricted cytotoxicity was induced at all virus 
concentrations tested. Killing of allogeneic infected target cells by the effector cells was 
minimal (Fig. 3.3b). 
In a second experiment the concentration of live virus in the induction cultures was 
titrated from 4.0x102 to 1.0x106 TCID50m1''. Significant (p40.05) killing, above mock- 
induced effectors assayed on autologous infected targets, could be demonstrated when 
1. ()X 104 TCID50ml-' was used in the induction culture (0.05m1 of virus corresponding to 
an approximate moi of 0.00027). Reducing the concentration of virus below this failed to 
stimulate the development of EHV-1 specific CTL. Mock-induced PBMC failed to kill 
autologous infected target cells. The induced CTL failed to kill allogeneic infected target 
cells (Fig. 3.4b). These results show that the concentration of virus initially used for the 
routine testing of EHV-1 specific CTL activity (2x106 TCID50mI see 3.2.2. ) allowed the 
maturation of precursor CTL into effector CTL. Increasing this concentration to 2x107 
TCID50ml" did not effect the cytotoxic activity. 
3.3.3. Inhibition of specific killing using cold targets 
The inhibition of CTL killing of a labelled target cell using an excess of unlabelled "cold" 
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Figure 3.3. Titration of the amount of EHV-1 used in CTL induction 
cultures. 
a) CTL from mare #302 on autologous EHV-1 infected targets. 
b) CTL from mare #302 on allogeneic EHV-1 infected targets. 
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Figure 3.4. Titration of the amount of . HH-1 used in CTL induction 
cultures. 
a) CTL from mare #302 on autologous EHV-1 infected targets. 
b) CTL from mare #302 on allogeneic EHV-1 infected targets. 
a) 
60 
40 
20 
0 
0 
b) 
60 
; 0-ý 
40 
r: + 
n 
u 
CJ 
LZ 
v 20 
1-21 
0 
0 0.0004 0.0016 0.01 0.04 1 
Abo added to induction culture (million TCID50/ml) 
Effector: Target ratio: 
® 50: 1 " 25: 1 Q 12.5: 1 " 6.25: 1 
103 
0 0.0004 0.0016 0.01 0.04 1 
Abo added to induction culture (million TCID5O/ml) 
targets is an established method of evaluating the specificity of CTL. Figure 3.5 shows 
the % inhibition of killing seen when autologous infected (open circles), allogeneic 
infected (open squares), autologous mock-infected (closed circles) and allogeneic mock- 
infected (closed squares) cold targets were included in a standard EHV-I specific CTL 
assay. The results indicated that a large percentage of the CTL activity was due to EHV- 
1 specific CTL as the killing was inhibited to a greater extent by autologous infected cold 
targets than by the autologous mock-infected cold targets. However, Fig. 3.5a also shows 
that there was some inhibition by autologous mock infected cold targets. Indeed, the 
base line inhibition started at 20% and increased to around 40%, indicating that there was 
an element of non-specific cytotoxicity present in CTL effector cell populations from this 
particular animal. Another explanation for this inhibition was that the autologous mock- 
infected targets may have decreased the contact between the CTL and the labelled target 
cells. Inhibition of CTL activity with both infected and mock-infected allogeneic cold 
targets was low (below 20%) when cells from 4302 were used as effectors. Inhibition of 
CTL activity with mock-infected cold targets was not seen using effector cells from horse 
#219 (see Fig. 3.5b). However, CTL from this animal were inhibited with allogeneic 
infected cold targets indicating that not all the CTL induced were genetically restricted. 
3.3.4. The generation and measurement of EHV-1 specific CTL 
The method for the generation and measurement of EHV-1 specific CTL described in 
section 3.2. was applied to a range of horses, some of which had a known history of 
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Figure 3.5. Cold target inhibition of EHV-1 specific CTL. 
a) Mare 9302 effector cells on autologous EHV-1 infected targets. 
l) Mare #219 effector cells on autologous EHV-1 infected targets. 
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EHV-1 infection and some of which did not. In order to determine whether EHV-1 
specific CTL develop after a primary infection, CTL were induced from cryopreserved 
PBMC derived from two SPF foals before and after infection. 
The two horses used to standardise the CTL assay in the previous section (#302 and 
#219) were immune animals which had experienced numerous previous experimental 
infections with EHV-1 (#219 received four infections and #302 received three infections 
within a three year period). Their CTL were EHV-1 specific and genetically restricted 
(Figs 3.6 and 3.7). Despite their similar infection histories, the induced CTL from these 
two animals were different. First, #302 consistently produced higher chromium release 
values although the background killing of mock-infected autologous targets was also 
higher (see Fig. 3.6a and 3.6b). Induced CTL from #219 consistently produced steeper 
dose response curves of % specific cytotoxicity against effector: target ratio than did those 
from #302. This may indicate a quantitative difference in frequency of CTL between the 
two animals and/or reflect an increased population of MHC non-restricted NK cells in the 
induction cultures of horse #302. Evidence for the latter comes from the relatively high 
level of % cytotoxicity seen when these effector cells were assayed using allogeneic 
infected target cells (i. e. from the ELA mis-matched horse #219). This was not seen in 
the reciprocal combination of effector and target cells. 
Figure 3.8 shows CTL activity measured from four horses of different infection histories. 
The effector cells used in this experiment were either EHV-1 Ab4-induced or mock- 
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Figure 3.6. EHV-1 specific CTL induced from mare #302 PBMIC. 
a) EHV-1 infected, autologous targets. 
b) Mock infected, autologous targets. 
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Figure 3.7. MV-1 specific CTL induced from mare #219 PBMC. 
a) EHV-1 infected, autologous targets. 
b) Mock infected, autologous targets. 
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Figure 3.8. EHV-1 specific CTL from four horses of various ages. 
a) Three week old foal. 
b) Ten month old foal. 
c) and d) Adult mares. 
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induced PBMC and CTL activity was assayed on autologous infected and mock-infected 
target cells. Figure 3.8a represents the CTL measured from a three-week old foal and was 
therefore, unlikely to have been exposed to either EHV-1 or EHV-4. Absence of 
detectable CTL activity was therefore not surprising. Figure 3.8b represents CTL activity 
from a horse which was 10 months old at the time of sampling. It is clear that this horse 
had experienced infection with either EHV-1 or EHV-4. The other two animals 
represented in Figures 3.8c and 3.8d were adult mares both of which had experienced 
both experimental and natural infections with EHV-1 and EHV-4. The CTL activity of 
cultures derived from the 10 month old animal (Fig 3.8b) decreased more rapidly at lower 
effector: target ratios than those from adult animals (Figs 3.8c and 3.8d). As mentioned 
above, this is likely to represent a difference in the frequencies of EHV-1 specific CTL 
between these animals. 
In another experiment (Fig. 3.9. ) it was not possible to demonstrate CTL activity, above 
that seen when CTL were tested using autologous mock-infected target cells, in an 18 day 
old (Fig 3.9b) or a4 month old foal (Fig 3.9. a). CTL activity was measurable from 
PBMC from adult mare (Fig. 3.9c). The data in Figures 3.8 and 3.9 suggest that foals 
become infected with either EHV-1 or EHV-4 before about 10 months of age, However, 
the possiblity exists that the CTL positive foal in Figure 3.8b had experienced more than 
one infection within 10 months, which makes it impossible to draw any conclusions 
about CTL induction after primary infection from these data. 
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Figure 3.9. CTL activity in PBMC from young horses tested on 
autologous, EHV-1 infected target cells. 
a) 4 month old foal. 
b) 18 day old foal. 
c) Adult mare. 
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The uncertainty about the number of infections experienced by young animals within the 
first year of life was overcome by measuring CTL activity in PBMC from EHV-1 
challenge of SPF foals (Gibson et al., 1992a). The PBMC from this experiment were 
recovered from cryopreservation prior to CTL induction with EHV-1 strain Ab4. The 
results in Figure 3.1Oa and 3.1Ob show CTL activity from SPF foal #3. Although CTL 
activity from this animal was low after infection, CTL activity was seen at the 50: 1 
effector: target ratio. Figures 3.1Oc and 3.1Od show CTL activity from SPF foal #4. CTL 
activity was seen after infection of this animal. This is formal proof that CTL activity can 
be induced after only one infection with EHV-1. The kinetics, duration and protective 
effect of this primary CTL response remain to be determined. 
3.3.5. Cross-reactivity of induced CTL 
Consideration of the infection histories of young animals prompted an experiment to test 
whether CTL induced with various isolates of EHV-1 and EHV-4 were able to kill EHV- 
1 strain Ab4/13 infected target cells. As it was not possible to infect equine blast cells 
with EHV-4 to a high enough level to produce usable target cells, CTL were induced 
using this virus and assayed on autologous EHV-1 strain Ab4/13-infected target cells. 
This experiment also represented the first use of the cloned and sequenced EHV-1 virus 
Ab4/13 as the target antigen in virus-specific CTL assays. The results from this 
experiment can be seen in Figure 3.11. 
The results presented in Fig, 3.11 showed that different EHV-1 viruses as well as an 
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Figure 3.10. CTL activity in PBMC from 2 SPF (EHV free) foals 
before and after infection with EHV-1 strain Ab4/13. 
a) Foal 3 before infection. 
b) Foal 3 after infection. 
c) Foal 4 before infection. 
d) Foal 4 after infection. 
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Figure 3.11. CTL induced using isolates of EHV-1 or EHV-4. 
a) #302 effector cells on autologous, EHV-1 Ab4/13 infected targets. 
b) #219 effector cells on autologous, EHV-1 Ab4/13 infected targets. 
c) #302 effector cells on autologous, mock-infected targets. 
d) #219 effector cells on autologous, mock-infected targets. 
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isolate of EHV-4 all induced CTL that killed targets infected with EHV-1 strain Ab4/13. 
In Fig. 3.1 la (effector CTL from horse #302) equivalent levels of specific lysis against 
autologous EHV-1 Ab4/13 infected targets were measured using EHV-1 strains Ab4/9 
and Ab4/13 as inducing viruses (between 20 and 35%), whilst significantly (p<0.05) 
reduced levels (between 10 and 20%) were seen when EHV-4 strain MD was used as the 
inducing agent at the same concentration. Killing of autologous mock-infected target 
cells was negligible (Fig. 3.11c). In Fig. 3.1 lb (effector CTL from horse #219) the 
pattern of reactivity of the induced CTL was very different. CTL from this animal 
induced with Ab4/13 and EHV-4 strain MD produced equivalent levels of specific lysis 
(around 20%) whilst CTL induced with Ab4/9 produced significantly (p<0.05, except at 
12.5: 1 E: T ratio which was not significant) lower values (approximately 0-10%). Again, 
killing of autologous mock-infected target cells was negligible (Fig. 3.11 d). 
The stability of the CTL induction pattern induced by the different viruses was studied by 
comparing levels of CTL activity in PBMC from a single immune animal (horse #219) on 
three separate occasions. Figure 3.12, shows that, despite differences in the absolute 
levels of % specific cytotoxicity, the pattern of CTL reactivity seen 68 days after 
infection was maintained until 238 days after infection. 
These results show that different levels of CTL activity can be induced from the same 
initial population of PBMC using different viruses. The CTL induced with EHV-4 and 
assayed on EHV-1 infected targets will be referred to as cross-reactive CTL. The pattern 
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Figure 3.12. CTL induced with EAV-1, EHV-4 or mock antigen in 
PBMC from mare 9219 on 3 occasions after EHV-1 infection. 
a) 68 days after infection. 
b) 203 days after infection. 
c) 238 days after infection. 
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of CTL reactivity induced was maintained over a long period and may be a function of 
the infection history of the individual horses or it may be related to MHC type. 
3.3.6. The effect of rhIL2 on EHV-1 specific CTL induction 
The autocrine T cell growth factor Interleukin 2 (IL2) plays a central role in the induction 
of CTL specific for many antigens in many species (Smith, 1988). In order to assess the 
effect of IL2 on the induction of equine EHV-1 specific CTL induction cultures were set 
up containing different amounts of rhIL2. 
The results in Figure 3.13 show that inclusion of rhIL2 in the CTL induction culture had 
little effect on the maximum levels of lysis of autologous or allogeneic target cells. 
However, the levels of killing obtained at low effector: target ratios were enhanced. This 
may reflect a higher frequency of effector CTL induced in these cultures due to the rhIL2. 
The inclusion of high levels of rhIL2 in the induction culture had no effect on the genetic 
restriction of the resultant CTL. Figure 3.14 shows results from the same experiment 
using #219 effector cells. Again, at 200 IUm1'' rhIL2 killing obtained at low 
effector: target ratios were enhanced. Using PBMC from #219 and 2 IUml-' rhIL2 the 
CTL activity became genetically non-restricted at 50: 1 effector: target ratio only. This 
result was difficult to explain and may be an experimental artifact. 
These results show that the inclusion of rhIL2 in the induction cultures had little obvious 
effect on either the levels of CTL induced or their genetic restriction. However, the 
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Figure 3.13. Effect of rhIIr2 on the induction of EHV-1 specific CTL. 
a) Mare #302 effector cells on autologous EHV-1 infected targets. 
b) Mare -302 effector cells on allogeneic EHV-1 infected targets. 
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Figure 3.14. Effect of rhIIr2 on the induction of EHV-1 specific CTL. 
a) Mare 9219 effector cells on autologous EHV-1 infected targets. 
b) Mare #219 effector cells on allogeneic EHV-1 infected targets. 
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increase in killing at low effector: target ratios when high levels of rhIL2 were used may 
reflect an increase in the efficiency of maturation of precursor CTL to effector CTL under 
these conditions. 
3.3.7. CTL activity in equine T cell sub-populations 
Figure 3.15 shows the results from an experiment in which CTL induced with live EHV-1 
were depleted of either CD4+ or CD8' cells and then used as effectors in a standard EHV- 
1 specific CTL assay. The resultant CTL were assayed on three target cell types, namely, 
autologous infected, allogeneic infected and autologous mock-infected. Very little killing 
was observed when any of the effector populations were assayed on allogeneic infected or 
autologous mock-infected target cells. Depletion of CD4+ cells from the effector 
population had no significant effect on killing of autologous infected target cells when 
compared with effector cells treated with the anti-equine thymocyte monoclonal antibody 
which has been shown not to bind to equine PBMC and therefore was used as a negative 
control. However, CTL depleted of CD8* cells did not kill autologous infected target 
cells above background levels. This is confirmation that EHV-1 specific CTL activity 
induced using live virus resides in the sub-set of cells expressing CD8 on the cell surface, 
3.3.8. Recognition of immediate early and late EHV-1 proteins by CTL 
As a first step towards the delineation of the specific antigens recognised by EHV-1 
specific CTL, experiments were carried out to determine the stage of the viral replication 
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Figure 3.15. In vitro depletion of T cell sub-sets from F. HV-1 specific 
effector cells. 
a) Autologous EHV-1 strain Ab4/9 infected targets. 
b) Allogeneic EHV-1 strain Ab4/9 infected targets. 
c) Autologous Mock infected targets. 
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cycle at which CTL target antigens are expressed. EHV-1 specific CTL were induced 
with live virus and then assayed for CTL activity against autologous infected and mock- 
infected cells which had been treated with cycloheximide and actinomycin D in order to 
restrict expression of viral proteins to the immediate early (IE) proteins only. The results 
are presented in Figure 3.16. 
Figures 3.16a and 3.16b show that assay of CTL on autologous, infected, untreated target 
cells resulted in high levels of specific killing whilst assay of the same CTL on 
autologous, mock-infected, untreated target cells resulted in no specific killing. 
Assay of the same CTL on autologous, infected target cells treated with cycloheximide 
and actinomycin D (Fig. 3.16c) resulted in reduced levels of specific cytotoxicity. 
However, the % specific lysis of the cycloheximide treated infected targets was 
significantly higher (p<0.01 at E: T ratios of 50: 1 and 25: 1 only) than that of 
cycloheximide treated mock-infected targets (Fig. 3.16d). This preliminary result shows 
that IE gene products may have been recognised by effector CTL induced with live EHV- 
1 although further work is necessary in order to confirm that only IE mRNA was 
produced in the cycloheximide/Actinomycin D treated target cells. 
3.4 Discussion 
In this chapter results were presented from experiments designed to characterise the 
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Figure 3.16. Recognition of EHV-l IE protein antigens by ESV-l 
specific CTL induced in PBMC from mare # 302. 
a) Autologous, EHV-1 infected targets. 
b) Autologous, mock infected targets. 
c) Autologous, EHV-1 infected, Cycloheximide treated targets. 
d) Autologous, mock infected, Cycloheximide treated targets. 
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EHV-1 specific CTL assay developed by Allen et al. (1995) with EHV-1 strain A183. 
The assay was optimised for use under our laboratory conditions in the light of our 
previous experience in handling cytolytic cells and with the eventual aim of using the 
technique for the measurement of CTL activity under limiting dilution conditions. The 
assay was also used to extend the results of Allen et. al. (1995) to include studies to 
identify which class of viral proteins were recognised by polyclonal CTL. As there are 
few other reports of assays measuring virus-specific CTL activity from horses it is not 
possible to discuss the results in the light of direct current knowledge. However, there is 
a vast body of work on herpesvirus specific CTL in other mammalian species and 
discussions of my work will take this into account. 
In general, in vitro incubation in the presence of specific antigens is required in order to 
differentiate CTL precursors (CTLp) into fully active cytolytic effector CTL (Lawman et. 
al., 1980b, Lawman et al., 1981, Hannant & Mumford 1989). Exceptions to this rule are 
CTL from humans infected with cytomegalovirus (Quinnan et. al., 1982), CTL from a 
proportion of humans infected with HIV (Rowland-Jones et. al., 1995) and CTL from 
equine infectious anaemia virus-infected horses (McGuire et. al., 1994). The first reports 
of CTL specific for herpes simplex virus (HSV) in the mouse model of human disease 
(Pfizenmaier et al., 1977) required that draining lymph node cells from sub-cutaneous 
injection of virus were cultured for 2-3 days before specific cytotoxicity could be 
demonstrated. One explanation for this need for in vitro incubation was that suppressor 
mechanisms were at work regulating CTL activity in vivo (Rouse & Horohov, 1984). 
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This appeared to be supported by experiments which showed that pre-treatment of mice 
with cyclophosphamide, a suppressor T cell (Ts1) inactivator (Asherson et. al., 1980), 
enhanced both allospecific (Rollinghoff et. al., 1977) and HSV-specific (Lawman et. al., 
1980b) CTL. It is clear from the results presented in 3.3.1. that equine EHV-1 specific 
CTLp require a period of in vitro incubation in the presence of viral antigens before 
antigen specific, genetically restricted CTL activity becomes measurable. There is 
evidence (see Fig. 3.1) that CTL activity generated early after initiation of in vitro 
induction culture was not genetically restricted. This activity, which was lost by day 4 of 
the culture, may have been due to NK or LAK cells generated as a result of the initial 
burst of endogenous lymphokine production. However, EHV-1 specific CTL induced for 
6 days and which killed autologous, infected target cells, did not kill the equine 
lymphosarcoma cell line EqT8888, which is sensitive to LAK cell killing (data not 
shown). The increase in the amount of allo-specific killing with increased time in culture 
seen with CTL from horse #302 (Fig. 3.2) is difficult to explain. The use of EgT8888 as 
a target for these genetically non-restricted CTL would determine whether the activity is 
LAK cell or NK cell mediated. 
In the induction cultures used here it was not necessary to include exogenous 
lymphokines to induce adequate CTL activity. The addition of large amounts of rhIL2 
(Figs. 3.13 and 3.14), shown previously to induce proliferation of activated equine T 
cells, had the effect of increasing the killing of autologous infected target cells by CTL at 
low effector: target ratios. However, the specificity and genetic restriction of the resultant 
125 
CTL remained unchanged. 
High levels of cold target inhibition of effector cell killing was achieved using 
autologous, infected PWM blast cells. Autologous mock-infected cold targets inhibited 
killing of CTL by a maximum of 20% indicating that either a second population of non- 
specific cytolytic cells had developed or that the cold targets were preventing efficient 
contact between the CTL and the labelled targets. The development of non-specific killer 
cells in the induction cultures was unlikely as autologous mock-infected, allogeneic 
infected and allogeneic mock-infected target cells were not efficiently killed in any CTL 
assays performed to date (see Figs. 3.1,3.2,3.6 and 3.7). The partial inhibition of killing 
using allogeneic, infected cold targets (see Fig. 3.5b, open squares) again indicates that, 
non-specific blocking of efficient contact between CTL and labelled target cells occurred. 
The induction of non-specific killers in induction cultures of the LAK cell type did not 
occur as CTL did not kill the LAK cell sensitive EqT8888 cell line (data not shown). 
Because of recent results presented at the second Equine leukocyte antigen workshop 
(Lake Tahoe, USA, 1995), it should be possible to measure the proportion of NK cells 
induced by depletion of the effector cell population using monoclonal 
antibodies specific for human CD16. This molecule, present on the surface of NK cells, 
is an Fc receptor and recognises approximately 10% of equine PBMC (J. Kydd, Animal 
Health Trust, Newmarket, personal communication). Another explanation for the 
inhibition of CTL activity by allogeneic infected cold targets (Fig. 3.5b, open squares) is 
that the effector cells may be MHC class II restricted. Although the two horses used in 
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this experiment were shown to be ELA class I disparate (as demonstrated by IEF of 
immune precipitated ELA antigens), they may have shared class II alleles. Whatever the 
mechanism behind the observed allo-specific inhibition, it is clear that genetically 
restricted CTL comprise the majority of the effector cell population because autologous 
cells were much more efficient as cold targets compared with allogeneic cells. 
Direct, evidence of the prevalence of CD8+ CTL in the induced population was obtained 
from the T cell depletion experiment (Fig. 3.15). The high levels of specific, genetically 
restricted cytotoxicity observed in the CD4-depleted but not in the CD8-depleted 
populations indicates a major role for CD8+ T cells in the killing of EHV-1 infected target 
cells in vitro. These results agree with those of Allen et. ai. (1995). Depletion rather than 
positive selection with monoclonal antibodies was used in this experiment in order to 
avoid modulation of CTL activity due to the binding of antibodies to cell surface 
molecules. 
The mechanisms involved in the development of EHV-1 specific effector CTL from 
CTLp using live virus are not obvious from the studies carried out. However, the 
observation that, in resting PBMC populations, up to about 20% of the cells are infectable 
with EHV-1 strain Ab4 (see chapter 2) means that these cells may act as antigen 
presenting cells for CTLp in induction cultures. The presence of neutralising antibody in 
the autologous serum prevents the release of live virus which may inhibit the proliferation 
of CTLp. The presence of activated, T cells of both the CD4 (17% infected) and CD8 
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(24% infected) phenotype (Allen et. al., 1995) precluded the need for the addition of 
exogenous lymphokines. 
Using this system it has been relatively easy to demonstrate high levels of specific, 
genetically restricted cytotoxicity in adult, immune animals. However, these 
experiments, whilst valuable in the development of CTL assay techniques, do not tell us 
much about the role of EHV-1 specific CTL in field infections. In order to begin to 
address this point, a wider range of horses, including foals of various ages, were studied. 
As outlined in chapter 1, it is known that foals become infected with EHV-1 or EHV-4 
early in life, thus developing a degree of immunity to each virus (reviewed in Allen & 
Bryans, 1986). This immunity has been characterised by the development of specific 
virus neutralising antibodies. However, until now, it has not been possible to assess 
whether virus-specific CTL develop after these early infections. The data presented in 
Figures 3.8 and 3.9 strongly suggests that the initial infection of young animals occurs 
before 10 months of age and that this primary infection results in the development of a 
degree of CTL activity. It is clear from Figures 3.8a, 3.9a and 3.9b that the animals 
represented here, one 18 day old foal, one 3 week old foal and one 4 month old foal, had 
no detectable CTL activity whilst the animal represented in Figure 3.8b, a 10 month old 
foal, had developed significant, measurable CTL. The measurement of weak CTL 
activity after a true primary infection (Fig. 3.10), indicates that this arm of the immune 
response to EHV-1 is not vigorous. The necessity of laborious and expensive production 
of small numbers of SPF animals (Chong et al., 1991) in order to study primary 
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responses to equine viruses was questioned by data presented in Figures 3.8 and 3.9. 
These data suggest that young, conventionally reared animals did not become infected 
with either EHV-l or EHV-4 until at least 4 months of age. This raises the possibility 
that with careful management and frequent immunological monitoring, these ponies 
could be used for the study of primary infections instead of SPF foals. 
In older animals, repeated infection with EHV-1 and/or EHV-4 results in the 
development of cross-reactive CTL (see Fig. 3.11 and Allen et. al., 1995). Results 
presented in Fig. 3.11 show that CTL induced from different immune animals reacted 
differently to various isolates of EHV-1 and EHV-4. Figure 3.12 shows that this 
differential pattern of response persisted over a long period and between different assays. 
This observation may reflect differences in the infection histories of the ponies or 
differences in the capacity of each pony to respond to particular epitopes on each of the 
viruses. Another possibility is that a reduced reaction to a particular virus (e. g. EHV-1 
Ab4 in Fig. 3.12) may have occurred due to a hyperactivation of cells in the in vitro 
culture system which subsequently depleted nutrients from the culture medium and hence 
produced a lower than expected % specific cytotoxicity value. More work is needed to 
characterise the nature of the cross-reaction and differential reactivity of CTL. The re- 
stimulation of cross-reactive CTL with EHV-1 and EHV-4 is analogous to the situation in 
which HSV induces both types of CTL activity in mice after infection (Eberle et. al., 
1981, Carter et al., 1982). Cross-reactive and type-specific cytolytic T cell clones 
against HSV-1 and HSV-2 have also been demonstrated in humans (Yasukawa & 
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Zarling, 1984). 
The preliminary studies presented in section 3.3.8 suggest that a proportion of EHV-1 
induced CTL recognise immediate early proteins. Further analyses of this type will 
determine which antigens from EHV-1 and EHV-4 are recognised by virus-specific CTL. 
In order to determine the cross-reactive or type-specific nature of the anti EHV CTL 
response the derivation of T cell clones or the use of limiting dilution analysis (LDA) is 
necessary. The cloning of equine EHV specific CTL has proven difficult (D. Hannant, 
Animal Health Trust, Newmarket, personal communication), however, an LDA assays for 
the measurement of anti EHV-1 and EHV-4 CTLp frequencies has been developed and is 
reported in chapter S. 
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4.1. Introduction 
The roles of antibody and in vitro proliferation of equine PBMC to inactivated EHV-1 
(iEHV-1) as indicators of immunity to EHV-1 have been widely studied (Stokes et. al., 
1991, Thomson & Mumford, 1977, Dutta et al., 1980). These studies (see also Mumford 
et. al., 1987, Hannant et al., 1993) have shown that high levels of virus neutralising 
antibodies do not prevent infection of horses with EHV-1. The conclusions from T cell 
proliferation studies have been that there was great variation in responses between 
individuals after infection with EHV-1 and that the levels of lymphocyte stimulation do 
not correlate with immunity. Evidence for effective immunity to EHV-1 has come from 
experiments in which animals were repeatedly infected with the virus. For example, 
Allen and Bryans (1986) showed that intranasal infection of seronegative weanling foals 
with EHV-1 and subsequent re-infection four weeks later with either EHV-1 or EHV-4 
resulted in immunity against challenge with the homotypic virus but not with the 
heterotypic virus. Further, it was shown that after three sequential infections with either 
EHV-1 or EHV-4 (second infection four weeks after primary infection and third infection 
five months later), foals were resistant to challenge with the heterotypic virus. In contrast 
to these results, Edington (1990) showed that two consecutive EHV-4 infections did not 
prevent infection or significantly reduce the duration of nasal shedding after EHV-1 
challenge. However, two consecutive infections of yearling ponies with EHV-l spaced at 
five month intervals protected against a tertiary infection five months later with EHV-4. 
Despite the differences seen in these studies, which may have been due to differences in 
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experimental design, both authors concluded that multiple infections with EHV-4 may 
give some protection against a potentially more serious EHV-1 infection. The protective 
mechanisms were not discussed in depth by either author. Conclusions would have been 
difficult to make given that the only immunological parameter measured was the level of 
circulating antibody. From these studies, it is clear that infection by either virus does not 
induce complete immunity against both EHV-1 and EHV-4. Moreover, the effector 
mechanisms responsible for resistance are as yet, not understood. Because serum 
antibody appears to play no role in protection, it is likely that cellular immune responses 
have important functions in immunity to EHV. 
Although there have been several studies documenting in vitro proliferative responses of 
PBMC to viral antigen after EHV infection, there is no evidence to suggest that high 
levels of PBMC proliferation correlate with immunity to infection. Therefore, a study 
was carried out to determine if in vitro measures of T cell function would be of value in 
this respect. T cell function was assessed using polyclonal activation of PBMC with 
mitogens and viral antigens, and by measuring the precursor frequency of EHV-1-specific 
proliferative T cells using limiting dilution analysis (LDA). The objectives were to 
measure T cell responses in horses before and after EHV-1 infection and by observation 
of the virological outcome of infection, to determine if these responses correlated with 
immunity. Four horses were examined in this study, 2 had received multiple previous 
experimental infections with EHV-I, whilst the other 2 had not. 
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4.2. Materials and Methods 
4.2.1. Animals and infection 
Four pregnant Welsh mountain pony mares (#24, #26, #219 and #302) were infected with 
108.4 TCID50 of a plaque-purified strain of EHV-i Ab4/13 (Telford et. al., 1992) by 
exposure to a nebulised aerosol as described (Mumford et. at, 1990 and 1994). This 
isolate has been shown to share the pathogenic characteristics of an earlier passage strain 
(Ab4/11 grown in RK13 cells) in specific pathogen free (SPF) foals (Gibson et. al., 
1992b). The mares were infected in the ninth month of gestation. Mares #24 and #26 
were obtained from a supplier and for 9 months before infection did not show any 
serological evidence of infection or recrudescence of EHV-1 or EHV-4 (Thomson et. al., 
1976b). Animals with a similar history have been shown to be susceptible to EHV-1 
infection (Mumford et. al., 1994). Mare #219 had received one previous experimental 
infection with EHV-1/Ab4 whilst pregnant and one whilst non-pregnant, and #302 had 
received one previous experimental infection with EHV-1/Ab4 whilst pregnant within the 
previous two years. 
4.2.2. Sampling, serology and virus isolation 
After infection, the mares were sampled regularly for the determination of serum 
complement-fixing (CF) antibody (Thomson et. aL, 1976a) and virus isolation from nasal 
swabs and heparinised blood (Mumford et. al., 1987). Rectal temperatures were recorded 
daily for two weeks. 
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4.2.3. Lymphoproliferation assays 
Equine PBMC were isolated from whole blood using Ficoll Hypaque (Pharmacia Biotech 
Ltd, Milton Keynes, Beds. ) as described in section 3.2.1. They were resuspended in 
complete RPMI (cRPMI), at a concentration of 2x106ml'1. 
Aliquots of PBMC (10041) were distributed into round bottomed microwell plates 
(Falcon, Becton Dickinson Labware, Cowley, Oxford) containing titrated amounts of the 
mitogens Con A (2.5ggml-' to IOµgml'') or PHA (0.625. tgm1'' to 2.5ggm1'') in 100µI 
volumes, giving a total culture volume of 2O0µl. Antigen-specific proliferation was 
assayed using iEHV-1 antigen (virus heat-inactivated at 60°C for 30 min) because 
preliminary experiments showed that PBMC did not respond to live virus antigen in vitro 
(data not shown). Moreover, live EHV-1 virus was shown to inhibit proliferation 
stimulated by mitogen or third party antigens (see below). Unstimulated control PBMC 
were set up in cRPMI only. 
The mitogen assays were incubated for 48 hours and the antigen cultures were incubated 
for 120 hours at 37°C in an atmosphere of 5% CO2 in air. Subsequently all cultures were 
pulsed with O. 5µCi of tritiated thymidine per well for 18 hours before harvesting onto 
glass fibre filters using a Skatron cell harvesting system (Skatron Ltd, Newmarket, 
Suffolk. ). Scintillation fluid (Ultima Gold. Canberra Packard, Pangbourne, Berks. ) was 
added to each filter disk (lml per disk) and the radioactivity was counted in a scintillation 
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counter (Packard). Results were presented as counts per minute (cpm) and stimulation 
indices (SI = cpm stimulated well/cpm control well). 
To demonstrate the effects of culturing live or iEHV-1 on the proliferation of viable 
PBMC stimulated with mitogens or third party antigens (Keyhole Limpet Haemocyanin- 
KLH), variations in the basic lymphoproliferation assay were made. In these 
experiments, live or iEHV-1 (strain Ab4/13) was titrated in cRPMI in microtire plates 
and 2x101 PBMC containing dilutions of mitogen (PHA) or KLH were added. In the 
experiments with KLH, the PBMC were obtained from a horse which had been 
immunised twice with 100µg KLH in an aluminium hydroxide adjuvant (alhydrogel). 
The virus used was titrated in log steps from 1x1076 to 1x 101.6 TCIDsoml'', the PHA was 
used at 2.5,1.25,0.625 and Oµgm1'' and the KLH was used at 25,12.5,6.25 and Oggm1'' 
in a total culture volume of 200µl. Again, all cultures were pulsed with 0.5pCi of 
tritiated thymidineEper well for the final 18 hours of the incubation period before 
harvesting. Comparisons were made between the pre- and post-infection cpm and SI 
values using Student's t test. 
4.2.4. Proliferative limiting dilution analysis 
A proliferative LDA assay was developed based on the assay described by Fischer et al. 
(1991). An explanation of the theory behind LDA is provided in Appendix B. 
.* -ýb- c6 G, I1, DL. 
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Varying numbers of responder PBMC were cultured in 200µl volumes in the presence of 
A 
20,000 autologous cells which had been treated with mitomycin C (Sigma) and a final 
dilution of 1/500 of iEHV-1 derived from pelleted virus (originally 1010.1 TCID5Q ml''). 
The cultures were set up in round bottomed microtitre plates. As negative controls, 
cultures were set up containing mitomycin C treated PBMC with antigen but no 
responder cells. Each responder cell concentration was set up using a replicate number of 
24 as recommended (Fazekas de St. Groth, 1982). 
The LDA cultures were incubated at 37°C for 6 days including an 18 hour pulse with 
0.5 jCi per well of tritiated thymidine and cultures were harvested and counted as 
described for the conventional lymphoproliferative assays. 
Positive wells were identified as those in which the measured cpm were greater than 3 
standard deviations above the mean cpm in the control wells. The data for each assay 
were tabulated and the frequency of responding cells was estimated using the computer 
program designed by Strijbosch et. al. (1988). The Jacknife version of the maximum 
likelihood method was used for statistical analysis as recommended (Strijbosch et. at, 
1987). Any frequency determinations which generated chi squared goodness-of-fit 
statistics greater than published values, using the dilution number minus one for the 
degrees of freedom, were rejected as not satisfying single hit kinetics (Bouma et, al. 
1992). The frequencies of responding cells in any two populations were considered 
significantly different if their 95% confidence limits did not overlap (Fischer et. at. 1991). 
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The statistical analysis is explained in more depth in appendix B. Examples of the data 
obtained from these experiments are shown in appendix C. 
4.3. Results 
4.3.1. The effect of EHV-1 on in vitro immune functions 
During EHV-I viraemia the in vitro proliferation of PBMC in response to mitogens is 
suppressed (Hannant et. al., 1991. see also figures 4.4,4.5,4.6 and 4.7). This may be due 
to the suppressive effects of cell-associated EHV-1 antigen present during viraemia. 
Experiments were carried out in order to determine the effect of live or iEHV-1 on in 
vitro proliferation of equine PBMC. Live or iEHV-1 were included, at various 
concentrations, in assays of proliferation to mitogen and specific antigen. 
Figure 4.1a shows that live virus suppressed the response of equine PBMC to PHA. At 
virus concentrations between 1x101.6 and 1x103.6 TCID50ml'', equivalent to multiplicities 
of infection (moi) of between 0.00002 and 0.2, the mean cpm of the PHA response was 
significantly (p<0.05) reduced by approximately 20%. When the TCID50 of the virus 
exceeded 1x10'-6 TCIDsoml'' the mean cpm decreased further until at an moi of 20 the 
proliferative response was reduced by approximately 95% (p<0.001). 
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Figure 4.1. The effect of live and inactivated EHV-1 on in vitro 
mitogen induced proliferation of equine PBMC. 
a) Live EHV-1 
b) Heat inactivated EHV- I 
Significant reductions in mean cpm occurred at: 
a) Between 1x10'"6 and 1x105'6 TCID50 p<0.05. 
Between 1x106.6 and 1x107.5 TCID50 p<0.001. 
b) Between 1X10'"6 and 1x101.6 TCID50 no significant decrease. 
Between 1x106.6 and 1x1O' TCID50 p<0.01. 
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When iEHV- I was used in an identical experiment (Fig. 4.1 b) the mean cpm remained at 
or above the level of proliferation induced in the absence of virus between virus 
concentrations equivalent to 1x101.6 and 1x10'"6 TCID50ml''. Mean cpm values above this 
level in this experiment reflected the contribution of antigen-specific proliferation to the 
total response. When the virus concentration was increased further, some suppression of 
the mitogenic response was seen (up to approximately 37% at an moi of 20), however, 
the reduction in mean cpm caused by iEHV-1 was much lower than that caused by live 
EHV-1. 
When the effects of live EHV-1 on antigen-specific responses to the third party antigen 
KLH were measured, the responses were, again suppressed. Figure 4.2a shows the 
reduction of the mean cpm in response to KLH caused by live EHV-1, Between virus 
concentrations of 1x10'"6 and 1x1056 TCID50m1'' the reduction of mean cpm was 
relatively constant (significant reductions occurring at a KLH concentration of 12.5µgml'' 
only). At higher concentrations of live virus, the mean cpm values decreased to 
significantly (p<0.01). When iEHV-1 was used, there was no significant reduction of the 
mean cpm (fig. 4.2b). 
Further analysis of the data from the KLH experiment revealed that when no KLH was 
included in the proliferation assay significant EHV-1"specific proliferative response 
occurred to iEHV-I at concentrations above 1xI06 TCID50ml-'. The results from this 
assay (Figure 4.3) showed that live EHV-l did not stimulate a proliferative response 
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Figure 4.2. The effect of live and inactivated EHV-1 on in vitro 
antigen induced proliferation of equine PBMC. 
a) Live EHV-1 
b) Heat inactivated EHRT-1 
Significant reductions in mean cpm occurred at: 
a) Between 1x10'"6 and 1x105.6 TCID50 p<0.05. 
Between 1x106.6 and 1x10'-5 TCID50 p<0.02. 
b) Between 1x10'"6 and 1x10'6 TCIDso no significant decrease. 
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above background levels. These results showed that it was not possible to use live EHV- 
1 to study virus-specific T cell proliferation. Hence, inactivated virus was used for all 
subsequent antigen-specific proliferation assays. Additionally, the data suggest that 
productive virus infection of PBMC during periods of cell-associated viraemia has the 
potential to suppress in vivo antigen specific proliferative responses. 
4.3.2. Responses to challenge infection with EHV-1/Ab4/13 
Of the four mares infected with EHV-1/Ab4/13, two (#24 and #26) had unknown 
previous infection histories, although they had no serological evidence of infection for 9 
months prior to the infection study. Of the other two mares, #219 had received one 
previous experimental infection with EHV-l/Ab4 whilst pregnant and one whilst non- 
pregnant, and #302 had received one previous experimental infection with EHV-1/Ab4 
whilst pregnant within the previous two years (see materials and methods for the timings 
of the previous infections). 
A summary of the clinical and virological responses of mares #219 and #302 to their first 
previous experimental infection (referred to as the initial infection) can be seen in Table 
4.1. The clinical and virological responses of all four mares to EHV-1/Ab4/13 infection 
are shown in Table 4.2a. 
Infection of mares #24 and #26 with EHV"1/Ab4/13 resulted in pyrexia (a body 
temperature of above 102°F or 38.9°C) in both animals for 2 days, However, no 
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Table 4.1. Clinical and virological responses following first 
experimental infection with EHV-1 Ab4/8. 
a) Duration of clinical and virological signs. 
Duration (Days) 
Mare Pyrexia Viraemia Nasal VI 
219 243 
302 186 
Nasal VI = Virus isolation from nasal swab extracts. 
Viraemia = Virus isolation from heparinised blood. 
Both ponies seroconverted as measured by CF. 
b) Level of virus in nasal swabs. 
Days after aerosol infection 
123456789 10 
219 ND 2.6 2.3 2.9 ------ 
302 3.6 4.1 3.6 4.1 3.6 2.4 ---- 
Results presented as TCID5Q ml` nasal swab extract 
ND = not determined 
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Table 4.2. Clinical and virological responses following infection with 151 EHV-1 Abo/8. 
a) Duration of clinical and virological signs. 
Duration (Days) 
Mare Pyrexia Viraemia Nasal VI 
24 2 54 
26 2 47 
219 0 23 
302 0 31 
Nasal VI = Virus isolation from nasal swab extracts. 
Viraemia ý Virus isolation from heparinised blood. 
All ponies seroconverted as measured by CF. 
b) Level of virus in nasal swabs. 
Days after aerosol infection 
123456789 10 
24 ND 5.6 4.6 3.3 3.6 ----- 
26 3.1 4.6 5.3 4.8 3.8 4.1 2.1 --- 
219 1.3 4.6 - 1.3 ------ 
302 3.6 - 
Results presented as TCID50 ml" nasal swab extract. ND = not determined 
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pyrexia was seen in mares #219 and #302 in contrast to their initial infections (Table 
4.1 a). The pyrexic responses of all four mares were markedly different to the well- 
documented biphasic pyrexic response seen after infection of "susceptible" mares 
(Mumford et. at., 1994). This suggests that mares #24 and #26 had a degree of immunity 
to EHV-I due to previous exposure. However, this degree of immunity was not as 
effective as that induced by previous experimental infections in #219 and #302, as these 
animals were protected against pyrexia after challenge. 
Mares #219 and #302 excreted less virus for a shorter time from the nasopharynx when 
compared with mares #24 and #26 (see Table 4.2b). After ETN-I Ab4/13 challenge both 
mares #24 and #26 showed signs of virus-induced disease. For example, mare #24 
became ataxic between 9 and 11 days after infection whilst mare #26 gave birth to a weak 
foal, which died soon after birth, I5 days after infection. Mares #219 or #302 showed no 
such disease and produced healthy foals at full-term. After their initial infection with 
EHV-1 Ab4, mare #219 aborted whilst mare #302 carried her foal to term despite the fact 
that she excreted 100 fold more virus from the nasopharynx than #219 and showed a 
longer period of cell associated viraemia (see Table 4.1). All mares seroconverted as 
measured by the CF assay (data not shown). 
4.3.3. Bulk culture iymphoproliferative responses 
Bulk culture, mitogen-induced proliferation of PBMC from mares #219 and #302 showed 
that the rapid reduction in responsiveness to PHA and Con A after EHV-1 infection, 
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reported by Hannant et. al. (1991), was delayed in these animals (see Figures 4.4 and 4.5) 
when stimulation index was used. SIs were equivalent to or slightly above pre-infection 
levels 7 days after infection but were reduced significantly 14 (p<0.001) and 21 (p<0.01) 
days after infection. However, when mean cpm were analysed, no reduction in the 
response of PBMC from either mare was seen (Table 4.3). The reduction in the SI values 
on days 14 and 21 post-infection were entirely due to increases in the background cpm on 
those days. 
Mitogen-induced proliferation of PBMC from mares #24 and #26 was monitored up to 
day 28 after infection. Pre-infection SIs were similar to those of mares #219 and #302. 
One day after infection responses of PBMC to both PHA and Con A were significantly 
lower (p<0.00I and 0.01 respectively, see Figures 4.6 and 4.7) than pre-infection SIs, 
except when PBMC from mare #26 were stimulated with Con A (see Figure 4.7a). The 
response was further reduced in both animals 7 days after infection (p<0.001). These 
reductions in SI values after infection with EHV-I were not due to increases in the 
background cpm (Table 4.4). Mitogen-induced SI values from these ponies were 
significantly increased above pre-infection levels 14 and 28 days after infection. 
However, when mean cpm were analysed, there was only a significant increase above 
pre-infection cpm values on day 14 post-infection. The significance of the observed 
reductions in the responsiveness of PBMC to mitogens and the subsequent enhancement 
of the response in these animals after EHV-1 infection is unclear, although a link with 
viraemia seems likely. 
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Figure 4.4. Mitogen-induced proliferation of PBMC from mare #219 
after MV-1 infection. 
a) Con A induced proliferation 
b) PHA induced proliferation 
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Figure 4.5. Mitogen-induced proliferation of PBMIC from mare #302 
after EHV-1 infection. 
a) Con A induced proliferation 
b) PHA induced proliferation 
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Table 4.3. Proliferation of PBNIC from mares #219 and #302 in 
response to mitogens before and after infection with EHV-1. 
Results are mean counts mint tritiated thymidine uptake 2x10$ cells'. 
Mean CPM 
Day post-infection with PHA (pg/ml) with Con A (µg/ml) 
1.25 2.5 2.5 5.0 Bkg 
Horse #219 
Pre-infection 1655 1323 
7 5482 4384 
14 6267 4303 
21 4919 3531 
2708 3924 123 
7152 11764 225 
10513 6266 1841 
5407 4192 519 
Horse #302 
Pre-infection 3471 2328 2450 4243 79 
7 7604 8288 7934 14608 228 
14 4444 3151 8652 5568 556 
21 3535 2721 5407 5052 175 
BKG = Background cpm without mitogen. 
CPM = Counts per minute. 
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Figure 4.6. Mitogen-induced proliferation of PBMýIC from mare #24 
after EHV-1 infection. 
a) Con A induced proliferation 
b) PHA induced proliferation 
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Figure 4.7. Mitogen-induced proliferation of PBMC from mare #26 
after EHV-1 infection. 
a) Con A induced proliferation 
b) PHA induced proliferation 
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Pre 17 14 28 
Days post EHV-1 infection 
Pre 17 14 28 
Days post EHV-1 infection 
Table 4.4. Proliferation of PBMC from mares #24 and #26 in 
response to mitogens before and after infection with EHV-1. 
Results are mean counts min- t tritiated thymidine uptake 2x105 cells''. 
Mean CPM 
Day post-infection with PHA (µg/ml) with Con A (4g/m1) 
1.25 2.5 2.5 5.0 Bkg 
Horse #24 
Pre-infection 29227 29219 29600 36842 886 
1 891 643 626 1020 54 
7 1171 919 1149 1793 331 
14 38974 38085 42893 37497 427 
28 28770 30815 18830 30815 269 
Horse #26 
Pre-infection 26083 28118 18866 22611 1062 
1 603 435 800 857 47 
7 917 819 689 988 90 
14 43540 45813 44333 27137 1143 
28 14078 15405 12721 16373 478 
BKG Background cpm without mitogen 
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The virus-specific proliferative responses of PBMC from mares #219 and #302 to iEHV- 
I are shown in Figure 4.8. Marc #219 had a pre-infection SI of 23.6 which fell to 3.5 on 
day 7,2.1 on day 14 and 1.0 on day 21 post-infection. A rise in SI occurred 28 days post- 
infection. The reduction in SI on day 7 post-infection was reflected in a reduction in the 
mean cpm. The subsequent reductions in SI were partly due to increases in background 
proliferation (data not shown). Mare #302 did not respond significantly to iEHV-1 up to 
day 21 after infection, the SI values being 2.6 pre-infection, 0.9 on day 7,0.9 on day 14 
and 1.7 on day 21 post-infection. This lack of response was reflected when the mean cpm 
was analysed. Lymphoproliferative responses of whole PBMC from mares #24 and #26 
to iEHV-1 were not analysed. 
4.3.4. Antigen-specific proliferative LDA 
The precursor frequencies of cells capable of proliferating to iEHV-1 in PBMC from all 
four mares before and 4-5 weeks after infection are shown in Table 4.5. The design of 
the proliferative LDA assay and the stringency afforded to the analyses are summarised in 
Appendix B. Examples of the experimental design, treatment of data and analyses of 
results in order to calculate the precursor frequency values given in Table 4.5 are shown 
in Appendix C. 
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Figure 4.8. ERN-1 induced proliferation of PBMC from mares #219 
and #302 after EHV-1 infection. 
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Table 4.5. Precursor frequencies of EHV-1-specific T cells in the 
peripheral blood of mares before and after infection with 
EHV-1/Ab4/13 as measured by limiting dilution analysis of antigen- 
specific proliferative responses. 
Reciprocal Frequencies of EHV-1 specific T cell precursors 
Mare No. Pre-infection 4-5 weeks post-infection 
#24 13,889 10,309 
(10,989 to 18,868) 
#26 8,547 
(6,369 to 12,987) 
#219 22,222 
(16,667 to 33,333) 
(8,130 to 14,286) 
2,532 
(1,805 to 4,255) 
4,651 
(3,788 to 6,024) 
#302 <250,000 2,387 
(undetectable) (1,946 to 3,096) 
95% confidence limits in parenthesis. 
N. B. Refer to the addendum located inside the back cover for further information concerning this 
data. 
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The frequency of precursor cells capable of proliferating to iEHV-1 before infection in 
PBMC from #219 was 1/22,222. This increased to 1/4,6515 weeks after infection. The 
frequency of precursors in PBMC from mare #302 before infection was less than 
1/250,000 (undetectable) and 5 weeks after infection was 1/2,387. 
The frequencies of precursor cells in PBMC from mares #24 and #26 before infection 
were higher than those in cells from mares #219 and #302 (Table 4.5). This was 
unexpected because mares #24 and #26 had not experienced experimental infections 
within the previous 2 years, unlike mares #219 and #302. The pre-infection frequencies 
were 1/13,889 in mare #24 and 1/8,547 in mare #26. The frequencies of precursor cells 4 
weeks after infection were 1/10,309 in mare #24 and 1/2,532 in mare #26. 
The presence of relatively high frequencies of precursor cells capable of proliferating to 
iEHV-1 in PBMC from pregnant animals which became infected and subsequently 
aborted suggests that antigen-specific T cell responses are not indicative of protective 
immunity from EHV-1 disease. This is supported by the observation that the frequencies 
of precursor cells in the multiply infected mares w Ed-C bw c%- 
prior to challenge even though -roLo were protected from abortion. 
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4.4. Discussion 
The results have shown that live EHV- I strain Abo suppressed the in vitro immune 
functions of equine lymphocytes. The mechanism of this suppression is unclear, 
although from the experiments showing the infection of equine blast cells presented in 
chapter 2, it is likely that the in vitro suppression was due to infection of stimulated 
lymphocytes by live EHV-1. It is clear that inactivated virus antigens only should be 
used for any in vitro study of antigen specific CMI based on proliferative responses of 
equine PBMC. 
The clinical and virological data from the infection of ponies with EHV-1 strain Ab4/13 
illustrated the importance of the collection of complete data sets for analysis. For 
example, although there was no obvious clear cut differences in the duration of the virus 
isolation from nasal swab extracts between the multiply infected (#219 and #302) and the 
initially infected (#24 and #26) mares, there was a difference in the total amount of 
excreted infectious EHV-1 when nasal swab extracts were titrated (see Table 4.2a & 
4.2b). The total amounts of virus measured in nasal swab extracts from mares #219 and 
#302 after initial infection (Table 4.1b) indicated that this parameter was not a reliable 
indicator of the outcome of infection as mare #219 aborted despite excreting 100 times 
less virus over a2 day shorter time period than mare 4302 which produced a healthy foal. 
McCulloch et al. (1993) carried out an exhaustive study of the changes in circulating 
leukocyte populations after EHV-1 infection, but did not report any data on nasal 
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excretion of virus or cell associated viraemia. The subsequent discussion of the inherent 
variability in the phenotype of cells in the blood after EHV-1 infection, therefore, took no 
account of the differences in the infection histories of the (previously infected) outbred 
horses in the study and thus missed the opportunity to correlate these changes with 
specific clinical outcome. 
The clinical differences between the initially infected (#24 and #26) and the multiply 
infected (#219 and #302) mares in this study were clear. Both of the initially infected 
mares aborted whereas both of the multiply infected mares did not. 
The responses of equine PBMC to mitogens have been studied by a number of 
investigators. Dutta et. al. (1980) showed that, after an initial increase in responsiveness 
to PHA, PWM and Con A, PBMC from infected mares became refractory to mitogenic 
stimulation. This suppression reached its lowest level 10 days after infection and 
recovered to near pre-infection levels by 14 days after infection. This initial increase in 
mitogen responsiveness prior to suppression was also reported by Bumgardner et, al. 
(1982). Hannant et. al. (1991) demonstrated that, after EHV"1 (strain V592) infection of 
young ponies, a relatively long-term suppression of the in vitro PHA response of PBMC 
ensued. This long term suppression did not occur in the present study. Instead, there was 
no suppression of the response to PHA or Con A in the two multiply infected animals, 
whilst a transient suppression followed by a significant enhancement of the response 
occurred in the two initial infection animals. 
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The reasons for these changes in responsiveness to mitogens after EHV-1 infection are 
unclear. During the non-responsive period, the only virus isolated, by co-cultivation of 
samples on a permissive cell line, was from the blood. The viraemia which occurs after 
EHV-1 infection typically lasts for up to 21 days (Mumford et. at, 1994) after infection 
as does the period of in vitro non-responsiveness using EHV-1 strain Ab4 (D. Hannant, 
AHT, Newmarket, personal communication). The observation of a temporal correlation 
between these two phenomena suggests that they are causally related. The data presented 
in Figures 4.6 and 4.7 support this speculation, as the periods of viraemia in the two 
mares span the periods of the most significant decreases in mitogen responsiveness (#24 
viraemic between days 3 and 11 after infection, #26 viraemic between days 5 and 11 after 
infection). 
The data presented in this chapter show that live EHV-1 interferes with the in vitro 
responsiveness of equine PBMC to mitogens (see figures 4.1 & 4.2). This has also been 
reported for bovine herpesvirus type 1 (BHV-1). Moreover, live BHV-1 is also able to 
reduce the proliferation of lymphoblasts to interleukin 2 (IL2, Carteret. al., 1989). Allen 
et. al. (1995) showed that EHV-1 was able to replicate in Pokeweed mitogen (PWM) 
induced blast cells but not in unstimulated equine PBMC (see also Thomson & Mumford, 
1977). Given that EHV-1 has not been shown to grow to any extent in equine 
monocytes, polymorphonuclear leukocytes or B cells, it may be that in vivo activation of 
PBMC could facilitate the cell to cell spread of virus for a period of up to 21 days, at 
which time virus-specific cell-mediated immune responses clears the viraemia. In primed 
159 
animals, T cell memory is enhanced, therefore cell associated viraemia is cleared quicker 
than in naive animals. 
Evidence exists for the in vivo activation of equine PBMC after EHV"l infection. 
Thomson et. al., (1976b) reported the spontaneous proliferation of equine PBMC in vitro 
after EHV-1 infection, whilst McCulloch et. al., (1993) reported the presence of blast 
cells in the blood of horses after infection, detected by analysis with a fluorescence 
activated cell sorter (FACS). These blast cells were readily detectable 4 days after 
infection and observed for a further period of about 10 days. It was not reported whether 
these blast cells were T cells, or whether they were permissive to EHV-1 infection, 
although they are obvious candidates for further study. If these blast cells are the source 
of viraemia, control by T cell-specific mechanisms has been suggested by the finding that 
treatment of SPF foals with cyclosporin A (CyA) during an EHV-1 challenge prevented 
clearance of viraemia (Slater et al., 1994). Viraemia was only cleared from these foals 
when CyA treatment was discontinued, suggesting aT cell-mediated clearance 
mechanism. 
The inherent variability of antigen-specific proliferative assays, after infection with EHV- 
1, was also demonstrated by Allen et. al. (1995) who showed that infection of six horses 
with EHV-1 strain A183 resulted in the production of antibody (as measured by ELISA) 
and antigen-specific in vitro proliferation of PBMC. Both of these immune parameters 
were variable between horses with the peak ELISA antibody titre varying between 
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approximately 1/4,000 and 1/12,000 and the peak antigen-specific proliferation Si 
varying between approximately 8 and 80. High ELISA antibody titre did not seem to 
correlate with high SI. 
The proliferative LDA described in this chapter was used primarily as a technique to 
determine whether the frequency of precursor T cells detected before challenge with 
EHV-1 correlated with immune status. The precursor frequency of antigen-specific T 
cells increased in 3 out of 4 horses after infection (Table 4.5). However, as the pre- 
infection frequencies of responding cells in the two initially infected mares were higher 
than those in the two multiply infected mares, no correlation between frequency and 
outcome of infection seemed to exist. The lack of antigen-specific T cell responses in 
bulk culture seen after infection was reflected in the proliferative LDA results. For 
example, the complete lack of any antigen-specific proliferative response in PBMC of 
mare #302 up to 21 days after infection was mirrored by the very low frequencies of 
proliferative cells in this animal before infection. 
Further work needs to be done to clarify the events which occur in the acute phase after 
EHV-1 infection. This work needs to include experiments to define the cell types 
involved in the establishment and control of viraemia, as this seems to be of central 
importance to the progression of disease. Finally, more relevant immune parameters 
must be identified in order to predict protection against and recovery from EHV-1. 
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5.1. Introduction 
The genetic (Studdert et. al., 1981), serologic (Homer, 1981) and pathogenic (Edington, 
1990) relationships between EHV-1 and EHV-4 have been well studied. However, there 
is no information on the potential for these viruses to stimulate CTL precursors (CTLp) to 
develop into effector CTL in vitro after infection. 
In chapter 3 it was shown that cross-reactive CTL activity could be induced in bulk 
cultures of PBMC of horses after infection with EHV-1/EHV-4. These bulk culture CTL 
assays had the capacity to distinguish between naive and previously infected horses (see 
chapter 3) but were less reliable when comparing CTL activities between the latter. In 
contrast, there is evidence that the measurement of the CTL precursor frequency may 
provide a more valuable indicator of effective CMI responses to virus infections (Doherty 
et. at., 1994. Klein et al., 1995). The experiments described in this chapter were 
designed to determine the frequencies of CTLp present in the blood of horses before and 
after infection with EHV-1 or EHV-4 and to assess the contribution of CTL to recovery 
from disease. Because the animals which were available for this study were adult horses, 
they were likely to have experienced previous infections with both viruses. In order to 
estimate precursor frequencies of both EHV-1 and EHV-4 CTLp from previously infected 
animals, a CTL limiting dilution analysis (LDA) assay was developed. This chapter 
describes the development and application of this assay to the measurement of CTL 
precursor frequency in peripheral blood. 
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5.2. Material and Methods 
5.2.1. Animals and infection 
Two infection experiments were carried out. In the first, 2 multiply previously infected 
adult Welsh mountain pony mares were re-stimulated with 1x106.6 TCIDsa EHV-1 strain 
Ab4/8 by exposure to a nebulised aerosol as described (Mumford et. al., 1994). In the 
second experiment, 4 Welsh mountain ponies were infected with EHV-4 strain V 1778 
(105.6 TCID50 total virus nebulised) as described (Mumford et. al., 1994). Subsequently, 
0.5m1 of the same virus was introduced into each nostril of each pony using a flexible 
plastic pipette. This strain of EHV-4 had not been extensively grown in tissue culture 
(used at 2"d passage in equine embryonic lung, EEL cells). 
5.2.2. Sampling, serology and virus isolation 
After EHV-1 and EHV-4 infection, the ponies were sampled regularly for the deter- 
mination of serum complement fixing (CF) antibody (Thomson et. at, 1976a) and virus 
isolation from nasal swabs. Heparinised blood samples were taken on days 2,4 and 6 
after infection in order to detect any viraemia due to infectious virus (EHV-I experiment) 
or re-activated EHV-1 (EHV-4 experiment), they were treated as described (Mumford et. 
al., 1987). Clinical observations including rectal temperatures were performed daily for 
two weeks (Mumford et. al., 1994). 
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5.2.3. EHV specific CTL LDA split well assay 
A split well LDA for CTL was developed based on that used to enumerate human 
cytomegalovirus specific CTLp (M. Wills, Department of Medicine, University of 
Cambridge, personal communication). In order to measure the precursor frequency of 
CTL which were virus-specific and genetically restricted, effector CTL were induced in 
individual wells of a microtitre plate for 7 days. The induction cultures are described in 
5.2.3.1. below. After induction, the cells in each well were split into three aliquots. The 
resultant effector cells were assayed using S'Cr-labelled autologous EHV-l infected cells, 
MHC mis-matched target cells (to control for allogeneic killing) and autologous mock- 
infected target cells (to control for promiscuous killing). 
PBMC were isolated from the ponies to be tested and from an ELA mis-matched horse. 
The ELA typing of all ponies used in this study was carried out by isoelectric focusing of 
immune-precipitated ELA class I molecules. This was kindly performed by Dr. M. 
Whelan, BBSRC Institute for Animal Health, Compton. All cells were suspended in 
AIM-V/SM + 5% autologous serum at 1x10$ cells ml'' (see appendix A for a description 
of the media formulations). 
5.2.3.1. Filler cells for CTL LDA 
4x10' autologous PBMC were treated with Mitomycin C (Mit C, 50µg Mitomycin C in 
lml of HBSS at 37°C for 30 min, then wash extensively) and resuspended at 6x105 cells 
m1'' in AIM"V/SM + 5% autologous serum with the following additives: 
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a) 10% equine conditioned medium (CM) from Con A stimulated PBMC. 
b) 20IUm1 recombinant human IL2. 
c) An optimum dilution of live EHV-1 or EHV-4. This depended on the TCID50 of the 
virus preparation in use at the time (see below). 
5.2.3.2. Induction of CTL under LDA conditions 
24 wells of a 96 round bottomed plate were filled with 200µl of live autologous PBMC at 
5x105 cells ml'' in AIM-V/SM + 5% autologous serum and l00µl of cells from the first 
set of wells was transferred using a multichannel pipette into the second 24 wells. The 
pipette tips were changed and 100µ1 of fresh medium was added to the second set of 
wells. This procedure was repeated until 7 sets of 24 wells (i. e. 24 wells short of 2 plates) 
contained 100µl of cell suspension in each well. One hundred microliters of fresh 
medium alone was added to the final set of 24 wells. The dilutions represented a range of 
cell concentrations from 50,000 cells per well to 781 cells per well. One hundred 
microliters of the Mit C treated filler cell suspension containing 6x104 cells was then 
added to each well. Thus, the final set of 24 wells contained filler cells only. 
The plates were then incubated at 37°C in an atmosphere of 5% C02 for 7 days. 
5.2.3.3. Target cell preparation 
The remaining PBMC in AIM-V/SM + 5% autologous serum at 1x108 cells ml's were 
incubated in 50m1 tubes with loose tops at 37°C for 5 minutes in an atmosphere of 5% 
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CO2 in air. The tops were then tightened and the tubes were stored at 4°C for 4 days. 
After 4 days PWM blasts were produced from the stored cells as described in 3.2.3. After 
48 hours in culture with PWM, the blast cells were infected and labelled with s'Cr as 
described in 3.2.3 in order to produce three sets of targets per pony tested, i. e. autologous 
EHV-1 infected, mis-matched EHV-1 infected and autologous mock-infected. After 12 
hours of infection/labelling the target cells were treated as described in 3.2.3. 
5.2.3.4. CTL assay under LDA conditions 
Each well of the induction cultures was split into three aliquots, with each new well 
containing 66µl from the original (one third of the original volume). Pipette tips were 
changed between each transfer, as each well potentially contained a different number of 
effector CTL compared with the others. 
Each set of plates was labelled as containing either autologous, infected; mis-match, 
infected or autologous, mock-infected targets, 100µ1(1x10; ) of each target cell was 
added to each well of the appropriate plates and the plates were then processed as for the 
standard CTL assays described in 3.2.3. Supernatants were harvested in strict order so as 
to allow comparison of CTL activities from one well against the 3 target cell types. 
Specific cytotoxicity values were derived for each well from the plates containing the 3 
target cell types. Cytotoxicity results derived from wells containing autologous virus- 
infected target cells were compared with the equivalent wells containing MHC mis- 
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matched virus-infected and autologous mock-infected target cells. If the CTL activity in 
a well containing autologous virus-infected cells had a% specific release value 10% 
above those of both the activity in an equivalent well containing mis"matched, infected or 
autologous, mock-infected targets, then it was scored as positive. Data were analysed 
using the LDA program described in 4.2.4 and appendix B. Examples of the raw data 
produced and the results obtained from this type of experiment are shown in appendix D. 
5.2.3.5. Optimisation of the assay 
An experiment was carried out in order to determine which components of the CTL LDA 
assay were necessary for the efficient maturation of CTLp to effector CTL. EHV-1 
specific CTLp were assayed from a multiply infected horse using the full assay (see 
above), without filler cells alone, or without filler cells and CM/rhIL2. 
The proliferative status of the cells in a CTL LDA assay on days 4 to 7 of induction was 
also determined in order to assess the contribution of proliferation to the maturation of 
CTLp into effector CTL. This was done by setting up culture wells (n=6) containing 
5x104 PBMC, varying the culture conditions and pulsing the cells in the assay for 18 
hours with tritiated thymidine after 4,5,6 and 7 days. Harvesting and counting of the 
labelled cells was carried out as described in chapter 3. 
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5.3. Results 
5.3.1. Development of a limiting dilution analysis (LDA) CTL assay 
Because incubating duplicate plates for either 7 or 14 days resulted in similar frequency 
estimates (data not shown) the shorter, more convenient, 7 day incubation was used 
throughout. Also, the shorter incubation period meant that there was less chance of 
particularly active cultures depleting nutrients from the medium and thus affecting the 
frequency determination. 
Table 5.1 shows the effect on the CTLp frequency determination of omitting either filler 
cells or CM/rhIL2 from the assay. All other components were as described in section 
5.2.3 except that the cells used in this experiment were recovered from cryopreservation. 
When the full assay was performed the CTLp frequency of EHV"1 specific genetically 
restricted CTL in PBMC from this mare (#302 sampled before experimental infection) 
was 1/19,231. When fresh cells from the same bleed were used in a similar assay the 
CTLp frequency was 1/13,158. These values were not significantly different (using the 
non-overlap of 95% CIs as an indication of a clear significant difference in CTLp 
frequency between two assays, Fischer et. al., 1991) which showed that cryopreservation 
of PBMC did not adversely effect the CTLp frequency. When filler cells were omitted 
from the assay the CTLp frequency was 1/32,258 and when filler cells, CM and rhIL2 
were omitted (i. e. the assay contained effector cells and antigen only) the CTLp 
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Table 5.1. The effect on CTLp frequency determination of omitting 
either filler cells or conditioned medium/rhIL2 from the assay. 
CTL assay Reciprocal pCTL frequency 95% CI 
Full assay 19,231 14,706 to 27,027 
No filler cells 32,258 25,000 to 45,456 
No fillers/No CM/IL2 58,824 43,478 to 90,909 
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frequency was 1/58,824. These results show that omitting any component of the CTL 
LDA assay had the effect of reducing the CTLp frequency. Although there were overlaps 
in the 95% CIs from these estimates, they were slight and the differences between the 
estimates were large. 
There was significant proliferation within the culture wells over the 7 day period of the 
assay. However, Table 5.2 shows that omitting these components of the CTL LDA assay 
had the effect of reducing lymphocyte proliferation within the culture wells. There was 
an increase in proliferation when effector cells were cultured alone over a7 day period, 
and in the assays examined to date this resulted in a small, but significant effector CTL 
production. There was also evidence for an increase in the thymidine uptake in the wells 
containing filler cells and antigen only (Table 5.2) between day 4 and 7 in culture. 
However, this never resulted in the generation of effector CTL. 
The determination of the CTLp frequency of cells induced from PBMC with EHV-1 and 
EHV-4 is shown in Table 5.3. The frequency of EHV-1 strain Ab4/13 specific CTLp in 
PBMC from an immune mare 193 days after an experimental infection with., homologous 
virus was 1/19,603 (95% CI 15,152 to 27,278). The CTLp frequency of EHV-4 strain 
MD cross-reactive CTL in the same PBMC population was 1/16,667 (95% CI 12,658 to 
23,810). As the 95% CI values overlapped extensively these frequencies were not 
considered significantly different. 
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Table 5.2. Proliferative response of cells in a CTL LDA assay and the 
effect on proliferation of omitting components of the assay. 
Day of induction 
Assay treatment 4567 
Full assay 1238 4574 16627 35643 
±228 ±1084 ±5631 ±5249 
Antigen only 1089 3998 6877 10697 
±746 ±1313 ±3451 ±5359 
Effectors 513 1519 4069 6283 
1177 1764 ±2406 ±3647 
Fillers 102 89 855 1292 
±11 t29 ±941 ±2497 
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Table 5.3. The precursor frequency of CTL induced with EHV-1 and 
EHV-4 in PBMC from an immune (i. e. multiple previous exposures 
to EHV-1) mare. 
CTL inducing antigen Reciprocal pCTL frequency 95% CI 
EHV-1 strain Ab4/13 19,608 15,152 to 27,278 
EHV-4 strain MD 16,667 12,658 to 23,810 
1.72 
5.3.2. CTLp before and after challenge with EHV-1 
The CTLp of EHV-1 specific CTL in PBMC from two multiply infected mares (#302 and 
#219) were measured before and after infection with EHV-1. Experimental infection of 
these animals did not result in pyrexia (a body temperature of above 38.9°C), or nasal 
shedding of infectious EHV-1. Only one day of viraemia was detected in one of the 2 
mares (#219 day 8 post-infection). Furthermore, there were no sero-conversions, as 
detected by the CF test, up to 35 days post-infection, although there were low levels of 
pre-existing CF antibody before infection. The clinical and virological measurements 
were consistent with the animals having a degree of immunity to EHV-1 induced by 
previous infection. 
The frequencies of EHV-1 specific CTLp in PBMC from both infected mares and from 
one non-infected control mare (which had received no previous experimental infections) 
before, 17 days after and 41 days after infection are shown in Table 5.4. Pre-infection 
CTLp frequencies were high in both previously infected mares (1/13,158 in #302 and 
1/17,857 in #219). The CTLp frequency in PBMC from the control mare was 
<1/150,000. This notation was used as the 95% CIs from estimates of frequencies less 
than 150,000 were so large that the accuracy of the estimate could not be guaranteed. 
These frequencies reflect the mares previous experience of EHV-1 and/or EHV-4 
infection. The multiply previously infected mares had high frequencies of CTLp whilst 
the non-previously infected mare had a very low CTLp frequency. After infection, the 
CTLp frequency in PBMC from mare #302 did not alter significantly, whilst the 
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Table 5.4. Frequency of CTLp in PBMC from two infected mares and one non- 
infected control mare (which had received no previous experimental infections) 
before, 17 days after and 41 days after infection with EHV-1. 
Reciprocal pCTL frequency 
Horse number Before infection 17 days after infection 41 days after infection 
#302 13,158 14,085 13,514 
#219 17,857 52,632 11,764 
#310 <150,000 <150,000 Not tested 
After challenge of horses #302 and #219 with EHV-1, infection could only be 
demonstrated (by cell associated viraemia on one day only) in #219. 
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frequency in PBMC from mare #219 decreased to 1/52,632. There was no significant 
change in the CTLp frequency in the uninfected control mare after this period. The 
decrease in CTLp in mare #219 may have been due to the transient viraemia detected at 
day 8 post-infection in this horse. CTLp frequencies were measured again 41 days after 
infection in order to determine whether the decrease in CTLp from mare #219 was 
transient or sustained. The frequency of CTLp in PBMC from mare #302 remained at 
1/13,514, whilst the frequency in PBMC from mare #219 increased significantly to 
1/11,764. The transient decrease in CTLp in PBMC from mare #219 warrants further 
investigation. 
5.3.3. EHV-4 challenge experiment 
An experimental EHV-4 infection of 4 young animals was carried out in order to 
determine the importance of CTL in protection from EHV-4 infection and also to assess 
the potential of bulk culture and LDA CTL assays to distinguish between uninfected and 
infected animals. 
All animals were screened for CF antibody two months before infection, at which time 2 
animals (#1 and #2) were seronegative whilst 2 (#3 and #4) showed serological evidence 
of recent previous infection (see below). 
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Complement fixing antibody titre 
Pony number EHV-1 Ab4 EHV-4 MD 
1 - - 
2 - - 
3 40 5 
4 160 40 
Table 5.5. CF titres of 4 ponies two months before an EHV-4 challenge experiment. 
CF antibody titres on the day of infection (day 0) showed that ponies #1, #2 and #3 had 
no antibody to either EHV-1 or EHV-4 whilst pony #4 showed a residual CF titre of 40 to 
EHV-1 and 10 to EHV-4. The post-infection CF antibody titres can be seen in Table 5.6. 
It is clear that ponies #1, #2 and #3 sero-converted to both EHV-I and EHV-4 whilst 
pony #4 did not. 
The body temperature of each pony was taken daily for five days after infection. The 
only signs of pyrexia (a body temperature of above 38,9°C) were in ponies #1 and #2 on 
day 2 after infection. Nasal excretion of live virus was observed on one occasion only 
after infection, in a nasal swab extract taken from pony #1 (a titre of 103.1 TCID50ml 
measured on day 4). No EHV-1 or EHV-4 was isolated from heparinised blood samples, 
although EHV-2 (confirmed by immunofluorescence) was isolated from samples taken 
from ponies #3 and #4 on day 6 after infection. 
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Table 5.6. Complement fixing antibody response of EHV-4 infected 
animals before and after infection. 
Antigen used in CFT 
Horse #/ Days after inf EHV-1 Ab4 EHV-4 MD 
#1 0 - - 
4 - 
7 80 160 
14 80 160 
#2 0 20 
4 - - 
7 20 20 
14 80 80 
#3 0 - 
4 10 - 
7 40 40 
14 40 20 
#4 0 40 10 
4 20 10 
7 20 10 
14 10 10 
A sero-conversion is considered to be a four fold increase in CF titre, e. g. 1/20 to 1/80. 
177 
The above evidence suggests that ponies #1 and #2 had not experienced recent infection 
with either EHV-1 or EHV-4 and were susceptible to infection with EHV-4 (pyrexic 
response in both and nasal excretion of virus in one pony). Ponies #3 and #4 however, 
had evidence of recent exposure to either EHV-1 or EHV-4 and were essentially 
protected from EHV-4 infection although antibody levels were boosted in pony #3. 
Bulk culture CTL assay results can be seen in Figures 5.1 i and 5.1 ii. These Figures 
show pre-infection (a, c, e and g) and 28 days post-infection (b, d, f and h) CTL activity 
in PBMC from each pony stimulated with EHV-4 strain MD (solid circles) and mock 
antigen (open squares). It is clear from these results that before infection, all 4 ponies 
showed CTL activity when PBMC were stimulated with EHV-4. Despite minor 
variations, post-infection CTL activities stimulated by MD were similar to pre-infection 
activities. 
The frequency of EHV-4 cross-reactive CTLp in PBMC from the four animals before and 
10 days after infection can be seen in Table 5.7. Before infection only pony #1 showed a 
measurable frequency (1/125,000). The frequencies of CTLp in PBMC from the other 
three ponies were <1/150,000. After infection, the frequencies of CTLp in PBMC from 
ponies #1 and #2 increased significantly to 1/15,625 (95% CI 1/11,765 to 1/23,810) and 
1/33,333 (95% CI 1/22,222 to 1/62,500) respectively. The post-infection CTLp 
frequencies in PBMC from ponies #3 and #4 were <150,000 and 1/111,111 (95% Cl 
1/76,923 to 1/200,000) respectively. 
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Figure 5.1i. Bulk culture CTL activity in PBMC from 4 ponies before 
and 28 days after infection with EHV-4. 
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b) #1 after infection 
c) #2 before infection 
d) #2 after infection 
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Figure 5.1ii. Bulk culture CTL activity in PBMIC from 4 ponies 
before and 28 days after infection with EHV-4. 
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Table 5.7. The precursor frequencies of EHV-4 cross-reactive CTL 
in PBMC from four ponies before and 10 days after an EHV-4 
infection. 
Reciprocal frequency 
Horse number Before infection After infection 
#1 125,000 15,625 
#2 <150,000 33,333 
#3 <150,000 <150,000 
#4 <150,000 111,111 
After challenge of all four horses with EHV-4, infection could only be demonstrated (by 
nasal excretion of live virus and/or pyrexic response) in ponies #1 and #2. 
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These results suggest that ponies #I and #2 became infected with EHV-4 and cleared the 
infection by producing an immune response involving both production of antibody and 
CTL. Pony #3 did not become infected with EHV-4 but did produce a modest antibody 
response against the virus which may have been stimulated by residual inactivated viral 
antigen draining into the local lymph nodes from the nasopharynx. Pony #4 did not 
become infected with EHV-4. 
These results show that EHV-4 infection induces CTL in vivo but that some animals may 
be protected from infection, even though the CTLp frequency in PBMC is <150,000. 
5.4. Discussion 
The humoral immune response to EHV-1 and EHV-4 has been well documented in 
conventionally reared (Stokes et. al., 1991, Mumford et al., 1987) and specific pathogen 
free (SPF) animals (Tewari et al., 1993, Gibson et at., 1992a). Conclusions from these 
studies suggest that the antibody response is predominantly type-specific after EHV-1 
infection but that a cross-reactive response develops after subsequent EHV-4 infection. 
Fitzpatrick and Studdert (1984) studied EHV-1 infection of SPF foals and concluded that, 
although serological responses were type-specific, cell-mediated responses, as measured 
by in vitro lymphocyte blastogenesis, were cross-reactive. The bulk culture CTL data 
presented in chapter 3 shows that CTL induced with EHV-4 were able to kill EHV-1 
infected target cells, i. e. that the CTL were cross-reactive. 
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Bulk culture CTL assays have their limitations (see chapter 2) in that, after infection, it is 
often difficult to determine, with certainty, significant differences between % cytotoxicity 
values derived from different assays. The LDA CTL assay presented in this chapter was 
developed as a way of quantifying the CTL response of horses to EHV infection. It 
provides an estimate of the frequency of CTLp whilst retaining the virus-specificity and 
genetic restriction controls built in to the bulk culture CTL assay. As with the bulk 
culture assay, EHV-4 was able to induce CTL activity but this virus was not able to infect 
PWM blast cells to a sufficient level to provide useable target cells. Therefore, CTL 
primed with EHV-4 in vivo and in vitro were assayed using EHV-1 infected target cells 
and were referred to as cross-reactive CTL. 
The CTL LDA development experiments showed that, in order to provide optimal 
conditions for the maturation of CTLp into effector CTL, Mitomycin C treated filler cells 
and growth factors were necessary additions to the culture. Failure to include these 
additives in CTL LDA cultures resulted in a reduction in the measured frequency of 
CTLp and a reduction in the amount of proliferation observed in the culture wells. 
The use of this assay to quantify the frequency of CTL against EHV-1 or EHV-4 in a 
population of PBMC from an immune animal (Table 5.3) showed that the frequencies of 
CTLp induced with each virus were equivalent. It is likely that the frequency estimates 
represent the same population of cross-reactive CTL, as only EHV"1 infected target cells 
were used. 
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Comparison of CTLp frequencies between viral assay systems is difficult as there are 
numerous factors which may affect the final estimate. These include the propensity of 
the virus to cause immune suppression or to replicate in immune cells. However, 
Schmid (1988) employed LDA to measure the frequencies of CTLp in the blood of 
humans infected with HSV-1. The CTLp frequencies were reported to be between 
1/4000 and 1/8000 although genetic restriction and specificity controls were not 
employed in this study. Hickling et. al. (1987) derived CTLp frequencies from human 
patients after VZV infection and found that precursors were present at a frequency of 
about 1/90,000 in an asymptomatic carrier and about 1115,000 in a subject with recent 
zoster. The frequencies measured in immune animals using the EHV CTL LDA assay 
are likely to be lower than if they were measured using the assay developed by Schmid 
(1988). This is because the virus-specificity and genetic restriction controls employed 
were not employed by Schmid. However, the frequencies reported are potentially more 
relevant, as the presence of non genetically-restricted, virus non-specific CTL in PBMC 
is likely to be a consequence of in vitro culture. 
The question of whether an EHV-4 infection stimulates cross-reactive immunity and 
hence protection against infection with EHV-1 has been addressed in a number of studies. 
Tewari et. al. (1993) showed that a true primary infection of SPF foals with EHV-4 strain 
MD resulted in mild respiratory disease (pyrexia for 1 day and nasal excretion of virus for 
5 days). Subsequent infection with EHV-1 strain Ab4, resulted in partial protection as 
evidenced by nasal excretion of virus on I day, pyrexia on I day and viraemia in one of 2 
184 
animals. The usual course of infection with the same EHV-1 strain in SPF animals was 
very much more severe than this, with nasal excretion lasting for up to II days and a 
heavy viraemia (Tewari et. at., 1993, Gibson et al., 1992a). When EHV-1 infected 
animals were re-infected with the same strain of EHV- I there was no pyrexia, no 
viraemia and nasal excretion of virus on only I day (2/2 animals). Edington (1990) 
showed that primary infection of conventionally reared horses with either EHV-1 strain 
Ab4 or EHV-4 field isolate 2252 did not prevent nasal excretion of live virus after a 
secondary infection with the homologous virus. Moreover, a subsequent (tertiary) EHV- 
I infection of animals given two EHV-4 infections resulted in infection as measured by 
nasal excretion (mean 5.2 days) and extensive viraemia (mean 2.3 days). In contrast, 
infection of ponies with EHV-4 after 2 previous EHV-1 infections resulted in no clinical 
signs i. e. full protection against EHV-4 infection. 
Taken together, these studies suggest that infection of ponies with EHV-1 is able to 
induce protection against subsequent infection with EHV-4 whilst infection with EHV-4 
only reduces the severity of subsequent EHV-1 infections. The implication is that the 
immune response stimulated by EHV-4 is either less cross-reactive or of a lower 
magnitude than that stimulated by EHV-1. 
The infection of two multiply infected mares with EHV-1 strain Abo, presented in this 
chapter, resulted in only one day of cell-associated viraemia in one of the mares (#219 on 
day 8 post-infection). Despite very few signs of infection, the CTLp frequency in PBMC 
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from this mare fell from 1/17,857 to 1/52,632 17 days after infection and then increased 
to 1/11,764 41 days after infection. The CTLp frequency in PBMC from an uninfected 
control mare remained undetectable over the first 17 days of the experiment. These 
results show that adult horses may become infected with EHV-1 but show few or no 
clinical signs but that these infections are reflected by changes in the frequency of CTLp 
in the blood. Serological screening would have failed to detect the establishment of 
subclinical infections in these animals. 
Infection of 4 younger animals with EHV-4 strain V1778, again, resulted in very few 
signs of infection. Two of the 4 animals selected for this study were found to have 
serological evidence of recent previous exposure (Thomson et. al., 1976a). The highest 
antibody responses were to EHV-1 rather than EHV-4 which suggested that a recent 
infection with the former had occurred (Thomson et. al., 1976a). Support for the 
previous infection of all 4 ponies came from the detection of significant CTL activity (by 
bulk culture methods) before experimental infection. Hence, ponies #3 and #4 had 
recently been exposed to EHV-1 (antibody data) whilst all four animals had been exposed 
to infection with either EHV-1 or EHV-4 (CTL data) some time previously. 
After infection, the only signs of disease were pyrexia for one day in ponies #1 and #2 
and nasal excretion of virus from pony #1 for one day. This strongly suggests that all 
ponies had experienced previous infections with EHV, as these signs were reduced when 
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compared with those seen after a true primary infection with EHV-4 (Tewari et, al., 
1993). 
The results of the bulk culture CTL assays after induction with EHV-4 showed that CTL 
activity did not increase for at least 28 days after infection. This may mean that EHV-4 
specific CTL were slow to develop (i. e. longer than 28 days) or that the bulk culture assay 
system was not sensitive enough to detect changes in CTL activity after infection. 
The frequencies of CTLp induced using EHV-4 MD showed significant rises between 10 
and 12 days after infection in ponies #1 and #2. These data show that, the CTL 
stimulated by infection of ponies with EHV-4 cross-reacted with EHV-1 but that ponies 
#3 and #4 did not become infected with EHV-4. The frequency of CTLp stimulated by 
infection of pony #1 with EHV-4 was 1/15,625 which was equivalent to the frequencies 
stimulated by infection of mares #219 and #302 with EHV-1. However, the frequency of 
CTLp stimulated by EHV-4 infection of pony #2 was significantly lower than those in 
mares #219 and #302. This suggests that the CTLp frequency stimulated by infection of a 
horse depends on a number of factors, i. e. the infectious load, previous infection history 
of the horse and the infecting virus strain. 
Although more work needs to be done, the development and use of CTL LDA assays 
described in this chapter have provided new information on CTL responses in horses after 
EHV-1 and EHV-4 infection. 
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6. General Discussion 
The work presented in this thesis shows that antigen-specific, genetically restricted, 
CD8'` cytotoxic T lymphocytes (CTL) can be measured in horses after infection with 
EHV-1 and that infection with EHV-4 induces cross-reactive CTL which can kill 
EHV-1 infected target cells. 
The bulk culture CTL assay used here was shown to be useful and robust. The 
induction of CTL in culture was dependent on the amount of live antigen added and 
was not affected by the addition of recombinant human interleukin 2, which suggests 
that all of the necessary cytokines were produced in the culture. 
Study of CTL activity from a range of horses showed that adult horses, which had not 
been recently infected, exhibited low levels of activity. After experimental infection, 
levels of CTL activity rose to a maximum of about 60% specific cytotoxicity in adult 
horses. In young animals, CTL activity was not demonstrated in conventional horses 
younger than 10 months, however after experimental infection of two specific 
pathogen free foals, low levels of anti EHV-1 CTL activity were demonstrated. These 
results taken together, suggest that horses develop only a weak CTL response after 
primary infection with EHV-1 which then becomes stronger as more infections or 
reactivitions occur. In the event of horses receiving multiple experimental infections 
spaced over a short time period, CTL activity was maintained for over one year. 
The cross-reactivity of EHV-4 induced CTL was shown by the lysis of EHV-1 
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infected target cells. The cross-reactivity or type-specificity of EHV-1 induced CTL 
remains to be shown and awaits the development of EHV-4 infectable target cells. 
The cross-reactivity of HSV-2 induced CTL for HSV-1 infected target cells was 
shown by Carter et al. (1982). In this study, HSV-2 infected target cells were less 
susceptible to lysis by either HSV-1 or HSV-2 induced CTL. This reduced 
susceptibility was not due to the lack of expression of viral antigens on the HSV-2 
infected target cell. The implications of the induction of cross-reactive CTL for the 
resolution of disease after EHV-1 or EHV-4 infection are not clear. Further work 
needs to be done in order to clarify the target antigens involved in the induction of the 
cross-reactive CTL. A glycoprotein (gG) containing cross-reactive epitopes (defined 
by antibody binding) has been described (Crabb & Studdert, 1993. Crabb et. al., 
1995) but whether this glycoprotein also provides CTL epitopes remains to be 
determined. Some work reported in chapter 3 of this thesis suggests that the EHV-1 
IE protein contains at least one CTL epitope. This has recently been confirmed by 
Allen (G. Allen, University of Kentucky, personal communication). This is analogous 
to the murine model of HSV infection in which CTL recognise at least 2 IE protein 
ICP27 peptides (Banks et. al., 1993). 
The experiments presented in chapter 4 of this thesis were designed to answer a 
number of questions: 
1) What is the effect of live vs inactivated EHV"1 on the in vitro proliferation of 
equine PBMC? 
2) Is there any difference between the immune reactivity (as defined by 
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proliferative response) of PBMC from multiply infected and initially infected mares? 
3) Does the precursor frequency of antigen-specific PBMC capable of 
proliferating in vitro in response to inactivated EHV-1 correlate with increased 
resistance to infection? 
It is clear that live EHV-1 has an effect on the in vitro functions of equine 
lymphocytes. Proliferation of lymphocytes was depressed to a greater extent when 
live EHV-1 was included in mitogen and antigen stimulated cultures than when 
inactivated EHV-l (iEHV-1) was included. The mechanism for this suppression of 
lymphocyte function is not clear, however, the proteins of EHV-1 are clearly not 
directly immunosuppressive as iEHV-1 did not reduce the proliferation of 
lymphocytes to the same extent as live EHV-1. Griebel et. al. (1990) showed that 
bovine herpesvirus type 1 (BHV-1) was able to induce lytic infections of bovine 
activated T lymphocytes, which occurred in the absence of any viral replication or 
detectable expression of viral proteins. Allen et, al. (1995) showed that equine 
activated T lymphocytes were infectable with EHV-1 and that high levels of viral 
antigen expression occurred. Furthermore, EHV-1 was shown to replicate in these 
cells as demonstrated by a greater than 10 fold increase in plaque titre of infectious 
virus 72 hours after infection with 0.1 pfu/cell. These data and the fact that EHV-1 
only infects between 10% and 20% of non-stimulated PBMC (see chapter 2) suggests 
that the cell-associated viraemia seen after EHV-1 infection may come about as a 
consequence of the virus replicating in in vivo stimulated blasting T cells. Further 
work needs to be done in order to confirm which cells are infected during viraemia. 
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Data presented here on the in vitro proliferation of equine PBMC in response to 
mitogens after EHV-1 infection of horses shows that the reporting of stimulation 
indices alone without ' supporting raw cpm data can be misleading. Also the 
importance of the collection of full data sets including virological and serological data 
was shown in chapter 4. The collection of all available data meant that potential 
relationships could be inferred e. g. between peak cell associated viraemia and 
suppression of in vitro mitogen stimulated proliferative responses in infected mares. 
The use of the proliferative LDA assay to measure the precursor frequency of cells 
capable of proliferating in response to iEHV-1 showed that mares which were 
protected from abortion after EHV-1 infection had a lower precursor frequency than 
mares which aborted. Increases in the precursor frequency of these cells occurred 
after infection in 3 of 4 mares tested. Despite the fact that all relevant controls were 
not included in this study (i. e. there were no parallel cultures containing all 
constituents except antigen) these data suggest that the measurement of precursor 
frequencies of proliferative cells alone does not discriminate immune from non- 
immune animals. This was also the conclusion of Denis et. al. (1994) who carried out 
similar experiments using BHV-1. 
In contrast, the CTL LDA method described in chapter 5 distinguished between 
recently infected and non-infected animals using both EHV-1 and EHV-4 as the 
stimulating antigen. Conclusions about whether this assay will distinguish between 
immune and non-immune animals must await its wider use, perhaps using 
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cryopreserved cells from past challenge infections from which clinical and virological 
data are available. 
In the horses tested to date, frequencies of CTLp in recently EHV-1 infected horses 
were of the order of between 1/10,000 and 1/20,000 (see Figure 5.4). This was also 
the case in an immune mare approximately 9 months after infection with EHV-1. A 
study by Chilmonczyk et al. (1985) showed CTL precursor frequencies of between 
W 
1/14,000 and 1/18,000 children and adults immune to HSV. An interesting finding 
has been the reduction in CTLp frequency in one mare after infection with EHV-1. 
This has not been shown using bulk culture CTL assays (Allen et. al. 1995). 
To my knowledge, this is the first report of the use of LDA techniques in the horse. 
The application of these methods to the study of CTL precursor frequencies in EHV- I 
infections will greatly improve our understanding of the potential of CMI in 
protection against or recovery from infection. A most valuable measure would be one 
which correlated with immunity (i. e. with protection from clinical disease, virus 
shedding and cell associated viraemial. If the measurement of anti EHV-ICTLp did 
correlate with immunity, there could be great potential for the use of CTL LDA as a 
predictor for the efficacy of both conventional (inactivated whole virus/subunit) or 
new (deletion mutants, recombinant virus) vaccines. 
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Appendix A 
This appendix outlines the media formulations used throughout this thesis. 
Hanks' Balanced Salts Solution 
500m1 lx Hanks' Balanced Salts (modified) without calcium or 
magnesium. ICN/Flow laboratories (Thame, Oxon) Cat. No. 
18-104-54. 
1000 units/ml Benzylpenicillin. Various suppliers. 
1000 units/ml Streptomycin. Evans medical Ltd, Letherhead, Surrey. 
0.075% Sodium Bicarbonate solution. Sigma, Poole, Dorset. 
Cat. No. S8761. 
complete RPMI 
500ml lx RPMI 1640 medium with 2.00g/ml Sodium Bicarbonate, 
without Glutamine. ICN/Flow laboratories (Thame, Oxon) 
Cat. No. 12-602-54. 
2mM L-Glutamine. ICN/Flow laboratories (Thame, Oxon). 
1000 units/ml Benzylpenicillin. Various suppliers. 
1000 units/ml Streptomycin. Evans medical Ltd, Letherhead, Surrey. 
50m1 Foetal Calf Serum. Mycoplasma tested. APP Ltd (Brierley 
Hilt, West Midlands). 
5.5xl 0'5M 2-Mercaptoethanol. 
AIM-V/SM Medium 
a) 50ml supplemented AIM-V (sAIM-V) medium. 
50ml AIM-V base medium. Life Technologies Ltd, Paisley, Scotland. 
Cat. No. 12030-029. 
2mM L-Glutamine. ICN/Flow laboratories (Thane, Oxon). 
50µg/ml Gentamycin. 
5.5x1 0'5M 2-Mercaptoethanol. 
b) 50m1 sensitisation medium (SM) with autologous serum. 
44m1 RPMI 1640 base medium. 
2mM L-Glutamine. 
50µg/m1 Gentamycin. 
5.5x10'5M 2-Mercaptoethanol. 
10mM Sodium Pyruvate. 
10mM MEM non-essential amino acids. 
Sml Heat inactivated, autologous equine serum. 
To prepare AIM-V/SM mix 50m1 sAIM-v (a) with 50m1 SM (b). 
Appendix B 
Limiting Dilution Analysis 
The use of Limiting Dilution Analysis (LDA) techniques in chapters 4 and 5 of this thesis 
has facilitated the estimation of the frequencies of particular cell types within peripheral 
blood mononuclear cell (PBMC) populations. This appendix describes the theory behind 
LDA. Lefkovits and Waldmann (1984) have written an excellent review of the 
background to LDA. 
LDA is a quantitative method which allows the estimation of the frequency of a 
responding cell type within a mixed population. The technique was first used to estimate 
the frequencies of antigen-specific B, T helper and T suppressor cells (Lefkovits, 1972. 
Lefkovits & Waldmann, 1979. Quintans et. al., 1973). Subsequently, LDA has been used 
to measure the frequencies of antigen-specific and allogeneic cytotoxic T lymphocytes 
(CTL) and cytokine producing cells (Taracha et al., 1992. Juretic & Knowles, 1991. 
Kaminski et. at, 1991. Schulick et. al., 1993., Deacock et. al., 1992). 
There is no simple morphological property which may be used to distinguish cells in a 
population which will respond to antigen from those which will not. It is, however, 
possible to use the fact that, under favourable conditions, a single immune cell can 
develop into a measurable clone of cells. In order for this to occur, the responding cell 
must be cultured with an excess of appropriate accessory cells and growth factors. If this 
line of reasoning is followed then it is clear that if a population of 1x106 PIIMC contains 
400 cells capable of responding to an antigen then the frequency of responding cells will 
be one in 2500. Random distribution of these 1x106 PBMC cells in, say, 400 culture wells 
(i. e. an average of one cell per well) may result in some wells receiving no cells, some 
receiving one cell and some receiving two cells etc. Each culture well will also receive 
an excess of other cells from the PBMC population which will have other antigenic 
specificities and will be functionally silent within this analysis. In this example we would 
obtain approximately 150 negative cultures (37%) and 250 positive cultures (67%) using 
a sensitive readout. The reason why a given fraction of negative (and positive) wells is 
obtained is not straightforward, however, in the common situation where we do not 
know, but would like to estimate, the precursor frequency of, say, CTL in a PBMC 
population we assess the number of negative wells at a number of appropriate PBMC 
inputs and from these values make a frequency estimate. It is not possible to estimate, 
accurately, the frequency of responding cells from only one dilution. Therefore, in 
practice, a range of dilutions is used. Provided with a sufficiently sensitive readout 
system and optimum conditions for growth, it is relatively easy to determine the 
proportion of responding and non-responding cultures in an experiment. 
The proportion of cultures which fail to respond (i. e. failed to receive any CTL) at a 
given PBMC input is defined by the following equation: 
Fo=e'° 
where Fo is the fraction of negative cultures, e is the base of the natural logarithm and u 
is the average number of precursor cells per culture. The above expression is the zero 
term of the Poisson distribution. The full derivation of the formula and its relationship 
to the binomial distribution is considered in detail in Lefkovits & Waldmann (1979). 
In order to yield an explicit expression of the average number of precursor cells per 
culture, it is necessary to convert the formula to its logarithmic form: 
u -in Fo 
This formula can also be represented graphically, providing a straight line on a 
semilogarithmic plot. In other words, the negative logarithm of the proportion of negative 
cultures is linearly proportional to the mean number of precursor cells per culture. The 
resultant straight line serves two purposes, firstly it allows an estimation of the frequency 
of responding cells in the original population (see below) and secondly, it serves as an 
internal control to verify that the system is measuring one limiting cell type (i. e. the curve 
is a single hit curve). Any deviation from linearity means either that the culture 
conditions are not optimal for the growth of a single cell type, that the readout failed to 
detect wells containing single clones or that complex cellular interactions are occurring 
within the culture well. Under these non-linear situations the data obtained can only be 
used to inform experimental redesign. It is obvious that visual estimation of the frequency 
of responding cells and the linearity of the resultant curve is inadequate; therefore 
statistical methods need to be applied to the experimental data. 
Estimation of the frequency of responding cells 
As mentioned above, if we plot the negative logarithm of the fraction of non-responding 
cultures (y axis) against the cell input (x axis), we can expect to obtain a straight line 
passing through the origin if the criteria outlined above have been met. The size of the 
original sample containing one precursor cell can be estimated by interpolating at the 
level of 37% non-responding cultures. This is explained by substituting u-I into the 
zero term of the Poisson distribution, thus: 
Fo=e" 
Then Fo = e" = 1/e = 1/2.7 
Fo = 0.37 
The choice of the statistical procedure for the calculation of the frequency of responding 
cells from the experimental data has been discussed widely (Taswell, 1981. Fazekas de 
St. Groth, 1982). As a result of this discussion three main statistical methods have been 
advocated. Lefkovits and Waldmann (1979) preferred to use the least squares method 
which is now thought to be inappropriate for the evaluation of LDA data as this method 
may reject inherantly valid data (Fazekas de St. Groth, 1982). Taswell (1981) proposed 
the method of chi-squared minimisation (MC) and likelihood maximisation (ML). 
Fazekas de St. Groth (1982) also advocated the use of the ML method but raised doubts 
about the use of the MC method. A comparison of the MC and the ML methods was 
carried out by Strijbosch et. al. (1987) who calculated the mean bias of each method 
when performing 2000 simulated LDA experiments. The authors concluded that a 
Jacknife version (see Miller, 1974, for basic definitions of the jacknife) of the ML 
method originally advocated by Reeds (1978) was the most appropriate for this type of 
data as it exhibited a mean relative bias of zero for the complete range of frequencies, 
closely followed by the ML method and, finally the MC method. 
Strijbosch et. al. (1988) have produced a computer program which provides a frequency 
estimate based on the ML, Jacknifed ML and MC methods, a 95% confidence interval 
for each estimation and a goodness-of-fit statistic which should be below published 
values using the stated degrees of freedom in order to satisfy the single hit model. 
All LDA data presented in this thesis have used this computer program to determine the 
frequency of responding cells the statistical method of choice being the Jacknife version 
of the ML method. 
Appendix C 
This appendix gives examples of the data obtained from two proliferative LDA assays 
reported in chapter 4. 
The design program supplied by Strijbosch et. al. (1988) was used to provide initial cell 
input values, x(i), the number of dilutions, m and the dilution factor, c. These parameters 
were as follows for the two assays reported: 
Horse #302 Before infection After infection 
x(i) 6545 760 
m 12 7 
c 1.35 1.65 
Variations in the design of the proliferative LDA were necessary in order to ensure that 
the correct range of cell inputs were used. Estimations of the approximate range of 
frequencies in a population were made using bulk culture proliferation assays as a guide. 
The LDA assays were performed as described in chapter 4. The raw data was tabulated 
using a computer spreadsheet package (Lotus 1-2-3). Tables C. 1 and C. 2 show the raw 
data in counts per minute (cpm) from proliferative LDA assays using PIIMC from horse 
#302 before (C. I) and 5 weeks after (C. 2) infection with EHV-1 strain Ab4/13. Table C. 1 
shows that increasing the cell number per well had little effect on the resultant cpm. 
Table C. I. An example of the raw data in counts per minute obtained 
from a proliferative LDA assay. 
PBMC from mare 1302 before infection. 
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Table C. 2. An example of the raw data in counts per minute obtained 
from a proliferative LDA assay. 
PBMC from mare #302 5 weeks after infection with EHV-1 Ab4/I3. 
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L. V 
The number of wells which produced a negative result, i. e. less than the mean cpm from 
the wells containing no responders +3 standard deviations, were entered into a word 
processing package (Wordperfect for Windows version 5.2) in the following format: 
x(1)_# of replicates per dilution j of negative wells 
x(2)_# of replicates per dilution j of negative wells 
x(3)_# of replicates per dilution j of negative wells etc 
This data was saved on a diskette as an ASCII text file. The Evaluate program was 
opened from the C: prompt. The input file name (i. e. the ASCII file name) and the output 
file names were specified and the evaluation was started. When the evaluation was 
complete, the output file was opened from the word processor. Examples of the output 
derived from two LDA evaluations are shown in tables C. 3 and C. 4. These results tables 
show the input cell number, x(i), the number of replicates, n(i), the number of negative 
wells, r(i) and the proportion of negative wells, r(i)/n(i). These data are fitted to a straight 
line passing through the origin and estimates of the frequency of responding cells are 
made using the three methods of Maximum likelihood, the jackknifed version of the 
maximum likelihood and the minimum chi squared (see appendix B). An estimation of 
the goodness-of-fit of the data to a straight line (Le. single hit kinetics) is produced using 
the chi squared method. Chi squared values above published values, using the number 
of dilutions minus 1 as the degrees of freedom, mean that the data must be rejected as not 
satisfying single hit kinetics. The statistics by which all of these values are derived was 
reviewed by Lefkovits & Waldmann (1979). An example of data from the proliferative 
LDA which do not conform to single hit kinetics is shown in table C. 5. 
Table C. 3. An example of the output produced from a proliferative 
LDA evaluation using the program of Strijbosch. 
PBMC from mare #302 before infection. 
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Table C. 4. An example of the output produced from a proliferative 
LDA evaluation using the program of Strijbosch. 
PBMC from mare #302 5 weeks after infection with EHV-1 Ab4/13. 
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Table C. 5. An example of the output from a proliferative LDA when 
the data did not conform to single hit kinetics. 
PBMC from mare #219 21 days after infection with EHV-1 Ab4/13. 
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Appendix D 
This appendix gives examples of the data obtained from two CTL LDA assays reported 
in chapter S. 
The design program supplied by Strijbosch et al. (1988) was not used to provide initial 
cell input values as no prior information was available to inform the design. Instead, the 
following design was set and used throughout the study: 
x(i) 781 
m 7 
C 2 
The LDA assays were performed as described in chapter 5. The raw data was tabulated 
using a computer spreadsheet package (Lotus 1-2-3). Tables D. 1 to D. 6 show the raw 
data in counts per minute (cpm) from CTL LDA assays using PBMC from horse #; 02 
stimulated with EHV-1 strain Ab4/13 (D. 1-3) and EHV-4 strain MD (D. 4-6). Infected 
target cells from horse #219 were used as the mis-matched target (see chapter 5). 
The number of wells which produced a negative result, i. e. when the specific "Cr release 
value using the autologous infected target cell was less than 10 above the corresponding 
well using both the mis-matched and the autologous mock-infected target cell, were 
entered into a word processing package (Wordperfect for Windows version 5.2) in the 
following format: 
Table D. 1. An example of the raw data in % specific cytotoxicity 
obtained from a CTL LDA assay. 
CTL induced using EHV-1 Ab4/13 from mare 43)42. 
Autologous infected target cells. 
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Table D. 2. An example of the raw data in % specific cytotoxicity 
obtained from a CTL LDA assay. 
CTL induced using EHV-1 Ab4/13 from mare #3302. 
Allogeneic (MHC class I mis-matched) infected target cells. 
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Table D. 3. An example of the raw data in % specific cytotoxicity 
obtained from a CTL LDA assay. 
CTL induced using EHV-I Ab4113 from mare #302. 
Autologous mock-infected target cells. 
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Table D. 4. An example of the raw data in % specific cytotoxicity 
obtained from a CTL LDA assay. 
CTL induced using EHV-4 MD from mare #302. 
Autologous infected target cells. 
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Table D. 5. An example of the raw data in % specific cytotoxicity 
obtained from a CTL LDA assay. 
CTL induced using EHV-4 MD from mare #302. 
Allogeneic (MHC class I mis-matched) infected target cells. 
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Table D. 6. An example of the raw data in % specific cytotoricity 
obtained from a CTL LDA assay. 
CTL induced using EHV-4 MD from mare #302. 
Autologous mock-infected target cells. 
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x(1)_# of replicates per dilution j of negative wells 
x(2)_# of replicates per dilution j of negative wells 
x(3)_# of replicates per dilution j of negative wells etc 
This data was saved on a diskette as an ASCII text file. The Evaluate program was 
opened from the C: prompt. The input file name (i. e. the ASCII file name) and the output 
file names were specified and the evaluation was started. When the evaluation was 
complete, the output file was opened from the word processor. Examples of the output 
derived from the two LDA evaluations are shown in tables D. 7 and D. 8. These results 
tables show the input cell number, x(i), the number of replicates, n(i), the number of 
negative wells, r(i) and the proportion of negative wells, r(i)/n(i). These data are treated 
in the same way as the proliferative LDA data in appendix C. 
Table D. 7. An example of the output produced from a CTL LDA 
evaluation using the program of Strijbosch. 
CTL induced using EHV-1 Ab4/13 from PBMC from mare #302. 
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Table D. S. An example of the output produced from a CTL LDA 
evaluation using the program of Strijbosch. 
CTL induced using EHV-4 MD from PBMC from mare #302. 
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Abbreviations 
ADCC antibody directed cell mediated cytotoxicity 
APC Antigen presenting cell 
BHV Bovine herpes virus 
BSA Bovine serum albumin 
pZM P2 microglobulin 
C9 the 9th component of the complement cascade 
CD Cluster of differentiation 
CMI Cell mediated immunity 
Con A Concanavalin A 
cpm counts per minute 
cRPMI RPMI base medium + 10% foetal bovine serum 
CTL Cytotoxic T lymphocytes 
CTLp Cytotoxic T lymphocyte precursors 
CyA Cyclosporin A 
DNA Deoxyribonucleic acid 
DTH delayed type hypersensitivity 
EBV Epstein Barr virus 
EHV Equine herpes virus 
EIAV Equine infectious anaemia virus 
ER endoplasmic reticulum 
FACS Fluorescence activated cell sorter 
FBS Foetal bovine serum 
G+C Guanine and Cytosine 
GM-CSF Granulocyte and Macrophage colony stimulating factor 
HBSS Hanks' Balanced Salts Solution 
hCMV Human Cytomegalovirus 
HIV Human immunodeficiency virus 
HSV Herpes Simplex virus 
ICAM inter cellular adhesion molecule 
IEF Isoelectric focusing 
IFN interferon 
Ig Immunoglobulin 
Ii invariant chain associated with the MHC class II 
IL interleukin 
K cells Killer cells 
K562 NK sensitive cell line 
KLH Keyhole Limpet haemacyanin 
LAK Lymphokine activated killer cell 
LCMV Lymphocytic choriomeningitis virus 
LDA Limiting dilution analysis 
LFA lymphocyte function associated antigen 
MC Minimum Chi squared 
mCMV Murine Cytomegalovirus 
MHC Major histocompatibility complex 
ML Maximum Likelihood 
MLR Mixed lymphocyte reaction 
moi multiplicity of infection 
NK cell Natural Killer cell 
PBS Phosphate buffered saline 
PHA Phytohaemagglutinin 
PM peritoneal macrophages 
PMA Phorbol Myristate Acetate 
PMN Polymorhonuclear neutrophil 
Prot A Staphylococcal Protein A 
PRV Pseudorabies virus 
PWM Pokeweed mitogen 
RNA Ribonucleic acid 
SFV Smeliki Forest virus 
SI Stimulation index 
SPF specific pathogen free 
TBS Tris buffered saline 
TCGF T cell growth factor 
TCID50 50% of the tissue culture infective dose 
TcR T cell receptor complex 
TGF Transforming growth factor 
Th T helper cell 
tk Thymidine Kinase 
TNF tumour necrosis factor 
VEC Vascular endothelial cell 
VLA very late antigen 
VSV Vesicular stomatitis virus 
VZV Varicella Zoster virus 
Addendum 
The results presented in Table 4.5 were based on raw data derived from scintillation counting. 
The raw counts per minute (cpm) used to derive these data were generally less than 1000, 
each sample having been counted for 1 minute only. The low level of the raw cpm means 
that the data may have been influenced by random events. Therefore, the results in Table 4.5 
should not be taken to be significant. A sample of the raw data to which these concerns 
apply, is given in appendix C (Tables C. 1 and C. 2). 
